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Abstract 
 
 Osteoclast-mediated focal articular bone erosion is a hallmark of rheumatoid 
arthritis, a disease of inflammation-induced bone loss.  Inflammation in the bone 
microenvironment enhances osteoclast differentiation leading to bone erosion.  
Simultaneously, inflammation also inhibits osteoblast-mediated bone formation, further 
contributing to the net loss of bone.  Previous studies have shown a paucity of mature 
osteoblasts at eroded bone surfaces correlating with suppression of bone formation and 
upregulation of antagonists of the Wnt pathway, a signaling cascade essential for 
osteoblast lineage commitment.  Despite these observations, the exact pathogenesis of 
impaired bone formation in the setting of inflammation is not clearly understood.   
This dissertation aims to delineate the mechanisms by which inflammation 
suppresses osteoblast differentiation and activity in inflammatory arthritis.   Specifically, 
this research elucidates how inflammation-induced alterations in the Wnt and bone 
morphogenetic protein (BMP) osteogenic signaling pathways contribute to bone loss and 
formation at distinct inflammatory microenvironments within the bone.  Secondly, the 
means by which cellular mediators, including lymphocytes and macrophages, facilitate 
bone erosion and formation was addressed. 
Taken together, the research in this dissertation underscores the relationship 
between inflammation-induced bone loss and alterations in osteogenic signaling.  Using 
an innovative murine inflammatory arthritis model, this study definitively demonstrates 
that resolving inflammation promotes osteoblast-mediated bone formation.  Repair of 
erosions correlates with upregulation of synovial expression of Wnt10b, a Wnt agonist, 
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and downregulation of sFRP1 and sFRP2, Wnt antagonists.  This work also directly 
evaluates the contribution of sFRP1 to inflammation-induced bone destruction. 
Furthermore, this research demonstrates that expression of BMP3, a negative regulator of 
BMP signaling, is upregulated in osteoblasts by IL-17, a pro-inflammatory cytokine.  
BMP3-expressing osteoblasts are also observed at erosion sites in murine arthritis.  
Lastly, evaluation of the mediators of inflammation-induced periosteal bone formation 
implicates BMP2 as a means by which inflammation may positively regulate osteoblast 
function.  
This dissertation further elucidates the role of T cells and macrophages in the 
erosion and formation processes, respectively.  In the absence of lymphocytes, bone 
erosion occurred normally, demonstrating that RANKL-expressing lymphocytes are not 
absolutely required for the bone erosion.  Preliminary studies also suggest that M2 
macrophages are potential mediators of bone formation via the expression of BMP2.  
In conclusion, this dissertation explores the ability of inflammation to act as a 
rheostat, which controls the fate of bone by modulating not only osteoclast 
differentiation, but also osteogenic signaling pathways and cellular mediators in the bone 
microenvironment.  The soluble mediators and cell types identified in this research 
highlight novel mechanisms by which inflammation may regulate osteoblast activity 
within the bone microenvironment.  Collectively, these data imply that strict control of 
inflammation may be necessary in order to create an anabolic environment that preserves 
bone architecture in diseases of inflammation-induced bone loss.     
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1
Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a progressive autoimmune polyarthritis affecting 
nearly 1% of the population worldwide.  This chronic inflammatory disease is 
characterized by joint pain and stiffness, but also cardiovascular and other systemic 
complications, resulting in increased mortality compared to healthy individuals.  RA 
morbidity is associated with autoantibody production, synovial hyperplasia, articular 
cartilage destruction, and focal bone erosion.  While the etiology of RA is unknown, the 
prevailing hypothesis suggests that environmental factors, such as smoking, trigger 
modifications in self-protein citrullination leading to a breakdown in self-tolerance, 
autoantibody production and ultimately, the clinical manifestations of RA (1).   
At the microscopic level, RA is distinguished by pathogenic alterations in the 
synovium lining the joint capsule.  In the normal joint, the synovium is a few cell layers 
thick and composed of synovial fibroblasts and macrophages.  In RA, the synovium 
undergoes significant hyperplasia as a result of the proliferation of resident synovial 
fibroblasts and the recruitment of macrophages to the synovial lining layer.  In addition, 
there is an influx of innate and adaptive immune cells, such as T cells, B cells, 
macrophages, mast cells, and neutrophils in to the subsynovium.  Production of pro-
inflammatory cytokines, chemokines, and inflammatory mediators, such as nitric oxide, 
by invading leukocytes and synovial fibroblasts perpetuates the chronic synovitis 
characteristic of RA.   
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Cellular Mediators of RA 
Due to the strong association of disease susceptibility with the shared epitope of 
the major histocompatibility complex (MHC) class II HLA-DRB1 allele, RA has 
traditionally been considered a CD4+ T cell driven disease.  Specifically, the Th1 subset 
of CD4+ T cells, which produce IL-2, lymphotoxin-α, and interferon-γ (IFN-γ), were 
considered to be the primary disease mediators.  Within the synovium, these CD4+ T 
cells are found in lymphoid aggregates and express activation markers including CD69, 
CD44, CD45RO, MHC class II molecules, as well as chemokine receptors CCR4, CCR5, 
and CXCR3, which are thought to be involved in joint trafficking (2, 3).    
CD4+ T cells have a variety of roles in the inflamed joint.  Through CD40 ligand 
expression, T cells promote B cell proliferation, antibody production, and dendritic cell 
activation (4).  T cells also activate macrophages, monocytes, and joint resident synovial 
fibroblasts to induce the production of pro-inflammatory cytokines, chemokines, and 
matrix metalloproteases (MMPs) that perpetuate the inflammatory cycle and joint 
damage.  Interestingly however, T cells isolated from the joint are hyporesponsive to T 
cell receptor activation in vitro (5, 6), suggesting that chronic cytokine exposure, but not 
antigen stimulation, may be required for the activation and effector functions of T cells in 
RA (7).  
Despite localization of T cells to the inflamed synovium and in vitro data 
demonstrating the contribution of T cells to the production of pro-inflammatory 
mediators, therapeutic targeting of T cells in RA has had variable success.  T cell-specific 
depletion agents, such as anti-CD3 and anti-CD4 antibodies, and non-specific depleting 
3
therapies, such as cyclosporine, have had limited efficacy and/or serious adverse events 
(1, 8).  In contrast, inhibition of T cell activation by blocking CTLA-4, a critical co-
stimulatory molecule on T cells, shows clinical efficacy, demonstrating a role for T cell 
activation in disease pathogenesis (9).   
The recent identification of a new subset of Th1 cells, Th17 cells, has broadened 
our understanding of the contribution of T cells to RA.  Th17 cells are CD4+ T cells most 
notable for the production of IL-17A, a potent pro-inflammatory cytokine, but also a 
multitude of other pro-inflammatory cytokines including IL-17F, IL-6, IL-21, IL-23, IL-
22, IL-26, and TNF, which activate leukocytes and joint resident cells.  Th17 and IL-17-
expressing cells have been identified in RA sera, synovial tissue, and synovial fluid (10, 
11). While the differentiation and cytokine profiles of Th17 cells differ between mice and 
humans, the role of Th17-derived IL-17 in RA pathogenesis has been demonstrated in 
animal models and RA patients. The importance of IL-17 in disease pathogenesis and as 
a therapeutic target will be discussed in the following section, Cytokines in RA.    
While the role of T cells in RA is well established, the contribution of B cells to 
disease pathogenesis is less thoroughly understood.  Due to the identification of B cell 
follicles and germinal centers in synovial tissue (12-14), it was traditionally believed that 
the primary role of B cells in RA was the production of antibodies directed against 
autoantigens.  Levels of circulating rheumatoid factor, antibodies against the Fc fragment 
of IgG, and anti-citrullinated peptide antibodies serve as diagnostic and prognostic tools 
for identification and treatment of patients; however, the significance of these 
autoantibodies to disease is unknown.  Currently, it is recognized that B cells also serve a 
4
variety of critical, antibody-independent functions including, antigen presentation via the 
B cell receptor, activation of T cells, as well as cytokine and chemokine synthesis (15, 
16).  Furthermore, the efficacy of anti-CD20 mediated B cell depletion in RA patients 
accompanied by variable alterations in autoantibody levels further highlights the critical 
contribution of antibody-dependent and independent B cell functions to disease 
pathogenesis (17, 18).  
In addition to the cells of the adaptive immune system, cells of the innate immune 
system, such as macrophages, mast cells, and neutrophils, also play vital roles in the 
pathogenesis of RA.  CD68+ macrophages are found in the synovial lining as well as the 
sublining and the number of macrophages correlates with radiographic disease 
progression and therapeutic efficacy (19).  Macrophages are responsible for phagocytosis, 
antigen presentation, pro-inflammatory cytokine production (including, but not limited to 
TNF, IL-1β, IL-6, IL-12, and IL-18), and synthesis of inflammatory factors (lipid 
mediators, reactive oxygen, and nitrogen intermediates).  Studies in animal models and 
clinical trial data support the idea that macrophages are essential to the inflammatory 
process in RA (19-22).  Despite their small numbers in the joint, mast cell activation, 
possibly through autoantibody binding to the Fc receptor ε, elicits production of 
histamine, tryptase, eicosanoids, cytokines, and chemokines that mediate acute and 
chronic inflammation in murine arthritis models (23).  Lastly, in contrast to macrophages 
and mast cells, neutrophils are a large component of the synovial fluid of RA patients, but 
not the synovial tissue.  Activated neutrophils produce cytokines, prostaglandins, 
proteases, and cytokines that contribute to synovitis and cartilage destruction (24). 
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Cytokines in RA 
As noted, infiltration of innate and adaptive immune cells into the joint is critical 
to RA pathogenesis due in large part to their production of numerous pro-inflammatory 
cytokines.  While a plethora of cytokines, including  IL-6, IL-12, IL-18, IL-21, IL-23, 
GM-CSF, M-CSF, TGF-β, and IFN-γ, have been implicated in RA, TNF, IL-1β, IL-6, 
and IL-17 are arguably the fundamental mediators of disease pathology. The critical 
contribution of these cytokines and their effector functions in RA is highlighted by the 
clinical efficacy of several biologic therapeutics, which have become the standard of care 
for RA patients.  As such, TNF, IL-1β, IL-6, and IL-17 will be discussed in detail below. 
TNF is produced by a variety of cells in the inflamed joint, most predominately 
by macrophages, but also by synovial fibroblasts and activated T cells.  The TNF receptor 
TNF-RI is expressed in most tissues, while the TNF-RII receptors are found mainly on 
cells of the immune system, highlighting the diversity of TNF-responsive cells.  Release 
of TNF stimulates the production of other equally pro-inflammatory cytokines by 
macrophages, synovial fibroblasts, and other immune cells, which perpetuates the 
inflammatory cycle of cellular activation.  TNF also promotes further leukocyte 
accumulation in the joint by inducing chemokine release (including IL-8, MCP-1, 
RANTES) in conjunction with upregulating endothelial-cell adhesion molecule 
expression (including E-selectin and VCAM-1).   Furthermore, TNF also has a broad 
array of essential roles in disease progression including, stimulating angiogenesis, 
synovial fibroblast proliferation, T cell activation, prostaglandin synthesis, and 
destruction of cartilage and bone (25, 26). 
6
The significance of TNF in RA pathogenesis has been convincingly demonstrated 
in numerous animal models of inflammatory arthritis and clinical trials.  Neutralization of 
TNF, administration of the soluble receptor, or genetic deletion of TNF prevents the 
development of rodent inflammatory arthritis (27), while overexpression of human TNF 
in mice leads to the spontaneous development of chronic, destructive polyarthritis, which 
can be prevented by anti-TNF blockade (28).  Ultimately, significant clinical research has 
proven the therapeutic efficacy of anti-TNF antibodies and a soluble TNF receptor fusion 
protein, which has revolutionized the treatment of RA patients (29-31). 
Similar to TNF, IL-1β is another pleiotropic pro-inflammatory cytokine produced 
primarily by macrophages, which is implicated in the initiation and progression of RA.  
Many of the pathologic activities of TNF are also shared by IL-1β, including the 
upregulation of cytokines, chemokines, and endothelial-cell adhesion molecules.  In 
addition to those activities, IL-1β has been proven to be essential for the production of 
prostaglandins and nitrogen oxide via induction of cyclooxygenase-2 (COX-2) and 
inducible nitrogen oxide synthase by synovial fibroblasts, monocytes, and endothelial 
cells (32, 33).  IL-1β also promotes cartilage loss by stimulating MMP production by 
synovial fibroblasts while simultaneously inhibiting collagen production by 
chondrocytes.  Furthermore, TNF and IL-1β are cross-regulated and their pro-
inflammatory actions are often synergistic creating a positive feedback loop of 
inflammatory activation. 
The importance of IL-1β in inflammatory arthritis has also been observed in vivo.  
Deficiency of IL-1β, antibody neutralization of IL-1, blockade by IL-1ra, a soluble IL-1β 
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receptor antagonist, or inhibition of various other IL-1β signaling components has been 
shown to be protective in various models of inflammatory arthritis (27, 33).  In addition, 
IL-1ra knockout mice develop spontaneous arthritis (34).  Despite the positive preclinical 
data, the clinical efficacy of soluble IL-1ra has been modest and not as successful as anti-
TNF therapeutics (35, 36).  It is currently unclear whether inhibition of IL-1β will be a 
viable therapeutic approach for the treatment of RA (37). 
TNF and IL-1 also induce expression of IL-6, a gp130 cytokine that is a potent 
mediator of the hepatic acute phase response to infection, trauma, and inflammation.  
Elevated levels of IL-6 are detected in the serum and synovial fluid of RA patients and it 
is expressed by activated macrophages, T cells, and synovial fibroblasts (38-41).  In the 
context of RA, IL-6 promotes angiogenesis, B cell maturation, antibody production, T 
cell differentiation, neutrophil trafficking, macrophage activation, synovial fibroblast 
proliferation, and cytokine production  (42, 43).  IL-6 in combination with its soluble 
receptor (sIL-6R) also induces RANKL expression by osteoblasts (44) and RA synovial 
fibroblasts, which directly promotes osteoclastogenesis in vitro (45, 46).  Lastly, in 
synergy with IL-1, IL-6 increases the expression of MMPs and ADAMTS in 
chondrocytes and synovial fibroblasts, suggesting a role for IL-6 in cartilage catabolism 
(42, 43). 
Similar to TNF and IL-1, strong preclinical data in rodent models have led to the 
development of IL-6 targeted therapeutics for RA patients.  Inflammation, bone erosion, 
and cartilage destruction are attenuated in IL-6 deficient mice (47-49) and with blockade 
of the IL-6 receptor (50, 51).  Furthermore, the protective effects of IL-6 deficiency or 
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IL-6 receptor blockade in rodent models have been attributed to reduced Th17 cell 
recruitment and IL-17 production (52-54).  A humanized monoclonal antibody targeting 
IL-6R has proven efficacious in reducing inflammation and the progression of bone 
erosions in RA patients (55).   
While the contribution of TNF, IL-1β, and IL-6 to RA pathogenesis has been 
known for decades, the recent identification and characterization of IL-17 production by 
Th17 cells has garnered growing interest in the role of IL-17 in the pathogenesis of RA.  
Like TNF and IL-1, IL-17 stimulates the production of COX-2, MMPs, complement, 
chemokines and cytokines, particularly IL-6 and IL-8, by synovial fibroblasts (56-58).  
IL-17-induced expression of angiogenic factors, such as vascular endothelial growth 
factor, promotes angiogenesis as well as the recruitment of leukocytes into the joint (59).  
Interestingly, IL-17 can also induce TNF and IL-1 expression and act synergistically with 
these cytokines to augment the expression of pro-inflammatory cytokines and mediators 
by leukocytes and synovial fibroblasts.   
Deficiency or neutralization of IL-17 in animal models has confirmed the 
contribution of IL-17 to inflammatory arthritis.  Loss of IL-17 activity reduces 
inflammation and joint destruction in collagen-induced and antigen-induced arthritis (60-
62).  Of note, inhibition of IL-17 activity during T cell dependent flares of antigen-
induced arthritis reduces inflammation and bone erosion, suggesting IL-17 is a key 
component of chronic disease.  Early clinical trial data have also demonstrated a decrease 
in disease activity following IL-17 neutralization, spurring continued interested in IL-17 
as a potential therapeutic target (63). 
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Pathogenesis of Focal Bone Loss in RA – Role of the Osteoclast 
Chemokine and cytokine-mediated infiltration and activation of inflammatory 
cells in the synovium leads to synovial hyperplasia and the formation of a specialized 
tissue called pannus.  A derivative of the synovial membrane, pannus attaches to and 
covers that surface of articular cartilage and bone.  Cells within the pannus express 
factors responsible for the destruction of bone and as a result, focal bone erosions form at 
the pannus-bone interface. 
 Focal bone loss in RA is mediated by bone resorbing osteoclasts.  Large, 
multinucleated osteoclasts are identified at the pannus-bone interface in murine 
inflammatory arthritis and human RA by their expression of the osteoclast markers 
tartrate-resistant acid phosphatase (TRAP), cathepsin K, and calcitonin receptor (64-68).  
Mice lacking osteoclasts due to a deficiency of critical osteoclast differentiation factors, 
receptor activator of nuclear factor (NF)-κB ligand (RANKL) or c-fos, were protected 
from focal bone erosion in the serum transfer and hTNFtg murine models of 
inflammatory arthritis, respectively (69, 70).  Furthermore, inhibition of osteoclast 
differentiation and activity via treatment with high dose bisphosphonates, anti-RANKL 
antibody, or osteoprotegerin (OPG), an anti-osteoclastogenic factor, also suppresses 
osteoclast-mediated bone loss in murine inflammatory arthritis without affecting 
inflammation (71-74).  Similarly, anti-RANKL antibody inhibits radiographic 
progression of bone erosion and structural damage in RA patients (75), demonstrating the 
significance of RANKL in the erosive process.   
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 In physiological bone remodeling, osteoclast formation from hematopoietic 
precursors requires the expression of RANKL and M-CSF, primarily by bone-lining cells 
of the osteoblast lineage.  Osteoclastogenesis is tightly regulated by the expression of 
OPG, a decoy receptor that inhibits the binding of RANKL to its receptor RANK on 
osteoclast precursor cells.  In the inflamed RA synovium, RANKL is expressed by 
activated T cells, B cells, and especially by fibroblast-like cells at the pannus-bone 
interface (66, 76-78).   In contrast, OPG expression is decreased in patients with active 
disease and minimal OPG is observed at the pannus-bone erosion sites (77, 79), leading 
to an imbalance of RANKL and OPG expression that favors osteoclastogenesis.  
Stimulation of synovial fibroblasts with the pro-inflammatory cytokines TNF, IL-1β, IL-
6, and IL-17, induces soluble and membrane-bound RANKL expression, which directly 
stimulates osteoclastogenesis in vitro (76, 80).  Expression of OPG by synovial 
fibroblasts is also altered by pro- and anti- inflammatory cytokines (81, 82).     
Activated T cells in the joint expressing RANKL directly promote the 
differentiation of osteoclast precursor cells in vitro (83-85).  However, CD4+ Th1 and 
Th2 cells, which are activated by the inflammatory process in RA, also synthesize IFN-γ 
and IL-4 respectively, potent anti-osteoclastogenic cytokines (86), highlighting the 
paradoxical contributions of Th1 and Th2 cells to osteoclastogenesis.  With the recent 
identification of the Th17 subset, T cell-mediated osteoclastogenesis is now largely 
believed to be mediated by the Th17 subset of CD4+ T cells (87).  Despite the expression 
of membrane bound RANKL, Th17 cells do not directly promote osteoclastogenesis in 
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vitro. Instead, expression of IL-17 by Th17 cells promotes RANKL expression on 
osteoblasts and synovial fibroblasts (86), which contributes to osteoclastogenesis.  
 In addition to RANKL, the pro-inflammatory cytokines in the inflamed synovium 
also influence osteoclast differentiation and activation.  TNF production by synovial 
fibroblasts, activated macrophages, and T cells stimulates CD11b+ osteoclast precursor 
cell recruitment to the joint and upregulates the expression of RANK on these cells (88-
90). In combination with M-CSF, TNF can directly promote osteoclast differentiation 
(91); TNF also synergizes with RANKL to promote robust osteoclastogenesis (92, 93).  
Similarly, IL-1 can also directly stimulate osteoclast formation, survival, and function 
(91, 94). 
 
Pathogenesis of Focal Bone Loss in RA – Role of the Osteoblast 
 In normal physiological bone remodeling, osteoclastic bone resorption is tightly 
coupled with osteoblast-mediated bone formation in order to maintain bone mass.  In RA, 
however, while osteoclasts are present at the pannus-bone interface at erosion sites, 
osteoblasts, or bone forming cells, are scarce.   Early committed osteoblast progenitors 
expressing PTH receptor (PTHR) are present on bone surfaces adjacent to erosion sites in 
RA (64).  PTHR-expressing bone lining cells are also found on endosteal bone surfaces 
of hTNFtg mice, a murine model of arthritis, at sites where pannus tissue has eroded 
through the cortical bone (95).  Immature osteoblasts expressing Runx2 are found at the 
pannus-bone interface in the serum transfer (STA) model of inflammatory arthritis (96).  
Nevertheless, a lack of osteoblasts expressing alkaline phosphatase (AlkP), a marker of 
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mid-stage osteoblast differentiation, and osteocalcin, a marker of mature, bone forming 
osteoblasts (96-98), at erosion sites suggests that osteoblast differentiation is impaired at 
these sites.   
Furthermore, osteoblast-mediated bone formation at erosion sites is compromised 
during the inflammatory phase of arthritis.  Unmineralized bone matrix, or osteoid, was 
produced by osteocalcin-expressing osteoblasts in murine arthritis models (95, 97) and 
RA patients (99).  Using dynamic histomorphometry in the STA model, Walsh et al. 
showed a reduction in the percentage of bone surfaces with osteoblast activity 
(mineralized surface/bone surface, MS/BS) and in the bone formation rate (BFR) at 
pannus-bone interfaces compared with bone surfaces without inflammation (96).  This 
study demonstrated an impairment of osteoblast-mediated bone matrix synthesis and 
maturation in the setting of inflammation. 
While the mechanisms responsible for the inhibition of osteoblast function in RA 
have not been fully elucidated, pro-inflammatory cytokines have been shown to inhibit 
the differentiation and function of osteoblasts in vitro.  TNF downregulates the 
expression of numerous genes in osteoblasts including, alkaline phosphatase, osteocalcin, 
type I collagen, insulin-like growth factor-1, vitamin D receptor, PTHR, platelet-derived 
growth factor, and N-cadherin (100), which are critical for osteoblast maturation and 
function.  Simultaneously, TNF upregulates iNOS, IL-6, MMPs, and M-CSF, 
contributing to matrix catabolism (100).  RANKL expression by osteoblast-lineage cells 
is also upregulated by TNF, promoting osteoclastogenesis (101). 
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TNF directly blocks the differentiation of osteoblast mesenchymal precursors in 
vitro by suppressing the expression of Runx2 and osterix, transcription factors 
responsible for osteoblast-lineage commitment and gene expression.  TNF decreases the 
stability of Runx2 mRNA and targets Runx2 protein for proteasomal degradation by the 
E3 ubiquitin ligases, Smurf1 and Smurf2 (102, 103).  The expression of osterix is 
inhibited via TNF-mediated activation of MEK1/ERK1 and upregulation of Prx1, a 
homeobox protein which is critical for skeletal patterning and limb bub formation (104, 
105).  As a result, the expression of Runx2 target genes, alkaline phosphatase, type I 
collagen (106, 107), and osteocalcin (108-110) is suppressed, leading to impaired bone 
matrix deposition, mineralization, and nodule formation (109, 111).     
IL-1 and IL-17 also have various inhibitory effects on osteoblasts, although the 
mechanisms have not been fully elucidated.  Similar to TNF, IL-1 elicits inhibitory 
responses in differentiating osteoblasts, including blockade of osteoblast differentiation, 
stimulation of RANKL expression, and suppression of matrix synthesis (112, 113).  The 
effects of IL-17 on osteoblast differentiation and bone matrix synthesis have not been 
demonstrated.  As previously noted, IL-17 upregulates membrane-bound RANKL on 
osteoblasts (86, 114) and has been implicated in periodontal bone loss (115), osteoporosis 
(116), and bone loss in murine inflammatory arthritis (60, 61, 117-119).   
Taken together, these data demonstrate that pro-inflammatory cytokines alter the 
osteoblast.  Inflammation in the bone microenvironment drives bone loss not only by 
enhancing osteoclastogenesis, but also by inhibiting osteoblast maturation and function.  
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As such, the lack of osteoblast-mediated erosion repair is a key contributing factor to 
inflammation-induced bone loss. 
 
Clinical Observations of Erosion Repair 
 With an increase in osteoclast activity and an impairment of osteoblast activity, 
there is a net loss of bone at focal articular erosion sites in RA.  Current clinical therapies, 
particularly biologic agents and to a lesser degree methotrexate, have been shown to stop 
the progression of erosions by radiography, MRI, ultrasonography, and microcomputed 
tomography (microCT) (120, 121).  It is recognized that the erosive process in RA is 
linked to inflammation.  As such, clinical markers of inflammation, including number of 
swollen and tender joints, erythrocyte sedimentation rate, and C-reactive protein levels, 
are predictive of structural damage (122).   MRI studies have demonstrated that synovial 
membrane volume is a predictor of erosion and the degree of synovitis correlates with 
joint destruction (123, 124).  Furthermore, bone damage did not occur in the absence of 
inflammation (123).   
 Repair of these erosions and restoration of the bone architecture in RA patients is 
uncommon.  Erosion repair occurs in approximately 10% of patients regardless of the 
treatment modality (125-134).  Interestingly, repair is most frequently observed in 
patients in remission or with well-controlled clinical disease (130, 131).  Although 
erosion repair occasionally occurs in the presence of persistent inflammation (135, 136), 
residual subclinical disease is typically associated with progression of bone destruction 
(137-139).  Taken together, these observations imply that inflammation plays a critical 
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role not only in osteoclast-mediated bone erosion, but also in the inhibition of osteoblast-
mediated erosion repair.   
  
Osteoblast Differentiation Pathways 
Osteoblasts originate from mesenchymal stem cell progenitors that arise from 
several sources, including the bone marrow, periosteal lining, circulation, and 
endothelium.  Under normal physiological conditions, regulation of osteoblast 
differentiation and maturation involves signaling via two essential pathways, the β-
catenin/canonical wingless (Wnt) pathway and the bone morphogenetic protein (BMP) 
pathway.   
 
Wnt Signaling Pathway 
 Wnt signaling is fundamental to embryogenesis, organogenesis, and 
tumorigenesis.  Strict control of cell proliferation, differentiation, activity, and apoptosis 
by Wnt signaling is required for the regulation of these morphogenetic events.  Notably, 
embryonic bone development, adult skeletal maintenance, and fracture repair are 
controlled by the canonical Wnt signaling pathway, the dominant pathway in bone 
development.        
Activation of the canonical Wnt signaling cascade is mediated by cysteine-rich 
Wnt ligands, which bind to a family of 7-transmembrane domain-spanning frizzled (Fzd) 
receptors (Figure 1.1).  In the absence of Wnt ligands, glycogen synthase kinase-3β 
(GSK-3β) forms a complex with the scaffolding proteins adenomatous polyposis coli 
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Figure 1.1: Canonical β-catenin Wnt signaling.  In the absence of receptor ligation, β-
catenin is bound in a scaffolding complex of APC and axin, which allows GSK-3β to 
phosphorylate β-catenin, targeting it for proteasomal degradation.  Binding of Wnt 
ligands, leads to the recruitment of axin, Frat-1, and Dsh to the cell membrane, which 
inhibits the formation of the scaffolding complex and the activity of GSK-3β.  As a 
result, β-catenin accumulates I nthe cytoplasm, translocates to the nucleus, and binds 
TCF/LEF to alter osteoblast gene transcription.  Wnt signaling is regulated by the sFRP 
family of Wnt antagonists, which bind Wnt ligands and inhibit their interaction with the 
Fzd and LRP5/6 receptors and by sclerostin and the DKK family, which bind LRP5/6.  
See full text for details.  Adapted from Krishnan et al. (140) with permission.   
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(APC), casein kinase (CK)-1, and axin.  Formation of this complex leads to GSK-3β and 
CK-1-mediated phosphorylation of conserved serine and threonine residues in the N-
terminus of β-catenin. Phosphorylated β-catenin is subsequently targeted for proteasomal 
degradation by E3 ubiquitin ligases.  Binding of a Wnt ligand to a Fzd receptor and the 
co-receptors, low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6), leads to 
the recruitment of phosphorylated Disheveled (Dvl) and Frat-1 to the intracellular 
domains of Fzd and LRP5/6.  Subsequent phosphorylation of LRP5/6 by CK-1 promotes 
the relocation of axin to LRP5/6, which disrupts the scaffolding complex and inactivates 
GSK-3β.  As a result, β-catenin accumulates in the cytoplasm and translocates to the 
nucleus, where it displaces transcriptional repressors and interacts with the transcription 
factors, T cell factor (TCF) and lymphoid enhancer binding factor (LEF), to modulate 
osteoblast gene transcription. 
Wnt signaling drives the expression of genes critical for the proliferation, 
differentiation, maturation, and activity of osteoblast-lineage cells (140).  Mesenchymal 
cell commitment to the osteoblast lineage is dependent on Wnt-mediated expression of 
Runx2, a master transcription factor that promotes expression of mature osteogenic genes 
(141).  These osteoprogenitors undergo a period of proliferation and begin to express the 
pro-osteoclastogenic factor, RANKL.  Subsequently, these pre-osteoblasts express 
alkaline phosphatase and downregulate RANKL to promote bone matrix deposition.  
Mature osteoblasts express osteocalcin, a critical mineralization protein, while also 
expressing osteoprotegerin (OPG), a negative regulator of osteoclast formation (142).   
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The significance of Wnt signaling in bone formation was initially demonstrated in 
humans exhibiting loss or gain of function mutations in LRP5.   One loss of function 
mutation of LRP5 leads to osteoporosis-pseudoglioma syndrome, characterized by low 
bone mineral density (143).  Dominant heterozygous missense mutations of LRP5 reduce 
the affinity of DKK1 for LRP5, leading to autosomal dominant high bone mass (144-
147).  In mice, inactivation of the LRP5 gene or overexpression of the human LRP5 
G171V gain of function gene leads to similar phenotypes, attributable to alterations in 
osteoblast proliferation, differentiation, and apoptosis (148, 149).  Furthermore, 
conditional knockout of β-catenin in mesenchymal osteoprogenitor cells promotes 
chondrocyte differentiation while blocking osteoblast differentiation, expression of 
mature osteoblast markers, and mineralized bone formation (150-153).   
The positive effects of Wnt signaling on osteoblast differentiation and function 
are mediated by canonical Wnt ligands.  While the Wnt ligand family is composed of 19 
members, only a few Wnts, including Wnt3a, Wnt 7b, and Wnt10b, have been 
demonstrated to contribute to bone formation.  Wnt3a is the most commonly described 
Wnt that stimulates differentiation and function of osteoblasts in vitro, which has been 
shown to regulate osteoblast proliferation, maturation, and matrix deposition in a β-
catenin dependent manner.  Another canonical Wnt, Wnt7b, is upregulated during 
osteoblast differentiation.  Expression of Wnt10b peaks prior to the expression of 
osteocalcin (154-156) and DKK2 (157), a Wnt antagonist, implicating Wnt7b in the 
regulation of osteoblast maturation.  As such, siRNA silencing of Wnt7b in osteoblast 
precursors blocks differentiation (158).  Osteoblasts also express Wnt10b.  Deletion of 
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Wnt10b reduces bone volume, while overexpression increases bone volume due to 
greater osteoblast-mediated bone formation (159, 160).  The anabolic effects of Wnt10b 
have been linked to the regulation of age dependent bone loss (161) and the PTH-
mediated anabolic effects of T cells (162).     
Wnt signaling antagonists are also essential for regulating normal bone mass.  The 
most thoroughly studied antagonists are the secreted frizzled-related proteins (sFRP1-5), 
the Dickkopf family of secreted antagonists (DKK1-4), and sclerostin.  sFRP family 
members bind directly to Wnt proteins through a cysteine-rich domain homologous to the 
Fzd receptors and prevent interactions with Fzd and LRP5/6.  In contrast, sclerostin and 
the DKK antagonists bind LRP5/6 and block downstream Wnt receptor signaling (163, 
164).  DKKs form a complex with LRP6 and Kremen, a transmembrane receptor, which 
stimulates the internalization and degradation of LRP6 (163). Regulation of Wnt 
signaling and bone formation is also mediated by Wnt inhibitory factor-1 (WIF-1), an 
antagonist similar in action to the sFRPs.  Less is known about WIF-1 and its actions. 
Direct roles for the sFRP family in regulating bone formation have been 
demonstrated by studies with transgenic mice.  Deletion of sFRP1 leads to a high bone 
mass phenotype characterized by an increase in trabecular bone volume and mineral 
apposition rate, demonstrating enhanced osteoblast activity (165).  Mechanistically, 
sFRP1 acts as a negative regulator of osteoblast and osteocyte apoptosis in vivo and 
stimulates osteoblast differentiation in vitro (165, 166).  In contrast, overexpression of 
sFRP1 reduced trabecular bone volume and mineral apposition rate by decreasing target 
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gene expression as well as osteoblast maturation and function (167). sFRP1 also binds 
RANKL and may serve as a negative regulator of osteoclastogenesis (165, 168). 
The function of the other sFRP family members in bone formation have not been 
fully addressed.  sFRP2 expression in vitro stimulates osteoblast apoptosis and inhibits 
osteoblast differentiation and mineralized nodule formation (169, 170), but an in vivo 
phenotype has not be described.  Contrary to the other sFRP family members, sFRP3 
stimulates osteoblast differentiation in vitro and does not inhibit Wnt3a-mediated 
upregulation of alkaline phosphatase (171). However, deletion of sFRP3 in vivo increases 
cortical bone thickness and long bone mechanical properties (172).  These conflicting 
observations suggest that there is a disconnect between in vitro and in vivo actions of 
sFRP3, possibly due to sFRP3-mediated regulation of non-canonical Wnt signaling 
pathways (171).  sFRP4 deficiency promotes trabecular bone formation and 
overexpression reduces bone mass (173, 174).  Interestingly, sFRP4 deletion decreases 
cortical thickness in a DKK1 independent manner, suggesting that sFRP4 may regulate 
cortical bone formation via non-canonical Wnt signaling pathways (175-177).  A role for 
sFRP5 in bone formation has not been reported.   
DKK1 is also a critical regulator of bone formation.  While DKK1deficient mice 
are embryonically lethal, DKK1 heterozygous mice exhibit enhanced bone formation as a 
result of an increase in the number and activity of osteoblasts (178).  In contrast, DKK1 
overexpression leads to decreased osteoblast differentiation and nodule formation in vitro 
and reduced bone mass and mineral deposition in vivo (178, 179).  DKK1 also regulates 
postnatal growth and adult fracture healing (180).  In contrast to DKK1 deficiency, 
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DKK2 deficient mice are osteopenic and have poorly mineralized bone matrix owing to 
decreased late stage osteoblast differentiation and reduced expression of osteocalcin and 
osteopontin (157).  Loss of DKK2 increases osteoclast number and the expression of 
RANKL and M-CSF mRNA by osteoblasts (157).  Finally, DKK3 inhibits osteoblast 
proliferation, AlkP production, and collagen I mRNA expression by osteoblasts leading 
to reduced heterotopic ossification (181).  The contribution of DKK4 to bone formation 
has not been reported.   
Mutations in sclerostin, an osteocyte-specific Wnt antagonist, are associated with 
sclerosteosis and Van Buchem disease, autosomal recessive diseases of high bone mass 
in humans (182, 183).  While originally believed to be an antagonist of the bone 
morphogenetic protein (BMP) pathway, sclerostin inhibits Wnt-mediated osteoblast 
proliferation, differentiation, matrix deposition, and apoptosis (183, 184).  Alterations in 
sclerostin expression modulate bone formation with deletion of sclerostin increasing 
trabecular and cortical bone volume (185) and overexpression of human sclerostin 
decreasing bone volume (183).  Under normal physiological conditions, sclerostin 
expression is modulated by mechanical loading (186) and PTH treatment (187).  
Neutralization of sclerostin by monoclonal antibody is currently being evaluated for the 
treatment of osteoporosis and fracture healing.        
In addition to modulating osteoblast activity, Wnt signaling also indirectly alters 
the differentiation and activity of osteoclasts.  Loss or gain of function of β-catenin in 
osteoblasts results in low and high bone mass, respectively.  Surprisingly, these 
phenotypes are a result of modified osteoclastic resorption, not osteoblast activity (188, 
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189).  Further analyses have shown that RANKL and OPG expression by osteoblasts is 
regulated by Wnt-responsive TCF and LEF binding sites in the promoters of these genes 
(188, 190).  As a result, β-catenin stabilization in osteoblasts inhibits osteoclast 
differentiation by increasing OPG and decreasing RANKL expression, while β-catenin 
destabilization decreases OPG and increases RANKL to promote osteoclast 
differentiation (188-190). 
While the role of the Wnt pathway in osteoblasts is well known, the function of 
Wnt signaling in the osteocyte is largely unknown.  Osteocytes sense changes in 
mechanical load and translate this information into signals regulating bone resorption and 
formation.  Mechanical loading in vivo upregulates the expression of Wnt proteins, 
receptors, and antagonists (191), while fluid flow induces β-catenin accumulation in the 
osteocytic cell line, MLO-Y4 (192).  Osteocytic deletion of β-catenin has been correlated 
with an increase in osteoclastic resorption (193).  In addition, it has been suggested that 
osteocytes regulate bone formation and homeostasis through the expression of DKK1 
(157), sclerostin (185), and RANKL (194, 195).  These data suggest that Wnt signaling in 
osteocytes is capable of regulating bone resorption and formation, but the mechanism by 
which this occurs has not been clearly elucidated.   
In addition to canonical β-catenin mediated Wnt signaling, Wnt ligands can also 
activate non-canonical signaling mechanisms in osteoblasts, including the planar cell 
polarity pathway and the Wnt/Ca+ pathway (196).  In the planar cell polarity pathway, 
non-classical cadherins interact with the Fzd receptors, which activate Disheveled and the 
downstream RhoA-like GTPases and JNK kinases.  These signaling events result in 
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cytoskeletal rearrangements and alterations in gene transcription.  Activation of 
heterotrimeric G proteins and phospholipase C by the Fzd receptors in the Wnt/Ca+ 
signaling pathway triggers intracellular calcium release and NFAT-mediated gene 
expression.  In addition, recent studies have suggested that LRP5 controls bone formation 
in a β-catenin-independent manner by regulating gut-derived serotonin synthesis and the 
proliferation of osteoblasts (197).  While these non-canonical signaling pathways have 
been demonstrated to participate in osteoblast differentiation and activity, these pathways 
are not well understood and are not yet considered primary mediators of bone formation. 
 
Bone morphogenetic protein (BMP) Signaling Pathway 
BMP signaling is fundamental to embryonic development including gastrulation, 
neurogenesis, organogenesis, hematopoiesis, and somite formation.  BMPs are 
constituents of the over 40 member transforming growth factor-β (TGF-β) superfamily, 
which also includes the TGF-βs, nodal, and activin.  The osteogenic capacity of BMPs 
was discovered in 1965 by Marshall Urist, who isolated factors from bone that induced 
ectopic bone formation (198). 
BMP signaling is transduced through the heterodimerization of serine/threonine 
kinase type I and II receptors (Figure 1.2) (199).  Type I receptors include: activin 
receptor-like kinase 2 (ALK2) which binds BMPs and activin, BMP receptor IA 
(BMPRIA) which binds only BMPs, and BMPRIB which binds BMPs and anti-mullerian 
hormone.  Type II receptors include: BMP receptor II (BMPRII) which binds only BMPs, 
activin type II receptor (ActRII) and ActRIIB which bind BMPs and activin.  These 
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Figure 1.2: Canonical Smad-mediated BMP signaling.  BMP ligands induce 
heterodimerization of serine/threonine kinase type I and II receptors, leading to the 
transphosphorylation of the type I receptor by the constitutively phosphorylated type II 
receptor.  The activate type I receptor phosphorylates R-Smads 1, 5, and 8, which forms a 
complex with co-Smad4.  The R-Smad/co-Smad complex subsequently translocates to 
the nucleus to mediate BMP-induced osteogenic gene transcription.  BMP3 antagonizes 
BMP signaling by binding ActRIIb and inhibiting receptor dimerization.  See full text for 
details.  Adapted from ten Dijke et al. et al. (200) with permission.   
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constitutively phosphorylated type II receptors transphosphorylate type I receptors at 
conserved glycine/serine residue-rich domains.  Activated type I receptors propagate 
intracellular signaling by recruiting and phosphorylating specific mothers against 
decapentaplegic (Smad) signaling proteins, Smads 1, 5, and 8 (200).  Initially, the type I 
receptor phosphorylates receptor-Smads (R-Smads) 1, 5, 8, which are specific to the 
BMP signaling pathway. BMP signaling can be regulated by inhibitory Smads (I-Smads) 
6 and 7, which compete with the R-Smads for type I receptor binding and promote 
ubiquitin-mediated receptor degradation.  Under non-inhibitory conditions, 
phosphorylation releases R-Smad from the receptor and allows it to bind common 
mediator Smad4 (Co-Smad4).    The R-Smad/Smad4 complex subsequently translocates 
to the nucleus to mediate target gene transcription.   
The DNA binding domain in the amino-terminal of R-Smad/Smad4 mediates the 
binding of the Smad complex to Smad-binding elements (SBEs) in the promoter of BMP 
responsive genes.  Transcriptional co-activators and repressors associate with the Smad 
complex and mediate the expression of the target genes collagen, alkaline phosphatase, 
osteocalcin, osteopontin, and bone sialoprotein (201).  Importantly, BMP signaling 
induces the expression of critical transcription factors including, Osterix, Msx2, Dlx3, 
Dlx5, and C/EBPβ, which directly regulate the commitment and differentiation of 
mesenchymal progenitors to the osteoblast lineage (199, 202).  In addition to directly 
inducing osteoblast differentiation, BMP-induced Runx2 also complexes with activated 
Smads and mediates the transcription of osteoblast target genes via Runx2 or Smad 
promoter elements (202).  BMP signaling also indirectly promotes osteoblast 
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differentiation by inhibiting myogenesis, adipogenesis, and neurogenesis, through the 
activation of the Id proteins, dominant negative inhibitors basic helix–loop–helix 
transcription factors (203). 
In addition to Smad-mediated gene regulation, BMPs also activate non-canonical 
Smad-independent pathways.  Receptor dimerization activates PLC as well as the 
mitogen activated protein kinases (MAPK), ERK1/2, JNK-1, JNK-2/3, and p38. MAPK 
activation can act independently or cooperatively with Smads to promote gene 
transcription, osteoblast differentiation, and skeletal development (204).  
Bone anabolic BMP signaling is mediated by a family of over 20 phylogenetically 
conserved members.  These BMPs are secreted as large precursor proteins with an amino-
terminal signal sequence and a pro-domain.  After disulfide bond formation, homo- and 
hetero-BMP dimers are secreted and cleaved into mature peptides, containing seven 
highly conserved cysteines.  BMPs 1-7 have been identified in skeletal tissue (205), with 
varying degrees of expression in osteoblast cell lines (206).  BMP2 and 4 are widely used 
to promote osteogenesis in vitro, but BMP5, 6, and 7 also have osteogenic capacity.    
Specific deletion of BMP4 or BMP7 in limb progenitors does not alter skeletogenesis or 
fracture healing (207, 208).  In contrast, BMP2 is required for fracture repair, but not 
physiological bone formation (209).  Deletion of BMP2 alters the expression of BMP4 
and BMP7 (209) and the combined loss of BMP2 and BMP4 led to a severe defect in late 
stages of osteogenesis (210).  Together, these observations suggest BMP expression is 
cooperatively regulated and as a result, there is complex pattern of functional redundancy 
in BMP expression at specific stages of bone formation. 
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As indicated, the importance of the BMP pathway in bone formation is 
demonstrated by numerous naturally occurring mutations of BMPs and BMP receptors in 
humans.  Ectopic bone formation characteristic of fibrodysplasia ossification progressiva 
(FOP) is a result of mutations in ALK2 (211).   The pathogenesis of various types of 
brachydactyly is associated with BMPRIB, Noggin, GDF5, and BMP2 (212-215).   
Similarly, in genetically manipulated mouse models, targeted deletion of BMP 
receptors revealed the significant, yet complex nature of BMP signaling mechanisms.  
Osteoblast-specific disruption of BMPRIA reduces bone mass early in development 
(216); however, there is an age-dependent increase in bone mass (217, 218).  
Surprisingly, osteoblast activity is decreased in BMPR1A deficient mice due to the 
overexpression of DKK1 and sclerostin, with increased bone volume resulting from 
reduced RANKL-mediated osteoclastogenesis (217, 219, 220).  In contrast, 
overexpression of dominant negative BMPRIB in osteoblasts decreases bone mass due to 
a blockade of BMP2 signaling and inhibition of osteoblast differentiation (221).    
In addition to the type I receptors, the type II receptors also variably contribute to 
bone formation.  BMPRII is not required for limb skeletogenesis or endochondral 
ossification (222).  ActRII and ActRIIB are expressed by osteoblasts in endochondral 
ossification and intramembranous bone formation during fracture healing (223).  
Interestingly, mice globally deficient in ActRIIB exhibit abnormal axial skeletal 
patterning, correlating with defects in chondrogenesis and mineralization (224, 225), but 
no changes in limb development (222, 225).  Global deletion of ActRII also does not alter 
endochondral ossification or limb development (201, 222, 225).  Together, these data 
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suggest that there is a functional redundancy in the actions of the type II receptors for 
bone formation in the limb.  Further supporting this idea, BMPRII and ActRIIB are 
functionally redundant in BMP-2 induced osteoblast differentiation in vitro (226).      
Strict regulation of BMP signaling is maintained by numerous extracellular BMP 
antagonists, such as noggin, gremlin, follistatin, twisted gastrulation (Tsg), BMP3, 
chordin, DAN, PRDC, and cerberus.  However, little is known about the contribution of 
some of these antagonists to bone formation; therefore, only the established roles of 
noggin, gremlin, follistatin, Tsg, and BMP3 in regulating osteoblast-mediated bone 
formation will be addressed.   
Noggin binds BMP2, 4, 5, 6, and 7 with varying affinity and inhibits interaction 
with the type I and II receptors (227).  Because noggin inhibits osteoblast differentiation 
and activity, it is widely used to inhibit BMP-induced signaling in vitro (228, 229).  
While noggin null mice die in utero, overexpression of noggin decreases bone volume, 
bone formation rate, and intra-membranous ossification in vivo, leading to spontaneous 
fractures (230, 231).   
The BMP antagonist gremlin is upregulated by BMP2 in differentiating 
osteoblasts and blocks BMP2-induced collagen synthesis and alkaline phosphatase 
activity, leading to an inhibition of osteoblast differentiation in vitro (232).  As a result, 
overexpression of gremlin induces osteoblast apoptosis, impairs osteoblast-mediated 
bone formation, and decrease trabecular bone volume (233).  To further support 
gremlin’s role in skeletogenesis, deletion of gremlin results in limb patterning 
abnormalities (234, 235).   
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By antagonizing the activity of BMP4 and activin A, follistatin regulates 
endochondral ossification and as such, neonatal follistatin null mice exhibit skeletal 
defects (236, 237).  Furthermore, follistatin is expressed early in osteoblast maturation 
and downregulation of follistatin is required for the conversion of cartilage to bone (237-
239).   
Tsg, another BMP antagonist, binds BMP2 and 4 directly or in complex with 
chordin; however, Tsg can also act as a BMP agonist under specific condition (204).  In 
vitro, Tsg inhibits the differentiation, mineralization, and osteogenic gene expression in 
ST-2 and MC3T3 cells (240, 241).  In contrast, homozygous Tsg null mutants have a 
transient reduction in trabecular bone volume, but adult skeletal maintenance is not 
altered, demonstrating the complex activity of Tsg to regulate bone formation (242).      
  Of particular interest to this dissertation is the BMP receptor antagonist, BMP3.  
BMP3 is expressed by differentiating osteoblasts and osteocytes (243) and is upregulated 
during distraction osteogenesis (244), fracture healing (245), and osteophyte formation 
(246).  BMP3 binds to the BMP type II receptor, ActRIIB (243, 247, 248), and 
antagonizes BMP2 or 4-induced osteoblast proliferation and differentiation by decreasing 
phosphorylation of Smad 1, 5, and 8 (243, 249, 250).    siRNA knockdown of BMP3 
promotes bone marrow stromal cell proliferation and osteogenic differentiation.  As a 
result, deficiency of BMP3 in vivo increases femoral bone density and trabecular bone 
volume (243, 249).  In contrast,  overexpression of BMP3 leads to the development of 
multiple, spontaneous rib fractures as a result of thinner cortical bone and decreased 
mineralization (224).  This phenotype is similar to that of ActRIIB receptor knockout 
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mice (224), demonstrating that BMP3 acts as a negative regulator of osteoblast-mediated 
bone formation via the ActRIIB receptor.  
 In addition to regulating osteoblast differentiation and activity, BMP signaling 
also directly and indirectly regulates osteoclast activity.  As differentiating osteoblasts 
produce RANKL and OPG, BMP-induced osteoblast differentiation indirectly contributes 
to osteoclastogenesis.  BMP2 regulates the expression of RANKL in osteoblast and 
osteoclast co-cultures (229).  As such, overexpression of noggin (251) or osteoblast-
specific deletion of BMPRIA (217) increases bone mass by decreasing the RANKL/OPG 
ratio and decreasing osteoclast number.  Similarly, overexpression of BMP4 (251) and 
deletion of Tsg (252) increases osteoclastogenesis in vivo.   
Osteoclasts also express BMPRIA and Smad signaling molecules (253).  
Therefore, in the absence of osteoblasts, BMP2 dose dependently induces differentiation 
and bone resorption by osteoclasts in vitro, which is inhibited by BMP antagonists (253, 
254).  Interestingly, deletion of BMPRIA in cathepsin K-expressing osteoclasts resulted 
in increased osteoblast-mediated bone formation, suggesting that BMP signaling may act 
as a coupling mechanism for osteoblasts and osteoclasts (218).  
Recent reports also suggest that osteocytes may contribute to BMP-induced bone 
formation.  Osteocytes in the developing osteophyte express BMP3, 5, 6, and 7 (246), 
while in fracture healing these BMPs as well as BMP2, 4, and 8 are found (255).  In 
addition, osteocytes in the fracture callus also express BMPRIA, IB, and II and 
phosphorylated Smad1/5/8, suggesting BMP signaling is activated in osteocytes (255).  
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Lastly, the expression of these BMP signaling components may be mediated alteration in 
by mechanical loading of the osteocyte (256). 
 
Wnt and BMP Signaling Pathways in Pathologic Bone Loss 
The notion that alteration of bone anabolic signaling pathways could account for 
inhibition of bone formation in diseases of pathologic bone loss originated from research 
in multiple myeloma (MM), a plasma cell malignancy.  Numerous studies have 
documented the contribution of abnormal Wnt signaling to impaired osteolytic bone 
lesion repair in MM.  Elevated DKK1 and sFRP2 expression in the sera and bone marrow 
of MM patients correlated with the presence of osteolytic bone lesions (169, 257), while 
sclerostin was detected in human myeloma cell lines and plasma cells from MM patients 
(258).  Culture media from MM cells inhibited canonical Wnt signaling and osteoblast 
differentiation, while depletion of sFRP2 from the culture media restored osteoblast 
differentiation (169, 259).  Furthermore, anti-DKK1 antibody treatment in vivo 
stimulated bone formation and repair of MM bone lesions by increasing osteoblast 
differentiation (260-262).  These data suggest that anabolic Wnt signaling can be 
downregulated in diseases of bone loss and promotion of Wnt signaling can stimulate 
osteoblast-mediated bone formation. 
In contrast to MM, the contribution of Wnt antagonist upregulation to impaired 
focal bone erosion repair in RA has not been fully explored.  Serum DKK1 levels 
correlate with radiographic progression of bone erosions in RA patients (263, 264) and 
are downregulated with anti-TNF therapy (265).  Synovial fibroblasts from RA patients 
32
express sFRP1, 3, and 4 (266, 267) and DKK1 (265), but the mechanisms regulating 
expression are unknown.  Canonical Wnt ligands Wnt7b and Wnt10b and the non-
canonical Wnt antagonist Wnt5a, which has been shown to regulate RANKL and MMP 
production, are present in RA synovium (268, 269).  Furthermore, TNF upregulates the 
expression of sclerostin in mature human osteoblasts (270).  Currently, little else is 
known about the contribution of Wnt agonists and antagonists to the inhibition of bone 
formation in RA patients. 
In the murine serum transfer arthritis (STA) model, sFRP1 and sFRP2 are 
upregulated in synovial tissue over the course of inflammation, while DKK2, DKK3, and 
sFRP4 mRNA expression increased late in the course of arthritis (96).  DKK1 is also 
expressed in the synovium of STA mice as well as human TNFα transgenic (hTNFtg) 
mice, a murine model of inflammatory arthritis (96, 265).  DKK1 upregulation in 
synovial fibroblasts is mediated by TNF-induced activation of p38 MAPKs (265).  As 
such, anti-DKK1 blockade in hTNFtg mice protects against systemic bone loss (271) and 
stimulates the formation of osteophytes, or bony projections, on the surface of articular 
bone (265).  However, anti-DKK1 treatment was initiated prior to the formation of bone 
erosions  and  therapy concurrently upregulated the expression of OPG, the negative 
regulator of osteoclast formation (265).  As a result, it is currently unknown whether 
DKK1 blockade simply inhibits osteoclastogenesis and erosion formation or stimulates 
bone formation and erosion repair by promoting osteoblast maturation and function.  
Thus, the contribution of Wnt signaling to osteoblast-mediated repair of focal bone 
erosion in RA remains unknown.   
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In contrast, the presence of BMPs in RA has been associated with joint 
homeostasis rather than osteoblast differentiation or activity.  BMP4 and 5 are 
downregulated in chronically inflamed tissue of RA patients compared to normal 
individuals, particularly in the synovial lining layer (272).  In contrast, BMP2 and 6 are 
present in macrophages and fibroblasts in the hyperplastic and lining layers of the 
synovium (273).  TNF and IL-1β upregulate BMP2 and 6 in RA and normal synovial 
fibroblasts, to regulate synovial fibroblast apoptosis (273).   
Similar observations have been made in animal models of inflammatory arthritis.  
Synovial fibroblasts in the hyperplasic lining layer of hTNFtg mice and mice with 
collagen-induced arthritis, a model of inflammatory arthritis, express BMP7 (274, 275) 
and to a lesser extent BMP2 (275).  This upregulation of BMP7 is associated with an 
increase in fibroblast proliferation and extracellular matrix production (274).  
Furthermore, the expression of BMP2, 4, 6, and noggin were shown to decrease as 
inflammation progressed (275).    
Nevertheless, pro-inflammatory cytokines have been shown to regulate the BMP 
signaling pathway.  While TNF does not alter the expression of BMP2, 4, and 6 in 
osteoblasts (109), surface expression of BMPRII is downregulated by TNF (276).  In 
murine and human bone cells, TNF inhibited BMP-induced alkaline phosphatase 
production, expression of osteoblast differentiation genes, and bone formation (109, 276, 
277).  TNF also upregulates BMP3 expression in dental follicle cells in vitro, possibly 
contributing to the regulation of tooth eruption (278).  Taken together, these studies 
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demonstrate that mediators of BMP signaling are altered in inflammatory conditions, but 
the contribution of the BMP pathway to bone loss is currently unknown.   
 
Animal Models of Inflammatory Arthritis  
 To determine the mechanisms responsible for the inhibition of osteoblast-
mediated erosion repair in inflammatory arthritis, two murine models of inflammatory 
bone loss will be utilized, the serum transfer arthritis (STA) model and the antigen-
induced arthritis (AIA) model. 
 
Serum Transfer Arthritis (STA) 
 The STA model was developed after the fortuitous crossing of diabetes-
susceptible NOD mice with KRN transgenic mice, which express a T cell receptor 
specific for a peptide of bovine pancreas ribonuclease in the context of I-Ak (279).  The 
resulting K/BxN mice spontaneously develop severe inflammation in the distal limbs at 
4-5 weeks of age that resembles the pathologic characteristics of human RA.  The 
initiation, but not progression of arthritis in these mice is dependent on the appearance of 
CD4+ T cells in the periphery.  These autoreactive T cells recognize a peptide of glucose-
6-phosphate isomerase (GPI), a ubiquitous glycolytic enzyme, in the context of Aβg7 and 
activate B cells to produce anti-GPI antibodies.  As a result, mice lacking B cells do not 
develop arthritis (279).   
 The critical role for anti-GPI antibodies in K/BxN arthritis was demonstrated by 
the passive transfer of serum from the K/BxN mice to naïve recipient mice (called serum 
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transfer arthritis (STA)), which rapidly developed joint inflammation, synovial 
hyperplasia, cartilage destruction, and bone loss, typical of RA(280).  The development 
of STA requires at least two different IgG1 monoclonal anti-GPI antibodies, which 
recognize different GPI epitopes (281, 282).  These pathogenic autoantibodies rapidly 
localize to the joint (283) and subsequently bind GPI present on the articular cartilage 
surfaces (284), leading to the formation of immune complexes and activation of 
complement.  In particular, the alternative pathway of complement, which leads to 
activation of C5a, is triggered, as mice deficient in factor B, C3, C5, and C5aR were 
resistant to disease (285).  In contrast, mannose binding lectin-1, C1q, C4, and C6 do not 
contribute to arthritis (285).  Activation of complement via the common Fcγ chain, and to 
a lesser extent FcγRII, is also essential to arthritis (285).   
In addition to activating complement, the anti-GPI antibodies rapidly increase 
vasopermeability in the joint leading to the influx of inflammatory cells (286).  T and B 
cells are not required for STA (280), but mast cells, neutrophils, and macrophages are 
rapidly mobilized to the joint after serum transfer (287-289).  FcγR engagement on these 
cells leads to the production of TNF and IL-1.  Interestingly, STA is dependent on the 
production of IL-1, but TNF is not absolutely required, as TNF deficient mice have 
reduced incidence and severity of disease (290).  IL-6 and IL-4 are dispensable for 
disease (290, 291).  The role of IL-17 in STA is not fully understood.  IL-17 
neutralization does not affect progression of STA (292); however, the absence of the IL-
17 receptor, IL-17RA, protected from arthritis in another study (293).  Furthermore, local 
administration of IL-17 can enhance inflammation in a TNF-independent manner (118). 
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Because of its similarities to bone loss in RA (280), the STA model has been used 
to elucidate the effects of inflammatory arthritis on bone.  Specifically, the requirement 
for RANKL-mediated osteoclastogenesis in bone erosion was demonstrated following 
transfer of arthritogenic K/BxN serum to RANKL deficient mice.  Despite similar levels 
of paw swelling and inflammation, mice lacking RANKL did not develop bone erosions 
compared to litter mate controls (69).   
 
Antigen-induced Arthritis (AIA) 
 Unlike STA, AIA is a T cell-mediated delayed-type hypersensitivity model.  
Following antigen immunization, mice are challenged by direct injection of antigen into 
the knee joint.  As a result, inflammatory arthritis is confined to the injected knee, while 
the contralateral limb remains unaffected.  Typically in this model, mice are immunized 
with methylated bovine serum albumin (mBSA), a cationic antigen that is retained in the 
knee joint through interactions with negatively charged proteoglycans in cartilage, 
ligaments, and tendons.  Charged-mediated antigen retention and antibody localization to 
the knee joint are necessary for the chronicity and severity of inflammation (294-296).  
To further bolster inflammation and synchronize disease initiation, mice are also 
administered lipopolysaccharide as an adjuvant. 
 As expected, T cells are required for the generation of the delayed-type 
hypersensitivity response in AIA.  Depletion of T cells at the time of antigen challenge 
significantly reduces the severity of the acute and chronic phases of arthritis (297, 298); 
however, T cell depletion after the initiation of disease only slightly decreases 
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inflammation (297).  Furthermore, inflammatory activity of CD4+ T cells in AIA (52, 
299) is primarily mediated by Th1 cells through the expression of IL-2 and IFN-γ (298).  
CD8+ T cells and B cells are not involved in AIA (52).     
Progression of inflammation and joint damage in AIA is mediated by Fc 
receptors.  Absence of FcγRIIb, the inhibitory Fc receptor, significantly enhances 
inflammation as well as cartilage and bone destruction (300, 301).  Interestingly, lack of 
the activating Fc receptors, FcγI, III, and III (FcγRI/II/III-/-) also enhances inflammation, 
inflammatory cell influx, and bone erosion, but cartilage is spared (300, 301).  Thus, the 
activating Fcγ receptors regulate cartilage destruction in AIA independent of 
inflammation by regulating MMP expression, while bone erosion in AIA correlates with 
Fc receptor-mediated inflammation and alterations in the RANKL/OPG ratio (300, 301). 
Fc expressing mast cells and neutrophils are two of the primary cellular mediators 
of the inflammatory process in AIA.  While mast cells are not required for acute phase of 
inflammation, they enhance secondary flares of disease (302).  Neutrophils are one of the 
primary cellular constituents in the joint infiltrate and are mobilized into the joint within 
hours of antigen challenge, via the chemokines CXCL1, 2, and 5 (303-305).  While the 
direct contribution of neutrophils in AIA has not been reported, inhibition of neutrophil 
chemotaxis via CXCL1/2 blockade decreases inflammation (303).  
Once in the joint, activated cells release a plethora of cytokines that perpetuate the 
inflammatory cycle.  IL-1 is not required for the acute phase of AIA, but IL-1 
neutralization decreases the severity of chronic disease and protects against cartilage 
damage (306).  IL-17 is upregulated in the synovium of acute and flare-induced AIA and 
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neutralization of IL-17 during AIA flares reduces disease severity and bone erosion by 
decreasing RANKL expression (117).  In contrast, initiation and progression of AIA is 
highly dependent on IL-6.  Mice deficient in IL-6 are protected against joint 
inflammation (48, 52, 307). Bone marrow cells expressing IL-6, as well as TNF and IL-1 
to a significantly lesser degree, are identified in AIA and adoptive transfer of IL-6 
expressing cells was sufficient to induce arthritis (308).  Absence of IL-6 in arthritis 
decreases CD4+ T cell antigen-induced proliferation and IL-17 expression (52).  
Deficiency or neutralization of TNF moderately reduces disease severity compared to IL-
6 deficiency, demonstrating the importance of IL-6 over TNF in AIA pathogenesis (52).   
 
Introduction of Dissertation Aims 
 Despite emerging evidence implicating bone anabolic pathways in the inhibition 
of osteoblast-mediated bone formation in diseases of inflammatory bone loss, a number 
of questions remain concerning the mechanisms involved.  The aim of this dissertation is 
to elucidate the mechanisms of inflammation-induced inhibition of osteoblast 
differentiation and activity.  To address this aim, the research in this dissertation is 
divided into two general, overlapping areas: (1) the osteogenic signaling pathways and 
(2) the cellular mediators driving inhibition of osteoblast differentiation and activity.  The 
dissertation outline and specific aims are diagramed in Figure 1.3.  
 First, as previously noted, reports of erosion repair in RA patients are infrequent.  
Interestingly, restoration of the bone architecture in these patients is associated with well 
controlled clinical disease or remission (130, 131).  Furthermore, in murine inflammatory 
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arthritis, inflammation suppresses osteoblast activity at sites of articular bone erosion 
(96).  These observations imply that inflammation not only promotes osteoclast-mediated 
bone erosion, but also simultaneously inhibits osteoblast activity.  Therefore, the research 
in Chapter II of this dissertation aims to test the hypothesis that resolution of 
inflammation will promote osteoblast-mediated bone formation and erosion repair.  
 In addition to evaluating the direct effects of resolving inflammation on bone 
formation, this dissertation endeavors to illustrate the bone anabolic signaling pathways 
fundamental for the inhibition and promotion of osteoblast differentiation and activity.  
While DKK1 neutralization promotes periosteal osteophyte formation, the contribution of 
Wnt signaling to focal articular erosion repair has not be demonstrated (265).  Moreover, 
murine and RA synovial fibroblasts express sFRP1 and 2 (96, 266, 267), suggesting that 
other Wnt antagonists may be impacting osteoblasts.  Chapter II assesses the involvement 
of other Wnt antagonists in the erosive and healing processes as well as that of the Wnt 
agonists, which have not been explored in RA.  Specifically, in Chapter III, this 
dissertation tests the hypothesis that sFRP1, which is highly upregulated in STA (96), 
contributes to the inhibition of osteoblast-mediated bone formation in disease of 
inflammatory bone loss. 
Not only is the Wnt pathway essential for osteoblast maturation and activity, but 
bone anabolic BMP signaling is also equally required. Despite the importance of the 
BMPs in bone formation, there are no reports establishing a role for BMP antagonists in 
inflammation-induced bone loss.  Therefore, Chapter IV of this dissertation investigates 
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the hypothesis that inflammation induces the expression of BMP3, a BMP antagonist, in 
osteoblasts and synovial fibroblasts in murine models of inflammatory arthritis.   
Lastly, the research described in this dissertation briefly examines other 
unresolved questions.  The studies in Chapter V test the hypothesis that T cell-derived 
RANKL is not required for bone erosion.  Appendix II investigates the hypothesis that 
the M1 and M2 macrophages express osteoinhibitory and osteoinductive factors, 
respectively.  The mechanisms of periosteal osteophyte formation in inflammatory 
arthritis are described in Appendix I as a means to understand bone formation under 
specific inflammatory microenvironments. 
Taken together, this research establishes that inflammation has extensive effects 
on the bone microenvironment specifically via alterations in the expression of cell-
derived osteogenic signaling factors that directly impair the maturation and function of 
the osteoblast.  Inflammation is therefore a rheostat ultimately controlling the fate of bone 
in inflammatory arthritis. 
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CHAPTER II 
 
Resolution of Inflammation Promotes Osteoblast-Mediated Bone Formation and 
Regulates the Wnt Signaling Pathway  
 
 
The work presented in this chapter is contained in the publication: 
Matzelle MM, Gallant MA, Condon KW, Walsh NC, Manning CA, Stein GS, Lian JB, 
Burr DB, Gravallese EM.  Resolution of inflammation induces osteoblast function and 
regulates the Wnt signaling pathway.  Arthritis Rheum 2011;64:1540-50. 
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Summary 
Inflammation in the bone microenvironment stimulates osteoclast differentiation, 
resulting in uncoupling of resorption and formation.  Mechanisms contributing to the 
inhibition of osteoblast function in inflammatory diseases, however, have not been 
elucidated.  Rheumatoid arthritis (RA) is a prototype of an inflammatory arthritis that 
results in focal loss of articular bone. The paucity of bone repair in inflammatory diseases 
such as RA raises compelling questions regarding the impact of inflammation on bone 
formation.  To establish the mechanisms by which inflammation regulates osteoblast 
activity, we characterized an innovative variant of a murine arthritis model in which 
inflammation is induced in C57BL/6J mice by transfer of arthritogenic K/BxN serum and 
allowed to resolve.  In the setting of resolving inflammation, bone resorption ceases and 
appositional, osteoblast-mediated bone formation is induced, resulting in repair of eroded 
bone. Resolution of inflammation is accompanied by striking changes in expression of 
regulators of the Wnt/β-catenin pathway, a pathway critical for osteoblast differentiation 
and function. Downregulation of the Wnt antagonists sFRP1 and sFRP2 during the 
resolution phase parallels induction of the anabolic and pro-matrix mineralization factors 
Wnt10b and DKK2, demonstrating the role of inflammation in negatively regulating Wnt 
signaling. Repair of articular bone erosion occurs in the setting of resolving 
inflammation, accompanied by alterations in the Wnt signaling pathway.  These data 
imply that in diseases of inflammation-induced bone loss, strict control of inflammation 
may not be achieved; however, regulation of inflammation may be essential for the 
generation of an anabolic microenvironment that supports bone formation and repair. 
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Introduction 
Inflammation-induced pathologic bone loss is characterized by activation of bone 
resorption and inhibition of bone formation. While the stimulatory effects of 
inflammation on osteoclast-mediated bone resorption are well established (66, 69, 70), 
the impact of pro-inflammatory cytokines on osteoblast function in vivo requires further 
elucidation (309).  TNF has been shown to suppress osteoblast maturation in vitro by 
inhibiting the expression of Runx2 (102), a transcription factor responsible for osteoblast-
lineage commitment and gene expression.  As a result, expression of the Runx2 target 
genes type I collagen, alkaline phosphatase, and osteocalcin is suppressed.  Bone matrix 
deposition and mineralization are thus impaired by TNF (100).  IL-1β elicits similar 
inhibitory responses in differentiating osteoblasts (112, 113).  Furthermore, pro-
inflammatory cytokines disrupt the Wnt signaling pathway (265, 270), an anabolic 
pathway that induces the differentiation and maturation of osteoblasts.  In this pathway, a 
family of secreted agonists activate downstream signaling, stabilizing β-catenin, a 
transcriptional co-activator of osteoblast target genes, including Runx2 (140, 141).  
Regulation of Wnt signaling is maintained by a number of secreted antagonists, including 
members of the secreted frizzled-related protein (sFRP) and Dickkopf (DKK) families.   
Inflammation-induced focal bone loss is perhaps best exemplified in rheumatoid 
arthritis (RA), a disease in which osteoclastic resorption leads to the development of 
articular bone erosions.  In the inflamed microenvironment of the RA joint, osteoblast 
maturation and function is compromised.  Studies have shown that although osteoblasts 
are located in the vicinity of focal articular bone erosions in human RA (64) and murine 
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inflammatory arthritis, few mature, osteocalcin-expressing osteoblasts are directly 
associated with eroded bone surfaces (96, 97).  In serum transfer arthritis (STA), a 
murine model of inflammatory arthritis, the paucity of alkaline phosphatase and 
osteocalcin-expressing osteoblasts at erosion sites correlates with limited bone formation 
(96).  Furthermore, upregulation of Wnt signaling antagonist expression has been 
implicated in the suppression of osteoblast activity during inflammation-induced bone 
loss (96, 265).   
With aggressive treatment for inflammation in RA, bone resorption is suppressed.  
Although osteoblast-mediated repair of bone erosions occurs, it is infrequent (128, 129) 
and when observed, repair correlates with well-controlled clinical disease (130, 131).  
This observation suggests that in patients in whom repair is not detected, subclinical 
inflammation in the joint may persist, suppressing erosion repair by osteoblasts.  We 
therefore hypothesized that resolution of inflammation would stimulate osteoblast 
function and ultimately result in the repair of established focal bone erosions.  To address 
this hypothesis, we utilized an innovative variant of the STA model in which 
inflammation was induced and subsequently allowed to resolve.  Using this model, we 
determined the capacity of osteoblasts to recover from inflammation-induced suppression 
of function and subsequently form bone at erosion sites.  For the first time, we show that 
with resolution of inflammation there is a significant increase in bone formation at 
previous inflammation-bone interfaces, correlating with altered synovial expression of 
Wnt signaling components that favor anabolic signaling. 
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Materials and Methods 
K/BxN Serum Transfer Model of Inflammatory Arthritis  
All animal procedures were performed in accordance with protocols approved by 
the Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School.  KRN T cell transgenic mice (provided by Drs. Benoist and Mathis, 
Harvard Medical School) were crossed with NOD mice (Jackson Laboratories) to 
generate K/BxN mice that spontaneously develop arthritis (279, 280).  At 60 days of age, 
blood was collected by cardiac puncture and the serum isolated.  Serum from individual 
arthritic K/BxN mice was pooled for STA studies as previously described (69, 96).   
STA was induced in twelve week old male C57BL/6J mice (Jackson 
Laboratories) by intraperitoneal injection of 150µl of arthritogenic K/BxN serum on days 
0, 2, and 7.  Non-arthritic mice received 150µl of sterile PBS.  Twelve week old male 
mice were used to avoid the juvenile growth spurt and the differential effects of estrogen 
on bone in males and females.  Clinical inflammation scoring was performed as 
previously detailed (69).  Briefly, for each paw, a score from 0 to 3 was assigned based 
on the following criteria: 0, normal; 0.5, visible redness and/or slight swelling; 1, visible 
swelling on the top and bottom of the paw, with swelling extending up the from the joint 
of the fore/hind paw; 2, obvious swelling that obscures bone landmarks, including the 
calcaneus; and 3, severe swelling that further obscures bone landmarks with significant 
swelling on the top of the foot and around the calcaneus.  At each time point, scores for 
the four paws were summed and the average calculated.  The average clinical score and 
standard deviation for each experimental group was reported.   
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Histopathologic Analyses  
Hind limbs were fixed in 4% paraformaldehyde (PFA) for 24 hours, decalcified in 
15% EDTA/0.5% PFA, and paraffin embedded.  For histological scoring of inflammation 
and bone erosion, 5 slides per mouse, separated by approximately 45µm, were stained 
with either Gill’s hematoxylin (Sigma) and eosin (Surgipath) (H&E) or tartrate resistant 
acid phosphatase (TRAP).  For TRAP staining, sections were incubated in 0.1M Tris-
HCL, pH 9.0 for 18 hours, followed 0.1M sodium citrate, pH 5.2 for 3 hours (310).  
Activated slides were incubated for 30 minutes at 37ºC in 0.005% Napthol AS-MX 
phosphate (Sigma)/0.01% N,N-dimethylformamide/0.03% Fast Red LB violet salt 
(Sigma)/50mM sodium tartrate in 0.1M acetate pH 5.0 and counter stained with Mayer’s 
hematoxylin (Sigma) (311, 312).  Slides were directly scored by two independent 
observers (MMM and EMG) using previously defined histopathological scoring criteria 
(69).  Briefly, to quantify inflammation, a score from 0 to 5 was assigned based on the 
following criteria: 0, normal; 1, minimal inflammation; 2, mild inflammation; 3, 
moderate inflammation; 4, marked inflammation; 5, severe inflammation.  Bone erosion 
was quantified using the following criteria: 0, normal; 1, small areas of resorption in the 
trabecular or cortical bone; 2, more numerous areas of resorption in the trabecular or 
cortical bone; 3, obvious areas of resorption in the trabecular and cortical bone; 4, full 
thickness defects of the cortical bone; 5, full thickness defects of the cortical bone with 
loss of bone architecture.  The data are represented as the average of both observers’ 
scores for each mouse.  Images were acquired at room temperature with a Zeiss Axioskop 
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40 microscope with an EC Plan-Neofluor 10x objective (N.A. 0.30) and an AxioCam 
HRC camera with AxioVision 4.7.2 software.   
 
In Situ Hybridization 
As previously described (96), digoxigenin labeled anti-sense and sense riboprobes 
specific for alkaline phosphatase (forward 5’-AACAACCTGACTGACCCTTCGCTC-3’, 
reverse 5’-ATTTTCCCGTTCACCGTCCACC-3’) and osteocalcin (forward 5’-
GTGTGAGCTTAACCCTGCTTGTG-3’, reverse 5’-
TGCTGTGACATCCATACTTGCAG-3’) mRNA were synthesized and were used to 
perform in situ hybridization on serial sections of hind paws from arthritic and non-
arthritic mice.  Following dewaxing and rehydration, sections were incubated in 0.2M 
HCL for 20 minutes and treated with 10μg/ml proteinase K (Roche) for 30 minutes at 
37°.  After post-fixing in 4% PFA for 15 minutes, sections were blocked with 2% 
blocking reagent (Roche) in hybridization buffer (50% formamide/0.2% SDS/0.1% N-
lauroylsarcosine) for 1 hour at 42°C.   Probe hybridization was performed with 1ng/μl of 
sense or anti-sense probe in hybridization buffer overnight at 42°C.  Sections were 
subsequently washed and blocked with 1% blocking reagent in 100mM Tris pH 7.5, 
150mM NaCl.  Digoxigenin labeled probe was detected using an alkaline phosphatase 
conjugated anti-dioxigenin antibody (1:500 dilution in 1% blocking reagent, Roche) and 
visualized with NBT/BCIP (Roche) in 100mM Tris-HCl, 100mM NaCl, and 50mM 
MgCl2, pH 9.5.  Images were acquired with a Nikon Eclipse E600 microscope with a 
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Nikon Plan Fluor 10x objective (N.A. 0.30) and a Nikon DS-Ri1 camera with Nikon 
NIS-Elements BR 3.10 software. 
 
Micro-computed Tomographic (microCT) Imaging 
Hind paws of arthritic and non-arthritic mice were fixed in 4% PFA for 24 hours 
and imaged at the MCI Core at the University of Massachusetts Medical School.  Distal 
tibia and midfoot bones were scanned using a SCANCO Medical μCT 40 with an 
isotropic voxel size of 8μm at 70kVp and 114μA.  Images were reconstructed in 1024 x 
1024 pixel matrices.  A threshold of 220-1000 Housenfeld Units was used to segment.  
Axial slices were reformatted to lateral slices.  Representative lateral slice images taken 
from approximately the same depth through the distal tibia and midfoot bones were 
obtained for each mouse at 3x magnification. 
 
Dynamic Histomorphometric Analysis 
For histomorphometic analysis of in vivo bone formation, arthritic and non-
arthritic mice were administered 50mg/kg alizarin and/or 30mg/kg calcein by 
intraperitoneal injection.  For qualitative assessment of bone formation, mice were given 
alternating injections of alizarin and calcein every ten days, beginning on day 5 (alizarin).  
Mice were sacrificed on day 58, three days after the last fluorochrome injection (calcein).  
For quantitative analysis, mice were given alizarin thirteen days prior to sacrifice and 
calcein three days prior (ten day inter-label period); therefore, mice sacrificed on day 28 
received alizarin on day 15 and calcein on day 25; mice sacrificed on day 38 received 
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alizarin on day 25 and calcein on day 35; and mice sacrificed on day 48 received alizarin 
on day 35 and calcein on day 45.  Mice sacrificed on day 10 received alizarin on day 5. 
Right hind limbs were fixed for 3 days in 10% neutral buffered formalin and 
embedded in methylmethacrylate.  As previously shown (96), the navicular bone of the 
midfoot is a reproducible site of bone erosion in STA and as such this site was chosen for 
quantitative measurements.  Specifically, cortical and endosteal surfaces within the 
navicular bone where pannus and inflammatory tissue invaded were analyzed separately 
from surfaces contacting normal marrow/connective tissue.  Following the resolution of 
active inflammation, the appearance of abnormal marrow, loss of adipocytic structure, 
and tissue fibrosis were used to identify areas where inflammatory tissue had been 
present earlier during the course of arthritis.  Quantification of bone formation was 
performed on images obtained from three sections (5μm, separated by 25μm) using 
Bioquant OSTEO 7.20.10 (Bioquant Image Analysis). Mineralized surface/bone surface 
(MS/BS), mineral apposition rate (MAR), and bone formation rate/bone surface 
(BFR/BS) were determined as previously described (96), using the guidelines established 
by Parfitt et al (313).  Briefly, for MS/BS, the percentage of bone surface with red or 
green fluorochrome incorporation was calculated with the following equation: MS/BS = 
[dL + (0.5 x sL)]/(sL + dL + nL) x 100. MAR (μm/d) was determined by calculating the 
width between the alizarin and calcein fluorochromes (interlabel width, Ir.Wi) and 
divided by the 10-day interlabel period.  BFR/BS (μm3/μm2/yr) was calculated as MS/BS 
x MAR x 365.  When only single label was present, a value of 0.3 was used for MAR in 
BFR/BS calculations.  For the non-arthritic group, data from mice sacrificed at days 10, 
51
28, 38, and 48 (total of n=15) were combined.  Images were acquired with an Olympus 
BX51 microscope with an UPlanFL N 10x objective (N.A. 0.30) and an Olympus DP72 
camera with cellSens Entry 1.2 software.     
 
Synovial Gene Expression 
Hind limbs were collected and stored in RNAlater (Ambion).  Synovial and 
associated soft tissue was dissected from the tibio-talar region of the joint.  Isolated tissue 
was ground in liquid nitrogen and RNA isolated by modified acid-guanidinium 
isothiocyanate phenol-chloroform procedure, as previously detailed (96).  Following 
removal of contaminating DNA (Turbo DNase Free kit, Ambion), 150ng of total RNA 
was used for iScript cDNA synthesis (BioRad).  qRT-PCR was performed on diluted 
cDNA samples using the iScript Sybr Green RT-PCR mix (BioRad) and an Eppendorf 
Realplex qPCR machine.  Primers for hydroxymethylbilane synthase (HMBS), IL-1β, 
TNF, RANKL, OPG, MMP13, sFRP1, sFRP2, DKK1, DKK2, Wnt7b, and Wnt10b were 
obtained from Qiagen (catalog numbers in Table 2.1).  Gene expression was normalized 
to the expression of HMBS, a reference gene, and data was expressed as the fold increase 
in arthritic gene expression compared to non-arthritic gene expression averaged over the 
course of the experimental time points (n=7-8 arthritic and non-arthritic mice per time 
point) using the 2ΔΔCt method (314).  
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Gene Name Qiagen Product Number 
HMBS QT00494130 
IL-1β QT01048355 
TNF QT00104006 
RANKL QT00147385 
OPG QT00106757 
MMP13 QT00111104 
sFRP1 QT00167153 
sFRP2 QT00101759 
DKK1 QT00146307 
DKK2 QT00124355 
Wnt7b QT00168812 
Wnt10b QT00113211 
 
 
Table 2.1: Catalog numbers for Qiagen qRT-PCR primers.  Catalog numbers for 
primers obtained from Qiagen and used in qRT-PCR assays. 
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Serum Measurements 
Serum levels of osteocalcin were measured by ELISA (Biomedical Technologies 
Inc.) and TRAP5b levels were determined by activity assay (Immunodiagnostics 
Systems) according to manufacturer’s instructions.    
 
Statistical Analysis 
Statistical analysis of the qRT-PCR data was performed using a Type III F test of 
homogeneity from ANOVA modeling to determine if differences existed among the days.  
For genes with a P value ≤ 0.05, the relative expression at day 10 was tested against the 
relative expression at subsequent days using a standard two-group t test assuming 
independent observations.  An informal Bonferroni correction for significance (0.05/5 = 
0.01) was used.  Outliers (defined as 3 sd +/- mean) were removed prior to statistical 
analysis.     
One way ANOVA analysis with a Dunnett posttest was used to determine 
statistical significance for the histomorphometry data, where the non-arthritic samples 
served as the comparator control.  Unpaired Student’s t tests were used to calculate 
statistical significance for histology scores and TRAP5b data. 
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Results 
Termination of Pro-Inflammatory Cytokine Expression and Osteoclastogenesis 
Characterize Resolving Inflammation.   
To evaluate the effects of abating inflammation on osteoblast activity, we 
characterized a variant of the STA model in which inflammation was induced with three 
injections of arthritogenic serum and subsequently allowed to decline.  After 
administration of arthritogenic serum on days 0, 2, and 7, mice rapidly developed clinical 
signs of inflammation (Figure 2.1A), which peaked at day 10.  Synovial tissue isolated 
from the tibio-talar joint of arthritic mice showed an upregulation of IL-1β and TNF 
mRNA at the peak of clinical inflammation (Figures 2.1B and 2.1C).  Expression of IL-
1β mRNA was upregulated approximately 20-fold and TNF mRNA approximately 1.5-
fold compared to non-arthritic controls, consistent with the dominance of IL-1β as the 
critical cytokine in this model (290).  Upregulation of pro-inflammatory cytokines was 
accompanied by significant infiltration of inflammatory cells into the joint, synovial 
hyperplasia, and invasion of pannus into the marrow cavities of the navicular bone 
(Figure 2.2A).   
Synovitis promotes osteoclast-mediated articular bone erosion through the 
upregulation of RANKL (69) and reproducibly generates cortical and endosteal bone 
erosions in the navicular bone (96).  As expected, RANKL mRNA was induced in the 
synovium in this model by day 10 (Figure 2.1E).  In contrast, expression of OPG mRNA, 
a soluble decoy receptor that binds RANKL and inhibits osteoclastogenesis, was 
downregulated by the inflammatory process (Figure 2.1F).  As a result, the RANKL/OPG 
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ratio was markedly elevated at day 10 leading to a significant increase in osteoclast 
numbers, as measured by serum TRAP5b levels, (Figure 2.1G) and osteoclast-mediated 
bone erosion (Figures 2.2B and 2.2D).  By day 10, the presence of TRAP+ osteoclasts on 
the endosteal and cortical surfaces of the navicular bone was associated with full 
thickness cortical defects (Figure 2.2B).  MMP13, a matrix metalloproteinase implicated 
in cartilage destruction and responsible for preparation of bone surfaces for osteoclast-
mediated resorption (315), was also induced by the inflammatory process (Figure 2.1D).       
With discontinuation of arthritogenic serum injections, clinical inflammation 
progressively decreased from day 10 onward (Figure 2.1A).  Expression of IL-1β and 
TNF mRNA in synovial tissue decreased rapidly and returned to non-arthritic levels, 
(Figure 2.1B and 2.1C) resulting in little cellular infiltration in the synovium and minimal 
synovial thickening by day 28 (Figure 2.2).  Decline in pro-inflammatory cytokine 
expression was accompanied by a precipitous downregulation of RANKL mRNA and 
upregulation of OPG mRNA (Figures 2.1E and 2.1F).  The resulting reversal in the 
RANKL/OPG ratio correlated with a reduction in osteoclast number (Figure 2.1G) and a 
marked decrease in active resorption of bone by day 15 (Figure 2.2B).  During the repair 
and remodeling phase from day 28 onward, the absence of IL-1β, TNF, and RANKL 
expression paralleled the absence of cellular infiltrates and osteoclast activity, with a 
slightly thickened synovium remaining (Figure 2.2A and 2.2B).   Furthermore, bone 
marrow cavities previously penetrated by inflammatory tissue were now devoid of 
normal marrow components and adipocytes (Figure 2.2A).   
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During the repair and remodeling phase from day 40 onward, the lack of IL-1β, 
TNF-α, and RANKL expression (Figure 2.1) paralleled the absence of cellular 
infiltration, synovial hyperplasia, and osteoclast activity (Figure 2.2A and 2.2B), while 
the presence of collagen fibers in arthritic mice compared to non-arthritic controls 
suggested that fibrotic tissue and capsule formation remained.  Furthermore, bone 
marrow cavities previously penetrated by inflammatory tissue were now vacant and 
devoid of normal marrow components and adipocytes (Figure 2.2A).   
The impact of resolving inflammation on the bone architecture was evaluated by 
microCT.  By day 15, endosteal and cortical erosion of the ankle and midfoot bones was 
clearly evident, resulting in roughened, irregular bone surfaces.  Consistent with the 
histological data, full thickness defects in the midfoot bones were apparent (Figure 2.3, 
white arrows).   By day 38, with the complete resolution of inflammation, bone 
architecture was similar to that of non-arthritic controls.   
We thus characterized three reproducible phases in this model of inflammation 
resolution using quantitative molecular and morphological parameters, including: (1) an 
inflammatory phase (days 0-10) exemplified by expression of pro-inflammatory 
cytokines and RANKL that induce bone erosion; (2) a resolution phase (days 10-28) of 
abating pro-inflammatory cytokine and catabolic factor expression leading to declining 
osteoclastogenesis; (3) a remodeling and repair phase (day 28 onward).   
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Resolution of Inflammation Promotes Osteoblast-Mediated Bone Formation and Erosion 
Repair. 
Given the apparently normal bone architecture observed at day 38 and 58 by 
microCT, we hypothesized that the decline of inflammation promoted osteoblast-
mediated bone formation.  To quantify the extent of osteoblast activity, in vivo 
fluorochrome incorporation at inflammation-bone interfaces was assessed using dynamic 
histomorphometry.  Little incorporation of alizarin was evident at inflammation-bone 
interfaces in the navicular bone at day 10, when peak inflammation was observed (Figure 
2.4A).  Quantification at day 10 revealed a slight decrease in mineralized surface/total 
bone surface (MS/BS) compared to non-arthritic controls (Figure 2.4B).  In contrast, with 
resolution of inflammation, significant alizarin and calcein incorporation was observed at 
inflammation-bone interfaces on days 28, 38, and 48 (Figure 2.4A).  At these time points, 
a statistically significant increase in MS/BS compared to non-arthritic controls indicated 
an increase in the mineralizing activity of osteoblasts at erosion sites (Figure 2.4B).  In 
addition, there was a statistically significant increase in the mineral apposition rate 
(MAR), a measure of the activity of individual osteoblasts (Figure 2.4C), and bone 
formation rate/total bone surface (BFR/BS), a value calculated from MAR and MS/BS 
(Figure 2.4D).  MAR and BFR could not be calculated at day 10, since only a single label 
(alizarin) could be administered. 
To observe bone formation over time, two fluorochromes were administered at 
alternating intervals every ten days throughout arthritis, resulting in a total of six 
fluorochrome injections over the course of 58 days (3 alizarin, 3 calcein).  Little to no 
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incorporation of fluorochrome at sites of navicular bone erosion was detected ten days 
following the induction of arthritis (Figure 2.5).   Strikingly, multiple layers of 
fluorochrome incorporation were observed over the 58 day period following the 
induction of arthritis, indicating that bone formation was a dynamic process that occurred 
throughout the resolution and remodeling phases. 
The presence of mature osteoblasts at inflammation-bone interfaces paralleled the 
increase in bone formation that occurred with resolution of inflammation.  At peak 
inflammation (day 10), there was limited to no expression of alkaline phosphatase 
(AlkP), a mid-stage osteoblast marker, or osteocalcin (OCN), a late stage osteoblast 
marker, by cells along the inflammation-bone interfaces (Figures 2.6A and 2.6B).  
However, as inflammation abated during the resolution phase, there was a progressive 
increase in the number of osteoblasts expressing AlkP and OCN, as well as an increase in 
the number of these cells lining the eroded endosteal bone surfaces.   AlkP-expressing 
cells were observed beginning at day 15, followed by an abundance of osteoblasts 
expressing OCN on endosteal bone surfaces as well as some eroded cortical surfaces by 
day 21.  From day 28 onward, there were fewer AlkP and OCN expressing osteoblasts 
and surfaces lined by these cells.  Taken together, these data demonstrate that osteoblasts 
populate bone surfaces and synthesize bone in parallel with declining inflammation. 
 
Alterations in Wnt Signaling Mirror Resolution of Inflammation.   
To address mechanisms related to osteoblast maturation and bone formation at 
eroded bone surfaces, we investigated the impact of inflammation on the expression of 
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antagonists and agonists of the Wnt signaling pathway.  Within arthritic synovial tissue 
there was induction of sFRP1 and sFRP2 mRNA expression relative to non-arthritic 
controls at day 10 (Figures 2.7A and 2.7B).  Timing of expression corresponded to the 
inflammatory phase of the model, when inflammation peaks and bone formation is 
suppressed.  Expression of sFRP1 and sFRP2 mRNA subsequently declined as 
inflammation resolved, until day 28, when expression levels were similar to non-arthritic 
controls.  In contrast, DKK1 mRNA was detected later in the inflammatory process, with 
the peak, approximately two-fold increase in expression occurring at days 28 and 38 
(Figure 2.7C).   
We further investigated the ability of declining inflammation to promote 
expression of anabolic Wnt ligands.  Expression of Wnt10b mRNA, a Wnt agonist that 
promotes osteoblastogenesis and in vivo bone formation (160), was upregulated 
compared to non-arthritic controls as inflammation declined (Figure 2.7D).  Although 
mRNA levels were low, we also examined the trends of DKK2and Wnt7b expression in 
this model.  Synovial expression of DKK2 mRNA, a Wnt antagonist that promotes 
matrix mineralization, was suppressed at the peak of inflammation and bone erosion (day 
10).  In contrast, expression increased during the resolution phase of inflammation 
(Figure 2.7E).  Upregulation of DKK2 mRNA correlated with a reciprocal 
downregulation of the canonical Wnt signaling agonist, Wnt7b (Figure 2.7F).  A similar 
reciprocal relationship between DKK2and Wnt7b expression in osteoblasts has been 
reported (157).  These data demonstrate that while inflammation induces expression of 
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Wnt antagonists that inhibit osteoblast differentiation, the decline of inflammation 
upregulates anabolic and pro-matrix mineralization Wnt signaling factors (Figure 2.7G).   
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Discussion 
Pathologic bone loss in inflammatory diseases is characterized by an imbalance of 
osteoclast-mediated bone resorption relative to osteoblast-mediated bone formation, 
resulting in a net loss of bone.  Our lab has previously shown in a murine model of 
inflammatory arthritis that the presence of inflammation at sites of articular bone erosion 
correlated with limited osteoblast activity (96).  This observation demonstrated that 
inflammation impairs the ability of osteoblasts to form bone and raised the question as to 
whether resolution of inflammation would promote osteoblast-mediated bone formation.    
We adapted the STA model, as previously described in a model of pain pathways 
(316), in order to establish the phases of inflammation-induced bone erosion repair.  In 
the STA model, repeated injections of arthritogenic serum containing pathogenic 
autoantibodies are required in order to maintain inflammation.  While the mechanisms 
responsible for resolution of inflammation in this model are unknown, it can be 
speculated that discontinuation of serum administration terminates the delivery of 
autoantibodies, ultimately leading to inflammation decline. This characteristic of the STA 
model, therefore allowed us to demonstrate that in the setting of declining inflammation, 
bone formation occurs, leading to repair of focal articular bone loss.   
By elucidating the temporal sequence of bone formation relative to the 
inflammatory process in this model, an understanding of the key events leading to 
inflammation-induced bone loss and repair was established.  The inflammatory phase was 
characterized by decreased mineralized bone surface (MS/BS) and by a paucity of AlkP 
and OCN-expressing osteoblasts at eroded surfaces, consistent with our previous studies 
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(96).  In the resolution phase of the present study, osteoblasts prominently expressing 
OCN populated previous inflammation-bone interfaces, in particular endosteal surfaces, 
co-incident with a significant increase in MS/BS, MAR, and BFR.   This increase in 
MS/BS, MAR, and BFR persisted through the repair and remodeling phase, 
demonstrating that resolving inflammation stimulates repair of bone loss. 
Repair of inflammation-induced bone erosion in this model is a result of both an 
increase in osteoblast activity and a reciprocal decrease in osteoclast-mediated bone 
resorption.  The removal of arthritogenic stimuli results in a decrease in expression of 
pro-inflammatory cytokines and RANKL, leading to a decrease in osteoclast formation 
and bone resorption. Activation of the canonical Wnt/β-catenin pathway has been shown 
to upregulate OPG expression to inhibit osteoclast differentiation (188, 189).  Our data 
demonstrate an increase in synovial OPG expression concurrent with the decline in 
osteoclast formation with resolving inflammation, consistent with activation of this 
pathway.  
Previously, synovial fibroblasts in RA have been shown to express inhibitors of 
the Wnt signaling pathway, including DKK1, sFRP1, 3, and 4 (265-267).  There is also 
increasing evidence implicating the Wnt antagonists,  DKK1 (265) and sFRP1 (96, 317) 
as factors that suppress osteoblast activity in models of inflammatory bone loss.  This 
study establishes that expression of both sFRP1 and sFRP2 is induced with inflammation 
and declines with decreasing inflammation.  
Restoration of osteoblast activity following the decline of inflammation in this 
study clearly demonstrates that inflammation perturbs the balance of anabolic bone 
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signaling, with profound effects on the Wnt signaling pathway.  Elevated DKK1 
expression has been associated with inflammatory bone loss and suppression of 
osteoblast activity in RA (265) as well as in multiple myeloma (260), while prophylactic 
DKK1 blockade stimulated periosteal osteophyte formation in the hTNFtg model of RA 
(265).  DKK1 is expressed in the synovium of arthritic hTNFtg mice and is upregulated 
in cultured human and murine synovial fibroblasts.  In this study, we found that synovial 
DKK1 mRNA expression was not significantly elevated at the time point examined 
during the inflammatory phase of STA (day 10), but trended upward later in the course of 
arthritis (days 28 and 38) during the phase of resolving inflammation.  However, as 
previously demonstrated, when more robust inflammation is induced in this model 
following 4 injections of arthritogenic serum, an upregulation of DKK1 mRNA was seen 
during the period of peak inflammation (96),  In the STA model, IL-1β is a predominant 
pro-inflammatory cytokine (290), and as such an alternative pattern of Wnt antagonist 
expression to that seen in the hTNFtg model may ensue.  In addition, in the STA model, 
expression of DKK1 mRNA is low; therefore, it is difficult to draw conclusions about the 
impact of DKK1 on osteoblast function following the resolution of inflammation in this 
study.   
Regulated Wnt agonist expression directs vertebrate limb and synovial joint 
development (318, 319) and as such, may promote bone formation.  In this study, bone 
formation correlated with increasing synovial expression of Wnt10b, a canonical Wnt 
agonist.  Overexpression of Wnt10b has been shown to increase bone mass and trabecular 
number by increasing osteoblast number and activity, while deletion of Wnt10b led to a 
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decrease in bone formation (160).  In this study, the upregulation of Wnt10b in the 
synovium following resolution of inflammation is a likely mechanism contributing to 
bone formation.   
The expression of Wnt7b is downregulated with declining inflammation.  
Previous studies have demonstrated that Wnt7b mRNA is expressed by trabecular 
osteoblasts in vivo (155) and peaks early in osteoblast differentiation in vitro (155, 157), 
suggesting that Wnt7b may promote bone formation.  Importantly, downregulation of 
Wnt7b expression in osteoblasts correlates with the induction of DKK2 expression, a 
Wnt antagonist that promotes osteoblast maturation and mineralization of newly 
synthesized bone matrix (157).  Indeed, in this study, we observed a similar inverse 
relationship between Wnt7b and DKK2 expression in synovial tissue, which was 
regulated by the presence of inflammation. With resolution of inflammation, decreasing 
Wnt7b expression may promote the expression of DKK2 by osteoblasts recruited to the 
sites of bone erosion, which subsequently can promote osteoblast maturation and direct 
mineralization of the newly formed bone at erosion sites. 
In addition to promoting osteoblast activity, canonical Wnt signaling has been 
associated with tissue patterning, regeneration, and repair.  For instance, Wnt7b has been 
implicated in tissue repair via extracellular matrix gene expression and cell cycle 
regulation (320-322), raising the possibility that Wnt7b expression early in inflammation 
may be a regenerative mechanism initiated by resident synovial fibroblasts to initiate 
repair of the joint microenvironment.   Synovial fibroblast and/or synovial macrophage 
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production of Wnt7b may also serve to stimulate extracellular matrix synthesis and/or 
scar tissue formation following inflammatory-mediated tissue destruction.   
To delineate the role of synovial fibroblast-derived Wnt7b and DKK2 in the 
stimulation of osteoblast activity and extracellular matrix secretion, further in vitro 
studies are required.  The expression of Wnt7b and DKK2 in the cell culture supernatant 
from pro-inflammatory cytokine stimulated synovial fibroblasts could be quantified and 
subsequently applied to differentiating osteoblasts.  Expression of osteoblast 
differentiation markers Runx2, alkaline phosphatase, and osteocalcin as well as matrix 
mineralization and nodule formation could be determined.  While resolution of 
inflammation has not been modeled in vitro, synovial fibroblasts could be treated with 
pro-inflammatory cytokines, followed by a period of cytokine washout.  Similar to the 
studies described above, the expression of Wnt7b and DKK2 could be assayed in the cell 
culture supernatant and used to stimulated osteoblast differentiation in vitro.  Together, 
these studies would determine if synovial fibroblast derived factors promote osteoblast 
differentiation and matrix mineralization. 
A similar in vitro model could be used to address the role of Wnt7b in 
extracellular matrix production.  Cell culture supernatant from the cytokine-stimulated 
and cytokine washed out synovial fibroblasts could be added to cultures of unstimulated 
synovial fibroblasts and macrophages.  The expression of extracellular matrix proteins, 
such as fibronection, collagen, and glycosaminoglycans could be quantitated as a measure 
of extracellular matrix synthesis.  Antibody-mediated depletion of Wnt7b from the cell 
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culture supernatant could subsequently be used to directly demonstrate a role for Wnt7b 
in extracellular matrix production.  
The observation that bone formation increases as inflammation resolves provides 
insight into an important conundrum in clinical disease, the relative lack of articular 
erosion repair in RA patients with excellent disease control or remission.  Therapy with 
potent anti-inflammatory drugs such as anti-TNF agents has been shown to slow or halt 
the progression of articular erosion, but repair of erosions is still limited, even when 
sensitive radiographic techniques such as high resolution computed tomography are 
employed to identify repair (134).  Our findings in this murine model of RA demonstrate 
that if inflammation is controlled, bone formation and repair of erosions occurs and 
suggests that in clinical disease in which repair is not seen, inflammation in synovial 
tissues likely persists.  Recent clinical data is consistent with this notion. When studying 
RA patients on DMARD therapy deemed to be in clinical remission, Brown et al. 
demonstrated that subclinical inflammation could be identified by the sensitive 
techniques of magnetic resonance imaging (MRI) and musculoskeletal ultrasound.  
Furthermore, a direct association between ongoing synovitis and structural progression 
was shown (138, 139).  In addition, in studies of patients judged to be in clinical 
remission, MRI, as well as synovial biopsies combined with ultrasonography or MRI, 
demonstrated the persistence of synovitis (323, 324).  Our findings, however, cannot 
exclude the possibility that other environmental, cellular, and/or epigenetic changes could 
have occurred that alter Wnt antagonist and agonist expression independent of the 
requirement of ongoing inflammation. 
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In conclusion, these studies in a murine model of resolving inflammation are the 
first direct demonstration that decline of inflammation within the bone microenvironment 
favors the restoration of osteoblast function and the repair of focal bone erosions.  
Furthermore, by altering the expression of Wnt antagonists and agonists in the synovium, 
inflammation significantly contributes to the regulation of Wnt signaling, a pathway that 
ultimately determines the fate of bone.  Therefore, aggressive control of synovial 
inflammation and close monitoring of synovitis with sensitive radiologic techniques may 
be required in order to stimulate bone formation and restore bone structural integrity in 
diseases of inflammation-induced bone loss.   
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CHAPTER III 
 
Inflammatory Bone Loss in the Setting of sFRP1 Deficiency 
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Summary 
Osteoclast activity outweighs osteoblast-mediated bone formation in 
inflammatory arthritis resulting in focal articular bone loss. Suppression of osteoblast 
function at bone erosion sites has been linked to the expression of antagonists of the Wnt 
pathway, an essential signaling pathway that promotes osteoblast differentiation and bone 
formation.  Inflammation-induced upregulation of sFRP1, a Wnt antagonist, has been 
documented in murine inflammatory arthritis.  Furthermore, downregulation of sFRP1 
expression in synovial tissue correlates with bone formation in a model of resolving 
inflammation.  Together, these data implicate sFRP1 as a contributing factor to the 
inhibition of bone formation.  To definitively establish the impact of sFRP1 on the 
inhibition of bone formation in the setting of inflammation, arthritogenic K/BxN serum 
was used to induce inflammatory arthritis in sFRP1 deficient mice and the development 
of bone erosions was quantified.  These studies demonstrate that the absence of sFRP1 in 
arthritis did not alter inflammation or the development of midfoot bone erosions.  
However, the presence of osteoblasts at inflammation-bone interfaces during the erosive 
phase, suggests that sFRP1 deficiency may promote osteoblast-mediated bone formation 
if sufficient time is allowed for the erosion repair process.   
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Introduction 
Osteoclast-mediated bone resorption is strictly balanced by osteoblast-mediated 
bone formation during normal physiological bone remodeling.  However, in rheumatoid 
arthritis (RA), the inflammatory process skews the balance of osteoclast and osteoblast 
activity.  Specifically, pro-inflammatory cytokines stimulate the recruitment of osteoclast 
precursors into the synovium, while also upregulating the expression of RANKL, a pro-
osteoclastogenic factor, in activated T cells (83, 84) and synovial fibroblasts (66, 76, 77). 
Subsequently, osteoclasts form at the interface of the inflamed synovium and bone, 
resulting in focal articular bone erosion. 
In addition to driving osteoclastic bone erosion, inflammation also suppresses 
osteoblast differentiation.  Immature osteoblasts expressing Runx2, a transcription factor 
responsible for osteoblast-lineage commitment, are identified at erosion sites in murine 
inflammatory arthritis (96).  In stark contrast, expression of alkaline phosphatase (AlkP), 
a mid-stage marker of osteoblast differentiation, and osteocalcin (OCN), a mature 
osteoblast marker, are infrequent at eroded bone surfaces in murine inflammatory arthritis 
models (96, 97) and in human RA (64), suggesting an impairment of osteoblast 
differentiation at these sites.  Consequently, osteoblast-mediated bone formation at 
inflammation-bone interfaces in murine arthritis models is suppressed (96).  Osteoblast 
activity is therefore insufficient to compensate for the increased bone resorption at these 
same sites, ultimately leading to a net loss of bone and inhibition of erosion repair. 
The pro-inflammatory cytokines characteristic of RA have been shown to directly 
suppress osteoblast differentiation and activity in vitro.  TNF inhibits osteoblast 
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maturation in vitro by inhibiting the expression of Runx2 and osterix (104, 105, 141).  As 
a result, the expression of Runx2 target genes AlkP, type I collagen (106, 107) and OCN 
(108-110) are suppressed.  Matrix deposition, mineralization, and subsequent nodule 
formation is reduced (109, 111).  IL-1β elicits similar inhibitory responses in 
differentiating osteoblasts (113).     
In addition to the actions of pro-inflammatory cytokines, alterations in the Wnt 
signaling pathway have also been implicated in the inhibition of osteoblast differentiation 
and activity in RA (265).  The Wnt signaling pathway is required for the differentiation 
of mesenchymal progenitor cells into mature, matrix-producing osteoblasts (140).  Wnt 
agonist ligation of the Fzd receptor and LRP5/6 co-receptors transduces a cascade of 
intracellular signals culminating in the stabilization of β-catenin, a transcription factor 
regulating the expression of osteoblast-specific target genes.  Wnt signaling is regulated 
in part by the dickkopf (DKK) and the secreted frizzled-related protein (sFRP) families of 
antagonists.  In the context of RA, DKK1 has been shown to regulate inflammation-
induced bone loss in the murine hTNFtg arthritis model (265).   
The Wnt antagonist sFRP1 binds Wnt ligands, thus preventing interactions with 
the Fzd and LRP5/6 receptors.   Absence of sFRP1 increases trabecular bone volume and 
protects against age-related bone loss in vivo (165) by inhibiting the apoptosis of 
osteoblast progenitors and stimulating osteoblast proliferation and differentiation (165, 
166).  Reduction in trabecular bone volume characterizes mice overexpressing sFRP1 
(167).  Interestingly, sFRP1 also binds RANKL in vitro and as such, acts as a negative 
regulator of osteoclastogenesis in vitro (165, 168), but not in vivo (165).   
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Alterations in sFRP1 expression have been implicated in homeostatic and 
pathologic regulation of bone formation, as deficiency of sFRP1 promotes fracture 
healing (325) and sFRP1 blockade reduces alveolar bone loss in periodontal disease 
(317), respectively.  sFRP1 mRNA is also highly upregulated in synovial tissue of mice 
with serum transfer arthritis (STA), a murine model characterized by inflammatory bone 
loss (96).  When inflammation in STA resolves, the expression of sFRP1 returns to non-
arthritic levels, correlating with increased osteoblast activity and repair of previously 
eroded bone (326).  Together, these observations suggest sFRP1 may be a factor 
contributing to inflammation-induced inhibition of osteoblast activity.   
In the setting of inflammatory bone loss, where few mature, osteocalcin-
expressing cells are observed (96), the absence sFRP1 may promote osteoblast-mediated 
erosion repair by two mechanisms.  First, sFRP1 expression has been shown to positively 
correlate with osteoblast lineage cell apoptosis in vitro and in vivo (165, 166).  Thus, the 
lack of sFRP1 expression at the pannus-bone interface may inhibit the premature 
apoptosis of osteoblasts due to pro-inflammatory cytokine exposure (100).  Secondly, 
deficiency of sFRP1 may promote the maturation of these mesenchymal progenitor cells 
at eroded bone surfaces.  Therefore, we hypothesize that in the context of inflammatory 
arthritis, the absence of sFRP1 would promote osteoblast-mediated bone formation and 
the repair of established erosions, resulting in a decrease in the observance of bone 
erosions.  To address this hypothesis, STA was induced in sFRP1 deficient and litter mate 
control mice and bone erosion quantified.  In this study, lack of sFRP1 did not protect 
against erosion formation and bone loss during the inflammatory phase.  However, 
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osteoblasts were prominent along the inflammation-bone interfaces in sFRP1 deficient 
mice compared to wildtype controls.  This observation suggests that the absence of 
sFRP1 may accelerate osteoblast differentiation and/or bone formation if sufficient time 
is allowed for the erosion repair process.   
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Materials and Methods 
K/BxN Serum Transfer Model of Inflammatory Arthritis  
All animal procedures were performed in accordance with protocols approved by 
the Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School.  K/BxN mice were generated by crossing KRN T cell transgenic mice 
(Drs. Benoist and Mathis, Harvard Medical School) with NOD mice (Jackson 
Laboratories) (279, 280).  Serum from individual arthritic K/BxN mice was isolated and 
pooled for STA studies as described previously (69, 96).   
Two independent sources of sFRP1 mutant mice were used in these studies.  
sFRP1 knockout mice previously generated by Joestring et al. (327) (hereafter referred to 
as Rubin sFRP1 mice) and by Bodine et al. (165) (hereafter referred to as Bodine sFRP1 
mice) were reported to have alterations in bone formation (both strains provided by Dr. 
Jane Lian, University of Massachusetts Medical School).  STA was induced in eight or 
twelve week old male sFRP1 deficient and wildtype litter mate control mice by 
intraperitoneal injection of 8µl/g of arthritogenic K/BxN serum on days 0 and 2, followed 
by 150µl of serum on days 7 and 14.  Non-arthritic mice received 150µl of sterile PBS.   
Clinical inflammation scoring was performed as previously detailed (69) and 
described in Chapter II.  At each time point, scores for the four paws were summed and 
the average calculated.  The average clinical score and standard deviation for each 
genotype was reported.  Hind paw ankle thickness was measured by caliper.  Change in 
ankle thickness was defined as the difference in ankle thickness from the baseline 
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measurement (69).  At each time point, the change in ankle thickness of the hind paws 
was determined.  The average and standard deviation for each genotype was reported. 
 
Histopathologic Analyses  
Hind limbs were fixed in 4% paraformaldehyde for 24 hours, decalcified in 8% 
formic acid/800mM sodium formate, and paraffin embedded.  For histological scoring of 
inflammation and bone erosion, sections were stained for hematoxylin and eosin or 
tartrate resistant acid phosphatase (TRAP), respectively, (326) and detailed in Chapter II.  
Slides were scored directly using previously defined histopathological scoring criteria 
outlined as previously described (69) and detailed in Chapter II.  The data are represented 
as the average score for each mouse.  Images were acquired with a Nikon Eclipse E600 
microscope with a Nikon Plan Fluor objective and a Nikon DS-Ri1 camera with Nikon 
NIS-Elements BR 3.10 software. 
 
Statistical Analyses 
Unpaired Student’s t tests were used to calculate statistical significance for 
histology scores. 
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Results 
Inflammatory Bone Loss in the Setting of sFRP1 Deficiency.  
The correlation between sFRP1 expression and bone formation in the serum 
transfer arthritis (STA) model suggests that sFRP1 may be a factor contributing to the 
inhibition of osteoblast activity and bone formation in inflammatory arthritis (96, 326).  
To determine the contribution of sFRP1 to the suppression of osteoblast-mediated bone 
formation and subsequent erosion repair, STA was induced in two independent strains of 
sFRP1 deficient mice, the Rubin (327) and Bodine (165) sFRP1 mutant mice, both of 
which were created by replacing exon 1 of the sFRP1 gene with a LacZ/Neo cassette.  As 
an indirect measure of erosion repair, bone erosion was quantified in each strain. 
Clinical inflammation developed similarly in the Rubin sFRP1 deficient and 
wildtype litter mate control mice following administration of arthritogenic K/BxN serum 
(Figure 3.1A, P = 0.759).  Quantification of histological inflammation was also 
comparable between genotypes at days 14 (data not shown, P = 0.130) and 16 of sacrifice 
(Figure 3.1B, P = 0.979).  In the Rubin mice, absence of sFRP1 did not protect against 
the development of erosions in the midfoot of the hind paw at day 14 (data not shown, P 
= 0.643) or at day 16 (Figure 3.1C, P = 0.187).  Erosion in the bones of the tibio-talar 
region was also not affected by the absence of sFRP1 (data not shown).  
However, further analyses revealed that in vitro osteoblast differentiation was not 
accelerated in the Rubin sFRP1 deficient mice nor did the knockout mice exhibit an 
increase in trabecular bone volume (data not shown, kindly performed by Dr. Tripti Gaur, 
University of Massachusetts Medical School), as previously reported by Bodine et al. 
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(165).  The cause of this unexpected phenotype is not currently known, but divergent 
backcrossing strategies have been implicated.   Both the Rubin and Bodine sFRP1 mice 
were generated in 129/Sv embryos and injected into C57BL/6J blastocysts (165, 327).  
The Rubin sFRP1 deficient mice originally created by this strategy were reported to have 
a bone phenotype (Jeffery Rubin and Natalie Sims, unpublished personal 
communication); however, the founding colony was backcrossed to C57BL/6 mice from 
the National Cancer Institute and the phenotype was no longer observable.  In contrast, 
the Bodine sFRP1 were maintained on C57BL/6 mice from The Jackson Laboratory. 
These observations suggest that differences in the genetic profiles of the C57BL/6 mice 
from the National Cancer Institute and Jackson Laboratories are a likely contributor to 
the difference in the bone phenotype.  Since the phenotype of the Bodine sFRP1 mice has 
been previously validated (data not shown, in conjunction with Dr. Tripti Gaur, 
University of Massachusetts Medical School), the Bodine sFRP1 mice were used for all 
subsequent analyses. 
The Bodine sFRP1 deficient and wildtype litter mate control mice developed 
equivalent, robust clinical inflammation and paw swelling (Figure 3.2A and 3.2B).  
However, as frequently observed in STA, some mice did not develop arthritis, 
contributing to the variability observed in the clinical inflammation scores and paw 
swelling measurements.  Mice which did not exhibit inflammation were removed from all 
subsequent analyses.  For those that developed inflammation, the wildtype controls 
exhibited moderate histological inflammation at day 18, characterized by the infiltration 
of inflammatory cells and pannus tissue formation (Figure 3.3A).  In contrast, sFRP1 
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deficient mice had little cellular infiltration into the midfoot bones and consequently they 
had lower, but not statistically different, levels of inflammation compared to wildtype 
controls (Figure 3.3C, P = 0.531).   
In the STA model, the navicular bone in the midfoot of the hind paw is a 
reproducible site of inflammation-induced bone erosion (96).  However, at day 18, few 
TRAP+ osteoclasts were present on the bone surfaces of the sFRP1 knockout or wildtype 
control mice, indicating that the osteoclast-mediated erosive phase had terminated as 
inflammation waned (Figure 3.3B).  Nevertheless, prior osteoclast activity earlier in the 
course of inflammation led to full thickness cortical bone erosions in sFRP1 wildtype 
mice, which caused significant loss of the navicular bone architecture and almost 
complete destruction of the adjacent cuneiform bone (Figure 3.3B).  sFRP1 deficient 
mice were spared from substantial osteoclast-mediated bone erosion (Figure 3.3D).  
Because of the lack of cellular infiltration into the midfoot bones, we cannot exclude the 
possibility that these mice may not have achieved the levels of inflammation required to 
induce bone erosion.  Therefore, we evaluated bone erosion earlier in the course of 
inflammation, when the inflammatory process was more robust.  
On day 16 after the induction of arthritis, sFRP1 deficient and wildtype mice 
exhibited similar influx of inflammatory cells into the joint, synovial hyperplasia, and 
invasion of pannus tissue (Figure 3.3E and 3.3G, P = 0.887).  TRAP+ osteoclasts were 
present on the endosteal and periosteal surfaces of the navicular bone at day 16 in the 
sFRP1 wildtype mice (Figure 3.3F).  The presence of TRAP+ osteoclasts in the wildtype 
mice was associated with full thickness cortical defects and distortion of the architecture 
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of the midfoot bones.  In the absence of sFRP1, osteoclast activity and bone erosion was 
similar to the wildtype controls, with osteoclasts eroding the trabecular and cortical 
surfaces of the navicular bone (Figure 3.3H, P = 0.671).  Unexpectedly, bone lining cells 
morphologically resembling osteoblasts were prominent along the inflammation-bone 
interfaces in sFRP1 deficient mice compared to wildtype controls (Figure 3.3E, 
arrowheads).  Taken together, these data demonstrate that sFRP1 does not impact 
inflammation-induced bone loss during peak inflammation; however, osteoblasts are 
prominent in sFRP1 deficient mice during the inflammatory process. 
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Discussion 
Osteoclast-mediated bone erosion in RA is well documented, but the defects in 
osteoblast-mediated bone formation contributing to the net loss of bone in RA have not 
been completely elucidated.  We have previously shown in a murine model of 
inflammatory arthritis that inflammation suppresses bone formation (96). Furthermore, 
osteoblast activity in this model inversely correlates with the expression of sFRP1 
mRNA, which is upregulated in synovial tissue during inflammation and downregulated 
as inflammation resolves (96, 326).  This observation suggests that increased expression 
of sFRP1 during inflammation contributes to the inhibition of osteoblast activity in 
inflammatory arthritis.   
By inducing murine inflammatory arthritis in the setting of sFRP1 deficiency, this 
study demonstrates that sFRP1 does not protect against inflammatory bone loss.  This 
observation implies that inflammation-induced upregulation of other factors, such as 
sFRP2, which is also highly upregulated in STA (96, 326), may regulate bone loss during 
peak inflammation in this model.  Interestingly, osteoblasts were prominent along the 
bone surfaces juxtaposed to inflammatory tissue, suggesting that osteoblast 
differentiation and/or bone formation may be stimulated in the absence of sFRP1. As 
such, if we extended the arthritis time course, osteoblasts may have had the capacity to 
repair eroded bone.   
Our previous work in Chapter II also demonstrated that synovial fibroblast 
expression of sFRP1 returns to non-arthritic levels in the setting of resolving 
inflammation, correlating with osteoblast-mediated erosion repair (326).  This 
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observation implies that decreasing expression of sFRP1 may be a factor contributing to 
bone formation as inflammation resolves.  Thus, while the absence of sFRP1 in this study 
did not protect against inflammatory bone loss, sFRP1 deficiency may accelerate repair 
of bone erosions in the setting of resolving inflammation.  As noted previously, sFRP1 
deficiency promotes the proliferation and maturation of osteoblast progenitors, while 
inhibiting apoptosis (165, 166). Consequently, absence of sFRP1 in the model of 
resolving inflammation described in Chapter II may foster the survival and differentiation 
of osteoblasts, ultimately leading to more rapid erosion repair. 
These observations suggest a need to determine if sFRP1 deficiency stimulates 
osteoblast differentiation and/or activity following an extended arthritis time course or in 
the context of resolving inflammation.  To address these questions, comprehensive 
histologic and histomorphometic (static and dynamic) analyses of osteoclast and 
osteoblast differentiation and activity will need to be performed.  The effect of sFRP1 
deficiency on the number of osteoblasts (Ob.N) and the amount of bone surface covered 
by osteoblasts (Ob.S/BS) during the inflammatory and repair phases could be quantified, 
while the expression of Runx2, AlkP, and OCN can be used to elucidate the maturation 
state of the osteoblasts found at these pannus-bone interfaces.  Furthermore, to determine 
whether sFRP1 deficiency alters osteoblast apoptosis and proliferation in inflammatory 
arthritis, apoptosis could be quantified in TUNEL (terminal deoxynucleotidyl transferase 
dUTP nick end labeling) stained samples, while bromodeoxyuridine (BrdU) 
incorporation and Ki-67 (nuclear proliferation antigen) staining could be used to assess 
proliferation.  
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Administration of the fluorochromes alizarin and calcein can be further used to 
identify areas of bone formation and quantitate osteoblast activity.  Fluorochrome 
incorporation into newly formed bone allows for evaluation of bone formation by 
individual osteoblasts (mineral apposition rate, MAR), bone formation by the entire 
osteoblast population (mineralized bone surface/bone surface, MS/BS), as well as the 
overall bone formation rate (BFR).   
In addition to promoting osteoblast differentiation and activity (165, 166), sFRP1 
also binds RANKL and inhibits osteoclastogenesis in vitro (168).  From these 
observations one could speculate that in diseases of inflammatory bone loss, the absence 
of sFRP1 might enhance bone erosion, due to increased availability of RANKL; however, 
this study suggests that sFRP1 deficiency does not qualitatively alter osteoclastogenesis 
or resorption in inflammation-induced bone loss.  In accordance with our findings, 
changes in bone resorption were not observed in sFRP1 deficient mice in vivo (165).  We 
cannot exclude the possibility that both osteoclast and osteoblast activity were increased 
in the absence of sFRP1 and that the increased osteoblast activity was unable to 
compensate for the increased osteoclast activity. 
Histomorphometry could also be used to address these questions regarding the 
effect of sFRP1 deficiency on the number of osteoclasts (Oc.N), the amount of bone 
surface covered by osteoclasts (Oc.S/BS), and the quantity of eroded bone surface (ES) 
as a result of inflammatory arthritis.  The expression of RANKL and OPG protein in 
isolated synovial tissue would be evaluated in order to determine whether the absence of 
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sFRP1 alters the expression and availability of pro- and anti-osteoclastogenic factors in 
the joint microenvironment.   
Lastly, in addition to preforming the aforementioned studies in sFRP1 deficient 
mice, these experiments could also be addressed using siRNA knockdown or antibody 
blockade of sFRP1 in vivo.  Both strategies to reduced sFRP1 expression could be 
employed at various time points over the course of peak and resolving inflammation.  
Thus, these strategies would delineate the critical time points at which sFRP1 expression 
is critical for the inhibition of osteoblast-mediated bone formation. 
In conclusion, this study demonstrated that the absence of sFRP1 does not protect 
against bone loss during ongoing inflammation.  The observance of osteoblasts along 
inflammation-bone interfaces suggests that sFRP1 deficiency may have stimulated 
osteoblast differentiation and/or activity, which was unable to compensate for the robust 
bone erosion observed in this study.  However, an extended repair period or resolving 
inflammation may be necessary in order to determine if sFRP1 deficiency promotes 
osteoblast-mediated bone formation and erosion repair.  Further studies may be 
performed to elucidate the contribution of sFRP1 to the erosion repair process.   
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CHAPTER IV 
 
Inflammation Induces Expression of BMP3, an Inhibitor of Bone Formation,           
in Osteoblasts 
 
 
The work presented in this chapter is contained within the manuscript: 
Matzelle MM, Shaw AT, Li J, Karmakar S, Manning CA, Walsh NC, Rosen V, 
Gravallese EM.  “Inflammation induces expression of BMP3, an inhibitor of bone 
formation”.  In preparation. 
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Summary 
Inflammation in diseases such as rheumatoid arthritis (RA) stimulates osteoclast-
mediated articular bone erosion and inhibits osteoblast-mediated bone formation, leading 
to a net loss of bone.  Suppression of osteoblast differentiation and activity in RA has 
been linked to inflammation-induced upregulation of antagonists of the osteogenic Wnt 
signaling pathway.  However, osteoblast maturation and function is also controlled by the 
bone morphogenetic protein (BMP) signaling pathway, which is negatively regulated by 
BMP3.  To examine the contribution of the BMP signaling pathway, particularly BMP3, 
to bone loss in RA, the ability of inflammation to induce BMP3 expression was evaluated 
in vitro and in vivo.  Specifically, synovial fibroblasts and bone marrow-derived 
osteoblasts, two cell types relevant to RA, were treated with pro-inflammatory cytokines 
and the production of BMP3 evaluated.  In two in vivo models of RA, the STA and AIA 
models, the cellular sources of BMP3 and its expression pattern over the course of 
inflammatory arthritis were establish.  In non-arthritic murine synovial fibroblasts, TNF 
and IL-1β, but not IL-17, induced expression of BMP3 mRNA, but not protein.  In vivo 
however, synovial lining cells and pannus tissue expressed minimal amounts of BMP3.  
In contrast, BMP3 expression was observed most notably by osteocalcin-expressing 
osteoblasts lining inflammation-bone interfaces late in the course of arthritis. In vitro, IL-
17 stimulation induced BMP3 expression in mature, osteocalcin-expressing osteoblasts.  
These data implicate BMP3, which is induced in osteoblasts at sites of articular bone 
erosion, as a novel factor that may contribute to focal bone loss in RA through 
impairment of osteoblast function. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by 
synovial hyperplasia and progressive loss of articular bone, resulting in joint destruction 
and disability.  Inflammation-induced expression of RANKL, a pro-osteoclastogenic 
factor, in conjunction with pro-osteoclastogenic cytokine expression, promotes the 
differentiation and activity of bone-resorbing osteoclasts (64, 66).  Consequently, 
osteoclasts form at the pannus-bone interface and mediate focal articular bone erosion 
(69, 70).  In addition to increased osteoclast-mediated bone resorption, osteoblast-
mediated bone formation in RA is also impaired.  Early osteoblast progenitors are present 
on bone surfaces adjacent to erosion sites in RA (64).  Although immature Runx2-
expressing osteoblast progenitors are present at the pannus-bone interface during peak 
inflammation in the murine serum transfer arthritis model, few mature, osteocalcin-
expressing osteoblasts are present at these sites (96). Moreover, bone formation at these 
inflammation-bone interfaces is limited (96).  Resolution of inflammation, however, 
stimulates the repopulation of these surfaces with mature, osteocalcin-expressing 
osteoblasts and promotes osteoblast function, ultimately leading to increased bone 
formation and repair of established bone erosions (326).  Thus, inflammation in the bone 
microenvironment impairs osteoblast differentiation and bone formation at sites of 
erosion, ultimately contributing to the net loss of bone over time. 
Pro-inflammatory cytokines that are central to RA pathogenesis also inhibit the 
differentiation and function of osteoblasts in vitro.  In particular, TNF directly blocks the 
differentiation of osteoblast mesenchymal precursors in vitro by suppressing the 
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expression of Runx2 and osterix, transcription factors responsible for osteoblast-lineage 
commitment (100, 105).  As a result, expression of the Runx2 target genes alkaline 
phosphatase, type I collagen, and osteocalcin is suppressed, leading to impaired bone 
matrix deposition, mineralization, and nodule formation (100).  Simultaneously, TNF 
upregulates RANKL and M-CSF to promote osteoclastogenesis as well as iNOS, IL-6, 
and MMPs to contribute to matrix catabolism (100, 101).  IL-1β elicits similar inhibitory 
responses in differentiating osteoblasts (113).  The direct effects of IL-17 on osteoblast 
differentiation and bone matrix synthesis have not been demonstrated; however, IL-17 
upregulates membrane-bound RANKL expression on osteoblasts (114).   
Alterations in the canonical Wnt signaling pathway, a pathway critical for 
osteoblast differentiation and activity, have been implicated as one mechanism by which 
pro-inflammatory cytokines impact osteoblasts.  We and others have shown that 
inflammation upregulates the expression of antagonists of the Wnt signaling pathway, 
including DKK1, sFRP1 and sFRP2, in the synovial tissue of arthritic mice (96, 265, 
326).  Furthermore, blockade of DKK1 expression in a TNF-driven arthritis model 
protects from articular bone erosion and promotes periosteal bone formation (157, 159, 
160).  Together, these data demonstrate that inflammation regulates the expression of 
catabolic factors, which control the fate of bone in diseases of inflammation-induced 
bone loss. 
Osteoblast differentiation and function is also dependent on the bone 
morphogenetic protein (BMP) signaling pathway.  BMPs, members of the transforming 
growth factor- superfamily, trigger dimerization of the serine/threonine associated type I 
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and type II BMP receptors, phosphorylation of the BMP-specific Smads1, 5, and 8, and 
the transcription of BMP-responsive osteogenic genes.  Notably, BMP2, 4, and 7, are 
critical for the early commitment and differentiation of mesenchymal precursor cells to 
the osteoblast lineage and are essential for regulating skeletal development and bone 
mass maintenance in adults (328).   
BMP-induced signaling is tightly regulated by a number of secreted antagonists, 
including noggin, gremlin, and a unique member of the BMP family, BMP3 (328).  
BMP3 antagonizes the BMP type II receptor, ActRIIB, and suppresses BMP-induced 
osteogenic responses (243, 247, 249, 250). Overexpression of BMP3 leads to the 
development of multiple, spontaneous rib fractures as a result of thinner cortical bone and 
decreased mineralization (224).  Deletion of BMP3 accelerates osteoblast differentiation 
(243) and mice deficient in BMP3 have increased femoral bone density due to increased 
trabecular bone volume (249).  Furthermore, ActRIIB receptor knockout mice exhibit 
defects in bone mineralization and chondrogenesis similar to BMP3 transgenic mice 
(224), demonstrating that BMP3 acts as a negative regulator of osteoblast-mediated bone 
formation via the ActRIIB receptor.  
Pro-inflammatory cytokines also directly impact the BMP signaling pathway.   
TNF inhibited BMP-induced alkaline phosphatase production, expression of osteoblast 
differentiation genes, and bone formation (109, 276, 277).  BMP3 expression in dental 
follicle cells was also upregulated by TNF in vitro (278).   Taken together, these studies 
suggest that alterations in BMP signaling, specifically, the upregulation of BMP3 
expression, may be a novel pathway by which inflammation inhibits osteoblast 
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differentiation and activity in diseases of inflammation-induced bone loss.  To elucidate 
the mechanism by which inflammation alters BMP3 expression, we quantitated the 
ability of select pro-inflammatory cytokines to regulate the expression of BMP3 in vitro 
in murine synovial fibroblasts and bone-marrow derived osteoblasts, two cell types 
relevant to bone erosion in inflammatory arthritis.  In conjunction with the in vitro data, 
we found that in two murine models of arthritis, BMP3 localizes to osteoblasts lining 
focal bone erosion sites and to a lesser extent, cells within the inflamed synovium, late in 
the course of inflammation.   
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Materials and Methods 
Animals 
All animal procedures were performed in accordance with protocols approved by 
the Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School.  Male C57BL/6J mice used for in vitro and in vivo studies were obtained 
from The Jackson Laboratory.  BMP3 LacZ knock-in mice were generated as previously 
described ((243, 329).  KRN T cell transgenic mice (provided by Drs. Benoist and 
Mathis, Harvard Medical School and the Institut de Genetique et de Biologie Moleculaire 
et Cellulaire, Illkirch, France) were crossed with NOD/ShiLtJ mice (Jackson 
Laboratories) to generate K/BxN mice that spontaneously develop arthritis (279, 280).  
At 60 days of age, arthritogenic serum from K/BxN mice was obtained and pooled for 
STA studies as previously described (69, 96).  
   
Antigen-Induced Arthritis Model 
Induction of antigen-induced arthritis (AIA) was adapted from previously 
published procedures (117, 301).  Twelve-week old male C57BL/6J mice were 
immunized subcutaneously at the tail base with 100µl of 4mg/ml methylated bovine 
serum albumin (mBSA, Sigma) emulsified in 4mg/ml complete Freund’s adjuvant (Difco 
Laboratories) supplemented with 2.5mg/ml M. tuberculosis H37 RA (Difco 
Laboratories).  Seven days later, arthritis was induced by intra-articular injection of 6µl 
of a 10μg/μl solution of mBSA in PBS in the left knee.  The right knee was injected with 
6l of sterile PBS as the negative control.  At the time of intra-articular mBSA injection, 
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mice were also injected intraperitoneally with 20µg of lipopolysaccharide to boost and 
synchronize initiation of arthritis development.   
 
K/BxN Serum Transfer Arthritis Model 
Serum transfer arthritis (STA) was generated in twelve-week old male C57BL/6J 
mice by intraperitoneal injection of arthritogenic serum on days 0, 2, 7, and 14, with non-
arthritic control mice receiving 150l of PBS at each time point.  Twelve week old male 
mice were used to avoid the juvenile growth spurt and the differential effects of estrogen 
on bone in males and females (69, 96).   
 
Histopathologic Analyses 
For histological assessment of inflammation, paraffin embedded hind limb (STA) 
and knee (AIA) sections were stained with hematoxylin and eosin (H&E).   
Immunohistochemical analysis of BMP3 protein expression was adapted from previously 
described methods (77, 96).  Briefly, paraffin sections were dewaxed and rehydrated 
prior to antigen retrieval in 10mM EDTA, pH7.5.  Endogenous peroxidase activity was 
inhibited with 3% hydrogen peroxide and non-specific binding was blocked using 10% 
fetal bovine serum/10% species specific serum.  Slides were stained with two different 
goat polyclonal anti-BMP3 antibodies (Abcam (ab18864) and Santa Cruz (sc-9031)), 
biotin-conjugated rabbit anti-goat IgG secondary antibody (DAKO), followed by HRP-
conjugated streptavidin (DAKO).  Positive antibody staining was visualized using DAB 
liquid chromogen (DAKO) and nuclei were counterstained with hematoxylin.  For 
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detection of BMP3 and osteocalcin mRNA, digoxigenin labeled anti-sense and sense 
riboprobes were generated as previously described (96).  BMP3 specific primers 
(NM_173404.3) were used to generate a 391bp murine BMP3 cDNA fragment which 
was cloned into the pGEMT-easy vector (Promega).  In situ hybridization was performed 
according to previously described methods (96).  Images were acquired with a Nikon 
Eclipe E600 microscope with a Nikon Plan Fluor objective and a Nikon DS-Ri1 camera 
with Nikon NIS-Elements BR 3.10 software. 
 
Tissue dissection and isolation of RNA   
For the hind limbs from STA, synovial and associated soft tissue was dissected 
from the tibio-talar joint.  For the tibiofemoral joints from AIA, the patellar ligament was 
removed and the synovial tissue of the tibiofemoral joint was dissected.  Tissue samples 
were processed for RNA as previously detailed using a modified acid-guanidinium 
isothiocyanate phenol-chloroform extraction (96).   
 
Synovial Fibroblast Isolation and Cytokine Stimulation  
Synovial fibroblasts were isolated from C57BL/6J as previously described (330).  
Briefly, hind ankles were digested with 1mg/ml collagenase (type IV, Worthington 
Biochemical) for 2 hours at 37°C.  Isolated synovial fibroblasts were cultured in DMEM 
supplemented with 10% FBS, 2mM L-glutamine, 100units/ml penicillin, 50µM 2-
mercaptoethanol, and essential and nonessential amino acids.  After the third passage, the 
cells had <1% F4/80+ and CD45+ macrophages as determined by FACS.  Cells were 
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used for experiments between passages 5-7.  For cytokine stimulation, 5x104 synovial 
fibroblasts/well were seeded into 24-well plates in 5% FBS culture media and treated 
with or without TNF (10ng/ml, Fitzgerald), IL-1 (10ng/ml, Fitzgerald), or IL-17A 
(50ng/ml, R&D Systems) in triplicate.  RNA was prepared with Trizol (Invitrogen) 
according to manufacturer’s instructions and contaminating genomic DNA was removed 
using the Turbo DNA-free kit (Ambion).  
 
Bone Marrow Stromal Cell Isolation and Osteoblast Differentiation   
Bone marrow stromal cells were flushed from the tibia and femur of C57BL/6J 
mice and RBCs were lysed with 15ml of sterile water for 30 seconds.  1.5x106 cells/well 
were seeded into 12-well plates and maintained in α-MEM supplemented with 20% FBS, 
0.2% penicillin/streptomycin and 1% L-glutamine for 10 days.  On day 0, the medium 
was replaced with osteogenic medium (α-MEM with 20% FBS, 0.2% 
penicillin/streptomycin 1% L-glutamine, 10mM -glycerolphosphate, and 25g/ml 
ascorbate).  Medium was changed 3 times per week beginning on day 2 and replaced with 
osteogenic medium containing 50g/ml ascorbate.  On days 7, 14, 21, and 28 of 
differentiation, cells were stimulated with or without IL-17A (50 or 100ng/ml) for 7 or 12 
hours.  Samples were performed in triplicate.  RNA was prepared with Trizol according 
to manufacturer’s instructions and genomic DNA was removed using RNeasy Plus Micro 
Kit (Qiagen).  
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Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
cDNA was synthesized using the iScript cDNA synthesis kit (BioRad) as 
previously described (96).  qPCR was performed using Qiagen primers for 
hydroxymethylbilane synthase (HMBS, catalog number QT00494130), BMP3 
(QT00137179), TNF (QT00104006), IL-1β (QT01048355), and IL-17A (QT00103278). 
iScript Sybr Green Supermix (BioRad) was used for the qPCR reaction.  Expression of 
BMP3 mRNA was normalized to expression of HMBS mRNA (reference gene).  Using 
the 2-ΔΔCt method (314), synovial tissue gene expression data was expressed as the fold 
increase in arthritic gene expression compared to average non-arthritic gene expression.  
Cultured synovial fibroblast RNA levels were expressed as fold increase in cytokine-
treated cells compared to unstimulated cells. Differentiated bone marrow stromal cell 
data was expressed as fold increase in cytokine-treated cells compared to unstimulated 
cells at each time point of differentiation (days 7, 14, 21, and 28). 
 
In vitro β-Galactosidase Staining 
At each time point of cytokine stimulation described above, differentiated bone 
marrow stromal cells and cultured synovial fibroblasts generated from BMP3 LacZ 
knock-in mice ((243, 329) and stained for β-galactosidase activity as previously described 
(165).  Briefly, cells were fixed in 0.5% glutaraldehyde and incubated for 3 hours at 37°C 
in  PBS (pH 7.4) containing 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 
2mM MgCl2, 0.02% Nonidet P-40, 0.01% sodium deoxycholate, and 1mg/ml X-Gal.  
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Images were acquired with a Nikon Eclipe TS100 microscope with a Nikon Ph1 ADL 
objective and a Nikon DS-Ri1 camera with Nikon NIS-Elements BR 3.10 software. 
 
Statistical Analysis 
For cultured synovial fibroblast stimulations, fold changes were calculated as the 
gene expression at hour X/gene expression at hour 0, where X = 7, 24, 48, 72. We 
assumed that fold change had a reasonably normal distribution. Descriptive statistics 
were calculated using statistical functions within Microsoft Excel. We used linear mixed 
effect model analysis in SAS (SAS Institute) to estimate the effect of the predictors 
treatment (TNF, IL-1, or IL-17), experiment (1, 2, or 3), and hour on the outcome of fold 
change of gene expression (331). This accounts for the absence of independence within 
experiments due to repeated measures over time of gene activity in the same samples. 
The fixed effect of treatment, experiment, and hour of observation on fold change was 
estimated with replicates considered to be a random effect.  Estimates of overall 
treatment effect, along with effects over time were obtained, and P values less than 0.05 
were considered to be statistically significant.  Because the data is represented as fold 
change from baseline to hour X, we assumed that, for the purposes of modeling, hour 7 
would represent the smallest fold change from baseline and thus, would be the baseline 
for the models. Therefore, the models show the effect of the predictors fold change from 
hour 7.  
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Results 
TNF and IL-1β, but not IL-17 induce BMP3 mRNA expression in synovial fibroblasts in 
vitro.   
TNF induced upregulation of BMP3 expression in vitro in dental follicle cells, a 
precursor population of cells which gives rise to the periodontal ligament, osteoblasts, 
cementoblasts, and fibroblasts involved in tooth eruption (278).  Based on this 
observation, we questioned whether pro-inflammatory cytokines expressed in 
inflammatory arthritis could induce BMP3 expression in synovial fibroblasts, a critical 
cell type in the pathogenesis of articular bone erosion. To address this question, synovial 
fibroblasts isolated from C57BL/6 mice were stimulated with TNF, IL-1β, or IL-17, pro-
inflammatory cytokines involved in bone erosion and implicated in the inhibition of 
osteoblast activity (100, 113, 114).  TNF induced BMP3 mRNA expression 
approximately 150-fold over the course of 72 hours, which was highly statistically 
significant compared to unstimulated controls (P = 0.009, with the 7 hour time point as 
the comparator) (Figure 4.1A).  Interestingly, IL-1 induced a transient 10-fold increase 
in BMP3 mRNA expression at 7 hours (Figure 4.1B), but expression declined by 24 
hours.  IL-1β-induced BMP3 expression remained approximately 2-fold upregulated 
compared to unstimulated cells from 24 hours onward (P = 0.022, with the 7 hour time 
point as the comparator). In contrast, IL-17 did not have a significant effect on BMP3 
mRNA expression by synovial fibroblasts (Figure 4.1C).  Having demonstrated that pro-
inflammatory cytokines differentially regulate BMP3 mRNA expression by synovial 
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fibroblasts in vitro, we sought to further evaluate the contribution of inflammation to 
BMP3 expression during the course of inflammatory arthritis. 
 
BMP3 is predominantly expressed in osteoblasts late in the course of murine 
inflammatory arthritis.   
To evaluate BMP3 expression in vivo, we required a murine model of 
inflammatory arthritis characterized by the expression of TNF, IL-1β, and IL-17.  
Therefore, we utilized the antigen-induced arthritis (AIA) model, a T cell-mediated 
delayed-type hypersensitivity model, which we and others have shown depends on TNF, 
IL-1β, and IL-17 (52, 117, 306).  In our lab, expression of TNF, IL-1β, an IL-17 mRNA 
in synovial tissue from AIA mice peaks two days after induction of arthritis and remains 
elevated until at least day 11 (data not shown).   
In contrast to the findings in vitro, we detected minimal expression of BMP3 in 
synovial fibroblasts and pannus tissue in this in vivo model (Figure 4.2B and 4.2C).  
Small amounts of BMP3 mRNA and protein were identified in the synovium by in situ 
hybridization or immunohistochemistry (data not shown).  Very low levels of BMP3 
mRNA and protein were identified in the pannus tissue at days 10 and 12, but not at 
earlier time points (Figure 4.2A and 4.2B, asterisks).  Consistent with these histologic 
observations, qPCR analysis of isolated synovial tissue from AIA confirmed that BMP3 
mRNA expression was not significantly induced in the synovium (Figure 4.2E).  In non-
arthritic mice, BMP3 mRNA and protein were not observed in any resident cell type in 
the joint (Figure 4.2A and 4.2B, left panel). 
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Interestingly, cells lining the cortical surfaces of the tibiofemoral joint, a 
reproducible site of inflammation-induced bone erosion in AIA, expressed BMP3 mRNA 
and protein by day 10, but not at earlier points during inflammation (Figures 4.2A-C).  As 
arthritis progressed, the number of BMP3-expressing bone lining cells increased along 
the inflammation-bone interfaces.  In serial sections, these cells also expressed the mature 
osteoblast marker, osteocalcin, (Figure 4.2D) identifying these BMP3-expressing cells as 
mature osteoblasts.  Notably, BMP3 was observed in osteoblasts as inflammation was 
resolving in AIA.  BMP3 was not observed in osteoblasts in non-arthritic mice (Figure 
4.2A and 4.2A, left panel).   
Expression of BMP3 was also examined in a second model of RA, the serum 
transfer arthritis (STA) model.  Unlike AIA, STA is dependent on the production of IL-
1β, but TNF is not absolutely required and reports on the role of IL-17 are conflicting 
(290, 292, 293).  In our lab, IL-1β mRNA is highly expressed in synovial tissue from 
STA mice.  TNF and IL-17 mRNA is also expressed, but at a lower level (data not 
shown).  
Similar to the findings in AIA, BMP3 expression was observed late in the course 
of arthritis, by days 15 and 18 (Figures 4.3A and 4.3B) in cells lining the endosteal 
surfaces of the navicular bone of the midfoot, a reproducible site of bone erosion.  
Expression was detected in osteocalcin-expressing cells at inflammation-bone interfaces, 
demonstrating that these cells are osteoblasts (Figures 4.3C and 4.3D). These osteoblast-
lineage cells were seen only at later stages in the process of inflammation in this model, 
as inflammation resolved.   
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Isolated cells in the inflamed synovium and within the invading pannus tissue also 
produced BMP3 mRNA and protein, although at lower levels than that seen in osteoblasts 
(Figure 4.3A and 4.3B, asterisks).  qPCR analysis of isolated synovial tissue from STA 
confirmed that BMP3 mRNA expression was not significantly induced (Figure 4.3E).  
Contrary to previous published reports, BMP3 was not observed in osteocytes in either 
model (243, 332).  Together, data from the AIA and STA models demonstrate that BMP3 
is induced in mature osteoblast-lineage cells at sites of bone erosion and to a far lesser 
extent within cells in the inflamed synovium as inflammation resolves late in the 
progression of arthritis. 
 
IL-17 induces BMP3 expression in osteoblasts.   
To elucidate possible mechanisms inducing BMP3 expression in osteoblasts, bone 
marrow stromal cells were isolated from non-arthritic C57/BL6 mice and differentiated to 
osteoblasts.  In unstimulated, differentiating bone marrow stromal cells, BMP3 mRNA 
expression increased as cells differentiated into mature, osteocalcin-expressing 
osteoblasts (Figure 4.4A).   
Observation of BMP3 expression in mature, osteocalcin-expressing osteoblasts in 
vivo led us to examine the effect of various pro-inflammatory cytokines critical to RA 
pathogenesis, including TNF, IL-1β, and IL-17, on BMP3 expression in relation to the 
stage of osteoblast differentiation.  Of the cytokines examined, IL-17 induced consistent 
changes in BMP3 expression; therefore, we evaluated the effects of acute IL-17 
stimulation at the different stages of osteoblast differentiation.  Studies evaluating the 
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effects of TNF and IL-1β on BMP3 expression by osteoblasts are currently ongoing.  
Since BMP3 is expressed as osteoblasts mature (Figure 4.4A), cytokine-induced effects 
on BMP3 mRNA expression were represented relative to BMP3 mRNA levels in 
unstimulated controls at each time point of differentiation.       
IL-17 treatment did not induce expression of BMP3 mRNA during the early (day 
7) or mid-stages (day 14) of osteoblast differentiation (Figure 4.4B and data not shown).  
In contrast, IL-17 stimulation of mature, differentiated osteoblasts at day 28 induced an 
approximately 2.5-fold upregulation of BMP3 mRNA above the baseline expression 
(Figure 4.4D).  In this representative experiment, no induction of BMP3 mRNA was 
observed at day 21 (Figure 4.4C); however, in some experiments, low levels of IL-17-
induced BMP3 mRNA were observed at this time point.  Inherent variability in the bone 
marrow stromal cell cultures reflects the observed variability in BMP3 mRNA 
expression. 
To further evaluate the ability of IL-17 to promote BMP3 expression in 
osteoblasts, bone marrow stromal cells were isolated from mice in which exon 1 of the 
BMP3 gene was replaced with the lacZ gene (BMP3 LacZ knock-in) (243).  Using these 
BMP3 reporter mice, BMP3 has previously been shown to be expressed in osteoblasts 
and osteocytes in the tibia of 4 week old mice (243).   
As osteoblasts from the BMP3 LacZ knock-in mice differentiated, BMP3 
expression increased as demonstrated by β-galactosidase staining, a measure of BMP3 
promoter activity (Figure 4.5).  In contrast, only isolated areas of β-galactosidase positive 
cells were observed in wildtype osteoblasts, reflective of background β-galactosidase 
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activity in apoptotic and/or senescent cells.  Consistent with the qRT-PCR data in Figure 
4.4, IL-17 stimulation induced little BMP3 at days 7 and 14 (Figure 4.5 and data not 
shown).  However, after 12 hours of IL-17 stimulation at days 21 and 28, β-galactosidase 
staining of osteoblasts intensified, indicating that BMP3 promoter activity increased with 
IL-17 stimulation.  By day 28, BMP3-expressing osteoblasts could be found abundantly 
throughout the developing bone nodules.  An increase in BMP3 expression was also 
observed following 4 and 7 hours of IL-17 treatment at days 21 and 28 (data not shown).  
BMP3 expression was also evaluated in synovial fibroblasts in vitro using cells 
from the BMP3 LacZ knock-in mice.  Similar to synovial fibroblasts isolated from 
C57BL/6J mice (Figure 4.1), TNF induced BMP3 mRNA expression in BMP3 LacZ 
knock-in and wildtype litter mate control mice (Figure 4.6a, data for IL-1β and IL-17 not 
shown).  BMP3 LacZ knock-in synovial fibroblast expressed a low level of baseline 
BMP3, as measured by β-galactosidase staining (Figure 4.6B).  Weak cytoplasmic 
staining was confined to isolated synovial fibroblasts in both the wildtype and LacZ 
knock-in cells.  TNF did not upregulate BMP3 expression in LacZ or wildtype synovial 
fibroblasts after 72 hours of stimulation.  IL-1β and IL-17 also did not alter BMP3 
expression after 72 hours (Figure 4.6B).  Similar results were observed with 7, 24, and 48 
hours of stimulation (data not shown). Together, these data demonstrate that BMP3 
expression is induced above constitutive levels in mature osteoblasts by IL-17, a potent 
pro-inflammatory cytokine in inflammatory arthritis.  However, synovial fibroblasts are 
not a major source of BMP3 in the inflammatory microenvironment. 
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Discussion 
Inflammation in RA not only stimulates osteoclastogenesis and bone erosion, but 
also inhibits osteoblast maturation and activity, which contributes to the net loss of bone 
at erosion sites. There is a paucity of mature, osteocalcin-expressing osteoblasts at sites 
of bone erosion, correlating with limited osteoblast-mediated bone formation (64, 96, 
326).  As inflammation resolves, however, erosion sites are populated by mature 
osteoblasts that form bone and repair previously established bone erosions (326).  These 
observations demonstrate that inflammation directly impacts the maturation and activity 
of osteoblasts.  Specifically, inflammation has been associated with upregulated 
expression of Wnt signaling antagonists, including sFRP1, sFRP2, and DKK1 (96, 265, 
326).  As a result of these findings, considerable attention has been focused on the 
contribution of the Wnt signaling pathway to inflammation-induced bone loss.  However, 
the BMP pathway, another pathway critical for osteoblast differentiation, may also play a 
role in the process of bone erosion in inflammatory arthritis. BMP7-expressing 
osteoblasts have been localized to erosion sites in murine inflammatory arthritis (95), but 
a direct role for BMP signaling in bone erosion and formation has not been demonstrated.  
Here, we show that inflammation induces expression of BMP3, an antagonist of the BMP 
signaling pathway, late in the course of inflammatory arthritis, predominantly in 
osteocalcin-expressing osteoblasts. 
We have elucidated the cellular sources and temporal sequence of BMP3 
expression in murine inflammatory arthritis. Although TNF, and to a lesser extent IL-1β, 
induce BMP3 mRNA expression in cultured synovial fibroblasts, induction of BMP3 
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promoter activity could not be demonstrated in these cells, as measured by β-
galactosidase activity in vitro.  Similarly, in the AIA and STA models of RA, synovial 
fibroblasts expressed minimal amounts of BMP3. Late in the course of arthritis in these 
models, isolated areas of BMP3 expression were observed in the synovial lining layer as 
well as in pannus tissue invading into marrow spaces.  Although observations from these 
murine models implicate synovial fibroblasts as a potential source of BMP3, synovial 
fibroblasts and pannus tissue are not the primary source of this factor.  Western blotting 
and ELISA measurements of BMP3 production by cultured synovial fibroblasts and 
isolated synovial tissue may be used to further validate these in vitro and in vivo findings.  
The reason for the disconnect between BMP3 mRNA expression and promoter activity is 
currently unknown; however, inflammation-induced upregulation of BMP3-targeted 
microRNAs may be one possible mechanism by which BMP3 protein is not expressed 
despite the presence of mRNA.   
In contrast, late in the course of arthritis, after inflammation has peaked, 
expression of BMP3 was upregulated, most strikingly in osteocalcin-expressing 
osteoblasts adjacent to erosion sites.  When inflammation peaks, mature osteoblasts 
expressing osteocalcin are infrequently at erosion sites.  However, as inflammation 
resolves, osteoblasts begin to accumulate on previously eroded bone surfaces to initiate 
the repair process (326).  In this study, the presence of osteocalcin-expressing osteoblasts 
on previously eroded bone surfaces was noted late in the course of arthritis, as 
inflammation began to wane.  Induction of BMP3 expression in mature osteoblasts was 
also demonstrated in vitro by the actions of IL-17.  While BMP3 is normally expressed 
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by differentiating osteoblasts, IL-17 induced BMP3 expression above constitutive levels, 
demonstrating that IL-17 regulates BMP3 in inflammatory microenvironments.  Based on 
our observation that BMP3 is expressed in STA, a model where evidence for the role of 
IL-17 is contradictory, we cannot exclude the possibility that other cytokines induce 
BMP3 expression in osteoblasts.  Studies to investigate the role of other cytokines in the 
induction of BMP3 in osteoblasts are currently underway.  
We hypothesize that BMP3 may contribute to inflammation-induced bone loss by 
inhibiting osteoblast maturation and function.  Late in the course of acute murine models 
of RA, like AIA and STA, inflammation begins to abate as a result of the decreased 
presence of inflammatory stimuli.  While osteoblasts are scarce at erosion sites during 
peak inflammation, resolving inflammation promotes osteoblast population of eroded 
bone surfaces in an attempt to repair the erosive lesion (326).  We hypothesize that at 
these early phases of resolving inflammation, maturing osteoblasts at erosion sites are 
subjected to the pro-inflammatory cytokines still expressed in the joint 
microenvironment.  Thus, pro-inflammatory cytokines, such as IL-17, can act on these 
maturing osteoblasts to induce the expression of BMP3.   Consequently, the observation 
that BMP3 is expressed late in the course of arthritis correlates with the timing of 
osteoblast population of the eroded bone surface.  As an antagonist of the ActRIIB BMP 
receptor, BMP3 suppresses the phosphorylation of Smad1/5/8 (243), leading to inhibition 
of BMP-induced mesenchymal progenitor differentiation.  However, the precise 
downstream alterations in gene transcription and mechanisms responsible for the 
repression of osteoblast maturation have not been described.  Thus in the context of 
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inflammatory arthritis, BMP3 expression may be a mechanism by which maturing 
osteoblasts inhibit the differentiation of osteoblast progenitors, until inflammation has 
more completely resolved.   
This study highlights a potential role by which IL-17 may contribute to 
inflammation-induced bone loss.  Th17 cells are potent stimulators of osteoclastogenesis 
(86) through IL-17-induced expression of RANKL on osteoblasts (114).  For this reason, 
IL-17 has been implicated in periodontal bone loss (115), osteoporosis (116), and bone 
destruction in murine inflammatory arthritis (60, 61, 117-119).  Our data suggests that in 
addition to inducing RANKL expression, IL-17 also stimulates expression of BMP3 in 
osteoblasts.  As a negative regulator of BMP-induced osteoblast differentiation and 
activity, upregulation of BMP3 may be a mechanism by which IL-17 inhibits osteoblast 
activity, contributing to inflammatory bone loss. 
Interestingly, IL-17 differentially regulates the expression of BMP3 depending on 
the differentiation state of the osteoblast.  Several other stimuli have also been shown to 
affect osteoblasts differently depending on their maturation status (109, 113, 333).  
Activation of the Wnt pathways promotes differentiation of immature osteoblasts, while 
inhibiting mineralization by mature osteoblasts (333).  Furthermore, stimulation of 
differentiating osteoblasts with TNF and IL-1β suppresses bone nodule formation when 
added early, but not late in the course of osteoblast differentiation (109, 113).  Inhibition 
of nodule formation in these immature osteoblasts was most pronounced when TNF or 
IL-1β was present for the first seven days of differentiation (109, 113).  Together with 
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our study, these observations suggest that osteoblasts are differentially influenced by the 
local inflammatory microenvironment depending on their stage of differentiation.   
In conclusion, this study demonstrates that inflammation induces expression of 
BMP3, an antagonist of the BMP signaling pathway, in mature osteocalcin-expressing 
osteoblasts.  Upregulation of BMP3 by IL-17 suggests an additional mechanism by which 
IL-17 mediates inflammation-induced bone loss.  Together, these data implicate BMP3 as 
a new factor that may contribute to inflammatory bone loss through impairment of 
osteoblast function and erosion repair. 
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CHAPTER V 
 
T and B Cells are not Absolutely Required for Focal Bone Erosion                             
in Inflammatory Arthritis 
 
 
The work presented in this chapter is contained within the manuscript: 
Matzelle MM, Pettit AR, Walsh NC, Gravallese EM.  “T and B cells are not absolutely 
required for focal bone erosion in inflammatory arthritis”.  In preparation. 
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Summary 
Osteoclast-mediated bone erosion in rheumatoid arthritis results from the 
expression of RANKL, a pro-osteoclastogenic factor, by T cells, B cells, synovial 
fibroblasts, neutrophils, and other cell types within the synovial pannus tissue.  While T 
cells have been implicated as the essential source of RANKL, the importance of T cells in 
the erosive process has not been directly demonstrated.  To elucidate the impact of 
lymphocytes on bone erosion in inflammatory arthritis, arthritis was induced in RAG-1-/- 
mice, which lack mature T and B cells, by transfer of arthritogenic K/BxN serum.  Bone 
erosion was quantitated by histology and qRT-PCR was employed to evaluate changes in 
the expression of RANKL and OPG mRNA in isolated synovial tissue.  In the RAG-1-/- 
mice, inflammation was clearly present, but less severe than in C57BL/6J control mice.  
Despite the more limited inflammation in the absence of T and B cells, erosions were 
clearly evident in the tibio-talar and midfoot bones.  Furthermore, RANKL mRNA was 
expressed in inflamed synovial tissues of RAG-1-/-mice.  Comparable RANKL/OPG 
mRNA ratios were observed in the synovial tissue of RAG-1-/- and controls, suggesting 
that lymphocyte deficiency does not alter the relative expression of RANKL and OPG.  
Together, these data demonstrate that T and B cells are not absolutely required for the 
development of bone erosions in inflammatory arthritis.  Furthermore, the presence of 
bone erosion in the absence of lymphocytes implies that other cell types within the 
inflamed synovium are the critical source(s) of pro-osteoclastogenic factors required for 
osteoclast-mediated bone resorption. 
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Introduction 
Articular bone destruction in rheumatoid arthritis (RA), a chronic autoimmune 
disease that principally affects the synovial joints, results from inflammation of the 
synovial tissue and influx of inflammatory cells into the joint.  Focal bone loss in RA is 
mediated by osteoclasts (64, 69, 70), which differentiate from monocyte precursors 
present in synovial tissues under the influence of receptor activator of NF-κB ligand 
(RANKL).  Under physiological conditions of bone remodeling, osteoblasts and 
osteocytes are the primary source of RANKL.  Immature osteoblasts express RANKL to 
regulate osteoclastogenesis locally, while osteocyte-derived RANKL is essential to the 
maintenance of adult bone mass (194, 195).   
However, in the inflamed synovium in RA, RANKL is also expressed by 
activated Th1 and Th2 CD4+ T cells, synovial fibroblasts, neutrophils, and B cells (66, 
76-78, 83, 334).  Activated T cells from RA patients express secreted and membrane-
bound RANKL, which promotes the differentiation of osteoclast precursor cells in vitro 
(83-85).  T cells also produce pro-osteoclastogenic cytokines, such as TNF, IL-1β, and 
IL-17.  In addition to promoting RANKL expression on synovial fibroblasts and 
osteoblasts (45, 82, 86, 114), these cytokines act synergistically with RANKL to promote 
osteoclast formation (93, 335, 336).  Blocking RANKL function by treatment with OPG-
Fc, an anti-osteoclastogenic factor, in antigen-induced arthritis, a T cell dependent model, 
leads to a decrease in osteoclast numbers and protection from bone erosion (83).  These 
observations have suggested that T cells are the primary mediators of bone erosion in 
diseases of inflammation–induced bone loss.   
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T cell-mediated osteoclastogenesis is largely believed to be mediated by the 
RANKL-expressing Th17 subset of CD4+ T cells (87).  Despite the expression of 
membrane bound RANKL, Th17 cells do not directly promote osteoclastogenesis in 
vitro, suggesting that Th17 cell-derived RANKL is not sufficient for osteoclastogenesis 
(86, 114). Instead, expression of IL-17 by Th17 cells promotes RANKL expression on 
osteoblasts and synovial fibroblasts (84).  
RANKL protein expression has also been observed in synovial tissue, especially 
by synovial fibroblasts and by cells at the pannus-bone interface (66, 77). Stimulation 
with the pro-inflammatory cytokines, TNF, IL-1β, IL-6, and IL-17, induces RANKL 
expression by synovial fibroblasts, which directly stimulates osteoclastogenesis in vitro 
(45, 76, 80, 82). Despite the significant presence of RANKL-expressing synovial 
fibroblasts in the inflamed synovium, the contribution of these cells to the erosion process 
has not been specifically resolved in vivo (337, 338).  
Neutrophils and B cells are also sources of RANKL in RA (78, 334).  Neutrophils 
from RA synovial fluid express membrane-bound RANKL and induce osteoclastogenesis 
and bone resorption in vitro (334).  In contrast, the functional significance of B cell-
derived RANKL in osteoclastogenesis has not been demonstrated.  Despite these 
observations, the contribution of neutrophils and B cells to the erosive process in vivo is 
unknown. 
It is currently unclear whether osteoclast-mediated bone resorption in 
inflammatory arthritis is a result of RANKL expression by T cells or by another cell type 
in the joint.  In this study, we sought to demonstrate the specific role of lymphocytes in 
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bone erosion in inflammatory arthritis. By employing the K/BxN serum transfer model of 
murine inflammatory arthritis, an innate immunity-mediated model that has previously 
been shown to be independent of lymphocytes (280), we demonstrated that T and B cells 
are not absolutely required for erosion formation.  Importantly, these studies highlight the 
critical role of RANKL derived from other cell types in the erosive process.     
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Materials and Methods 
Serum Transfer Model of Inflammatory Arthritis  
All animal procedures were performed in accordance with protocols approved by 
the Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School.  As previously described, K/BxN mice that spontaneously develop 
arthritis were generated by crossing KRN T cell transgenic mice (Drs. Benoist and 
Mathis, Harvard Medical School) with NOD mice (Jackson Laboratories) (279, 280).  
Serum from individual arthritic K/BxN mice was isolated and pooled for STA studies as 
described (69, 96).   
STA was induced in twelve week old male B6.129S7-Rag1tm1Mom/J (RAG-/-) 
(Jackson Laboratories and provided by Dr. Ann Marshak-Rothstein, University of 
Massachusetts Medical School) and control C57BL/6J mice (Jackson Laboratories) by 
intraperitoneal injection of 150µl of arthritogenic K/BxN serum on days 0, 2, 7, and 14.  
Non-arthritic control mice received 150µl of sterile PBS at each time point.  Twelve 
week old male mice were used to avoid the juvenile growth spurt and the differential 
effects of estrogen.   
Clinical inflammation scoring was performed as previously detailed (69) and 
described in Chapter II.  At each time point, scores for the four paws were summed and 
the average calculated.  The average clinical score and standard deviation for each 
experimental group was reported.  Hind paw ankle thickness was measured by caliper.  
Change in ankle thickness was defined as the difference in ankle thickness from the 
baseline measurement (69).  At each time point, the change in ankle thickness of the hind 
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paws was determined.  The average and standard deviation for each experimental group 
was reported. 
 
Histopathologic Analyses  
Hind limbs were fixed in 4% paraformaldehyde for 24 hours, decalcified in 15% 
EDTA/0.5% PFA, and paraffin embedded.  For histological scoring of inflammation and 
bone erosion, sections were stained for hematoxylin and eosin (H&E) or tartrate resistant 
acid phosphatase (TRAP), respectively, as previously described (326) and detailed in 
Chapter II.  Slides were directly scored by two independent observers (MMM and EMG) 
using previously defined histopathological scoring criteria outlined in Chapter II (69).  
The data are represented as the average of both observers’ scores for each mouse.  Images 
were acquired with a Nikon Eclipe E600 microscope with a Nikon Plan Fluor objective 
and a Nikon DS-Ri1 camera with Nikon NIS-Elements BR 3.10 software. 
 
Synovial Gene Expression 
RNA was generated from tibo-talar synovial and associated soft tissue of the hind 
paw as previously detailed (96, 326).  cDNA was synthesized from 250ng of RNA using 
iScript (BioRad).  qRT-PCR was performed on cDNA samples using the iScript Sybr 
Green RT-PCR mix (BioRad).  Primers for hydroxymethylbilane synthase (HMBS, 
catalog number QT00494130), RANKL (catalog number QT00147385), and OPG 
(catalog number QT00106757) were obtained from Qiagen.  Gene expression was 
normalized to the expression of HMBS, a reference gene, and data was expressed as the 
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fold increase in arthritic gene expression compared to average non-arthritic gene 
expression for each genotype (n=4-5) using the 2ΔΔCt method (314).  
 
Statistical Analysis 
Unpaired Student’s t tests were used to calculate statistical significance for 
histology scores. 
 
 
 
 
 
 
 
 
 
 
 
 
132
Results 
T and B cells are not Required for Bone Erosion in Murine K/BxN Serum Transfer 
Arthritis. 
 To evaluate the contribution of T and B cells to bone erosion, serum transfer 
arthritis (STA) was induced in RAG-1-/- mice, which lack mature T and B lymphocytes 
(339).  In accordance with the previous demonstration that T and B cells are not required 
for the initiation or progression of STA (280), administration of arthritogenic K/BxN 
serum to RAG-1-/- mice in this study led to the development of clinical inflammation and 
ankle thickening (Figure 5.1).  Inflammation in the RAG-1-/- mice was decreased, albeit 
not statistically different from that of C57BL/6J control mice.  Furthermore, assessment 
of histological inflammation was not statistically different between the RAG-1-/- and 
C57BL/6J control mice (Figure 5.2A, 5.2B, and 5.2C).    Both strains exhibited 
significant inflammatory cell influx, synovial hyperplasia, and pannus formation in the 
tibio-talar and midfoot regions of the hind paw, characteristic of inflammatory arthritis in 
this model.   
 As a result of inflammation, TRAP+ osteoclasts were abundant on the trabecular 
and cortical surfaces of the tibio-talar and midfoot bones of C57BL/6J control mice 
(Figure 5.2A and 5.2B).  TRAP+ osteoclasts populated trabecular and cortical bone 
surfaces and were associated with roughened, irregular erosion surfaces and full-
thickness defects of the cortical bone.  Despite the absence of T and B cells, erosion in 
the tibio-talar region of the hind paw of RAG-1-/- mice was similar to that of C57BL/6J 
control mice (Figure 5.2A and 5.2D).  In the midfoot, however, osteoclast-mediated bone 
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erosion was more evident in C57BL/6J control mice compared to RAG-1-/- mice (Figure 
5.2B and 5.2E).  Bone erosion in the C57BL/6J control mice was characterized by 
marked trabecular bone loss and distortion of the cortical bone surface, while erosion in 
the RAG-1-/- mice was primarily confined to discreet areas on either the trabecular or 
cortical surface.  In spite of the differences in degree and localization of bone erosion, 
osteoclast differentiation and resorption in inflammatory arthritis progressed in the 
absence of T and B cells. 
 
Synovial Expression of RANKL and OPG mRNA.  
 Having demonstrated that osteoclastogenesis and erosion occurs in the setting of 
T and B cell deficiency, we sought to determine if the expression of the osteoclastogenic 
factors, RANKL and OPG, was altered in the absence of lymphocytes.  While low, the 
expression of RANKL and OPG mRNA was slightly increased in isolated synovial tissue 
of C57BL/6J control mice compared to RAG-1-/- mice (Figure 5.3A and 5.3B).  However, 
the ratio of RANKL to OPG mRNA was similar in RAG-1-/- mice and C57BL/6J control 
mice, indicating that the absence of T and B cells does not significantly alter the relative 
expression of RANKL and OPG in synovial tissue. 
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Discussion 
Focal articular bone erosion in RA has been definitely demonstrated by our group 
as well as others to be mediated by osteoclasts (69, 70); however the essential cellular 
source of RANKL required for osteoclastogenesis has yet to be defined.  From numerous 
in vitro and in vivo studies, it has been suggested that T cells are the primary mediators of 
erosion (83, 84, 86, 87, 114). However, Th1 and Th2 CD4+ T cells, the largest cellular 
infiltrate in the synovium, also synthesize IFN-γ and IL-4, potent anti-osteoclastogenic 
cytokines (86), highlighting the paradoxical contribution of T cells to inflammatory bone 
erosion.  None of these studies directly evaluated the role of RANKL-expressing T cells 
to erosion in vivo.  As a result, the contribution of T cells to the erosive process is still 
speculative.  The role of B cells and other cell types in bone erosion has also not been 
addressed.   
Unlike previous studies that evaluated bone erosion in T cell-dependent models of 
inflammatory arthritis (83), we utilized the STA model, which does not require T and B 
cells for initiation or progression of disease (280).  As such, we were able to evaluate the 
requirement of T and B cells for erosion formation in the setting of inflammatory 
arthritis. From these studies, we demonstrate that T and B lymphocytes are not absolutely 
required for bone erosion.   
T cells have been previously purported to be the primary drivers of 
osteoclastogenesis.  However, our data suggests that T cells are not necessary for erosion 
formation, but may augment the severity of erosions.  Interestingly, while erosion was 
similar in the tibio-talar region of RAG-1-/- mice and controls, erosion was significantly 
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decreased in the midfoot region of RAG-1-/- mice.  Typically in STA, erosion is more 
prominent in the midfoot bones due to the infiltration of inflammation tissue into the 
bone marrow cavities.  RAG-1-/- mice had slightly less inflammation, which may account 
for the lower level of erosion observed in the midfoot region of these mice compared to 
controls.  It is also possible that T cells may impact bone differently depending on the 
degree of inflammatory infiltration present.   
Our data also demonstrates that B cells are not required for erosion in the STA.  B 
cells are not found in the inflammatory infiltrate in STA to any significant degree (data 
not shown) and are not required for STA (280).  Therefore, we cannot entirely exclude 
the possibility that B cells may contribute directly or indirectly to bone erosion in a 
different murine model which requires B cells as part of the inflammatory process.   
Since erosions formed in the absence of T and B cells, our data suggest that 
osteocytes, osteoblasts, synovial fibroblasts, or neutrophils are the critical source of 
RANKL in inflammatory arthritis.  Osteocytes and osteoblasts in the joint 
microenvironment express RANKL to control physiological bone remodeling.  
Osteocyte-derived RANKL also regulates unloading-induced bone loss (194, 195) and 
increased RANKL expression by osteoblasts is associated with bone loss in multiple 
myeloma (340, 341), suggesting that RANKL production by osteocytes and osteoblasts is 
dysregulated in conditions of pathologic bone loss.  Despite these observations, the 
contribution of osteocyte and osteoblast-derived RANKL to bone erosion in the setting of 
inflammation has not been explored.      
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However, in the context of inflammatory arthritis, synovial fibroblasts have been 
shown to directly and indirectly promote osteoclastogenesis of infiltrating osteoclast 
precursor cells via the expression of RANKL and pro-inflammatory cytokines (45, 76, 
80, 82).  Localization of RANKL-expressing synovial fibroblast-like cells to the pannus-
bone interface (66), where the erosive process occurs, also precisely positions the 
synovial fibroblast to regulate osteoclastogenesis.  Together with these observations, our 
data suggest that synovial fibroblasts may be an important cellular source of RANKL for 
bone erosion in inflammatory arthritis; however, the contribution of neutrophil-derived 
RANKL to the erosive process cannot be excluded from our study.   
Several additional experiments are required to conclusively determine which cell 
types are involved in the erosive process.  Immunohistochemistry and in situ 
hybridization could be used to identify cellular sources of RANKL.  FACS analysis of 
isolated synovial tissue could further delineate the specific cell types in the synovium 
expressing RANKL.  However, the definitive demonstration of the cell types required for 
inflammation-induced bone erosion requires induction of STA in cell type-specific 
RANKL knockout mice.  To delete RANKL in defined cell populations, mice with floxed 
Tnfsf11 (RANKL) alleles would be bred with transgenic mice expressing Cre 
recombinase under the control of a specific promoter for B cells (CD19 or mb1), 
osteocytes (DMP1), osteoblasts (col3.6, col2.3, or OCN), or neutrophils (lysozyme M, 
Ela2 or MRP8).  A synovial fibroblast specific promoter has not be defined, thus the 
contribution of synovial fibroblasts to erosion can only be inferred indirectly from the in 
vivo studies defined above.   
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In conclusion, these studies are the first demonstration that T and B cells are not 
absolutely necessary for the formation of focal bone erosions in inflammatory arthritis.  
Activated synovial fibroblasts or neutrophils are therefore implicated as the RANKL-
expressing cell that is essential for inflammation-induced bone erosion.  
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CHAPTER VI 
 
Discussion 
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Inflammation present in the bone microenvironment promotes excess bone 
resorption by osteoclasts, resulting in bone destruction.  In diseases of inflammation-
induced bone loss, such as RA, bone formation is also compromised at these sites, 
contributing to a net loss of bone.  In RA, few mature osteoblasts are localized to eroded 
bone surfaces (99).  Similarly, immature but not fully differentiated osteoblast-lineage 
cells populate erosion sites in murine models of RA, correlating with a suppression of 
osteoblast activity (96).  Inhibition of osteoblast activity at erosion sites has been linked 
to the expression of inhibitors of the canonical Wnt signaling pathway (96, 265), but 
questions regarding the role of bone anabolic signaling in erosion repair still remain.  The 
objective of this dissertation is to elucidate the mechanisms mediating the impairment of 
osteoblast activity during inflammation-induced bone loss by illustrating the 
interconnections between inflammation, bone anabolic signaling pathways, and bone 
formation. 
The observation that erosion repair, although rare, occurs in RA patients with low 
disease activity following conventional disease-modifying anti-rheumatic drug therapy 
(125-134), strongly suggests that inflammation regulates osteoblast-mediated bone 
formation.  By modifying the murine STA model so that inflammation was allowed to 
resolve, Chapter II of this dissertation definitively demonstrates that the presence of 
inflammation impacts the ability of osteoblasts to form bone at previously eroded bone 
surfaces.  As such, resolution of inflammation promotes the maturation of osteoblasts at 
inflammation-bone interfaces and stimulates bone formation, leading to the repair of 
established erosions.   
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The restoration of osteoblast activity following resolution of inflammation 
correlates with alterations in the expression of factors in the Wnt signaling pathway.  Wnt 
antagonists sFRP1, 3, and 4 have previously been shown to be expressed by RA synovial 
fibroblasts (266, 267), while sFRP1 and 2 mRNA expression in murine synovial tissue 
has been associated with inflammation (96).  Research in Chapter II further demonstrates 
that declining inflammation returns the expression of sFRP1 and 2 to non-arthritic levels.  
As such, inflammation regulates the Wnt signaling pathway in the bone 
microenvironment, via increases in synovial expression of Wnt antagonists, which 
correlate negatively with osteoblast-mediated erosion repair. 
Furthermore, the data in Chapter II is the first to suggest that inflammation 
modulates the expression of canonical Wnt agonists related to bone formation.  While 
previous studies have shown that RA synovial fibroblasts express Wnt5a, a non-canonical 
Wnt agonist, Wnt5a activity was associated with cytokine and MMP expression, not bone 
anabolic signaling (268, 269, 342).  In this study, upregulation of Wnt10b mRNA in 
synovial tissue following resolution of inflammation correlates with bone formation, thus 
implicating Wnt10b as a mediator of bone formation, through the enhancement of bone 
anabolic Wnt signaling.  Concurrent upregulation of DKK2 and downregulation of 
Wnt7b may also be critical for the mineralization of newly formed bone matrix, as 
previously proposed (157). Together, the data in Chapter II indicates that stimulation of 
bone formation in the joint microenvironment is a complex, dynamic process and the 
synovium is an active participant in regulating this process.   
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We also speculated that declining inflammation restores osteoblast activity by 
removing inhibitors of osteoblast maturation and activity.  In particular, pro-
inflammatory cytokines, such as TNF and IL-1β, have been shown to block the 
differentiation of osteoblast mesenchymal precursors and inhibit matrix deposition by 
osteoblasts (100, 112, 113).  Thus, the decline in synovial pro-inflammatory cytokine 
mRNA expression may promote the withdrawal of cytokine-mediated inhibition of 
osteoblast differentiation and activity, ultimately leading to bone formation.  The 
complexity of the in vivo model makes it difficult to tease out the contribution of 
cytokine withdrawal verses activated Wnt signaling in the promotion of bone formation.  
While this study suggests that declining inflammation stimulates bone formation 
through the downregulation of Wnt antagonists and the upregulation of Wnt agonists, 
activation of Wnt signaling was not demonstrated.  The involvement of Wnt signaling in 
the restoration of osteoblast differentiation and activity in the setting of declining 
inflammation could be evaluated by several approaches.  Application of this novel model 
of resolving inflammation to Wnt signaling reporter (TOPGAL) mice would delineate the 
temporal sequence of Wnt activation in relation to inflammation as well as positively 
identify cells, particularly osteoblasts, with activated Wnt signaling.  Antibody-mediated 
neutralization of Wnt10b, Wnt7b, or DKK2 during the resolution phase of osteoblast-
mediated bone formation would be the most valuable tool to identify the critical 
participants as well as the sequence of events in the erosion repair process.  Notably, the 
activity of many of the Wnt agonists is redundant, thus one individual factor may not be 
the master regulator of the erosion repair process.   
145
Similar blockade studies established that DKK1 contributes to bone formation in 
the hTNFtg model of inflammatory arthritis.  Neutralization of DKK1 in this model 
promoted periosteal bone formation; however, this is not the site of interest for the 
assessment of bone erosion and repair  (265).  Antagonist blockade was initiated prior to 
the formation of bone erosions and concurrently upregulated the expression of OPG, 
suggesting that blockade of DKK1 suppressed osteoclastogenesis and bone resorption. As 
a result, it is currently unknown whether DKK1 blockade inhibits osteoclastogenesis and 
erosion formation or stimulates new bone formation and erosion repair by promoting 
osteoblast maturation and function.   
Despite these lingering questions, DKK1 has received considerable attention as a 
regulator of osteoblast activity in inflammation-induced bone loss.  In STA, DKK1 
mRNA expression is low and is expressed primarily late in the inflammatory and repair 
processes (96).  In contrast, expression of sFRP1 mRNA is induced in the synovium of 
mice with STA to a greater extent than DKK1 (96).  These observations in inflammatory 
arthritis combined with the data demonstrating that sFRP1 is a negative regulator of 
trabecular bone formation (165), suggest that sFRP1 may be a significant contributor to 
inflammation-induced bone loss in STA.  However, Chapter III of this dissertation 
demonstrates that sFRP1 is not the primary inhibitor of bone formation.  Interestingly, 
osteoblasts are prominent at inflammation-bone interfaces in the setting of sFRP1 
deficiency.  Determination of the potential role of these osteoblasts to erosion repair is 
still required, as outlined in the discussion of Chapter III.  
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Furthermore, the research in this dissertation is the first to implicate the BMP 
signaling pathway in the inhibition of osteoblast activity during inflammatory bone loss.  
BMPs have been shown to be upregulated in murine and RA synovial fibroblasts; 
however, similar to the Wnt agonists, their activity has not been associated with bone 
anabolic activity in this setting (273, 274).  Chapter IV of this dissertation demonstrates 
that inflammation induces expression of BMP3, a negative regulator of the BMP 
signaling pathway and osteoblast activity.  TNF-stimulated synovial fibroblasts and IL-
17-stimulated mature osteoblasts express BMP3 mRNA.  In the STA and AIA models of 
inflammatory arthritis, BMP3 mRNA and protein are observed primarily in osteocalcin-
expressing osteoblasts at erosion sites as inflammation declines.  These observations 
suggest that osteoblast-derived BMP3 may serve as a paracrine signaling mechanism to 
inhibit the differentiation of mesenchymal progenitors recruited to eroded bone surfaces.  
As such, Chapter IV is the first evidence that the osteoblast may not be just a bystander, 
but also may be active participant in suppression of bone formation in the setting of 
inflammation.  Further studies are designed to assess the erosion formation and repair 
process in the absence of BMP3.   
Together, this work demonstrates that osteoblast differentiation and bone 
formation in diseases of inflammatory bone loss are regulated by factors expressed not 
only by the synovium, but also by osteoblasts.  Furthermore, preliminary data in 
Appendix II suggests that polarized macrophages may also be a contributing cell type.  
While M1 polarized inflammatory macrophages are not shown to produce antagonists of 
the Wnt or BMP signaling pathways, M2 polarized alternatively activated macrophages 
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express BMP2 mRNA, in accordance with previous reports (343).  Further studies are 
necessary to elucidate the involvement of M1 and M2 macrophages in the erosion 
formation and repair processes and well as the temporal localization of these 
macrophages in the joint microenvironment.  Previously published reports in fracture 
repair (344, 345) strongly implicates macrophages as another mediator of erosion repair.  
Thus, the role of macrophages in inflammatory bone loss bears further exploration. 
In addition, increasing evidence in the last several years implicates osteoclast and 
osteoblast coupling to pathologic bone loss.  Dysregulated expression of the contact-
dependent coupling mediators ephrin/Eph and semaphorin 4D/plexin-B1 or the soluble 
coupling factor semaphorin 3A have been implicated in bone destruction in cancer and 
osteoporosis, respectively (346-348).   Furthermore, osteoblast expression of Wnt5a 
induces RANK expression on osteoclasts via Ror2-mediated non-canonical Wnt 
signaling, resulting in enhanced osteoclastogenesis (349).  Neutralization of Ror2 
protected against bone erosion in murine inflammatory arthritis, demonstrating the 
importance of coupling in the pathologic setting.  Despite these noteworthy reports, 
questions still remain as to the mechanisms by which inflammation dysregulates 
osteoclast and osteoblast coupling in diseases of inflammatory bone loss.  While these 
pathways have not been explored in this dissertation, they represent an exciting new 
avenue of exploration and may ultimately elucidate potential new therapeutic targets for 
diseases of bone loss.  
Inhibition of bone formation is a characteristic of rheumatoid arthritis (96, 326); 
however, other rheumatic diseases, such as AS and OA are characterized by pathologic 
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bone formation and ankylosis.  As such, understanding inflammation-induced bone 
formation in SpA and OA may provide new insight into therapeutic approaches for the 
promotion of osteoblast activity in diseases of inflammatory bone loss.   
In the STA model, in addition to bone erosion, inflammation also induces distinct 
microenvironments of periosteal bone formation resembling ankylosing spondylitis.  
Using these microenvironments as a model system, the research in Appendix I 
demonstrates that the process of endochondral ossification at the periosteal bone surface 
does not require TNF, RANKL, lymphocytes, or Cox-2 expression in accordance with 
clinical and mouse model data (350-354).  In contrast to previous reports, Appendix I 
definitely demonstrates that T and B lymphocytes are also not required for bone 
formation (95).  However, expression of BMP2 mRNA at the periosteal surface prior the 
initiation of bone formation provides novel insight into the mechanism of bone formation 
and potential therapeutic treatments.   
Lastly, research in Chapter V of this dissertation evaluates the cellular sources of 
RANKL in pathologic bone loss.  Osteoblasts and osteocytes primarily express RANKL 
in physiological bone remodeling (194, 195), while in RA, RANKL is also expressed by 
activated T and B cells, synovial fibroblasts, and neutrophils (66, 76-78, 83, 334).  
Several in vitro and in vivo studies have indirectly suggested that T cell-derived RANKL 
is the primary mediator of bone erosion (83-85).  However, there has been no direct 
demonstration of the contribution of T cells to the erosive process.  By inducing STA, a T 
and B cell independent model of arthritis (280), in lymphocyte deficient mice, Chapter V 
of this dissertation demonstrates that osteoclast differentiation and resorption progresses 
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in the absence of T and B cells.  This observation implicates other cell types, such as 
osteoblasts, osteocytes, synovial fibroblasts, and neutrophils, as potential sources of 
RANKL required for osteoclast differentiation and activity.  Direct demonstration of the 
critical cell type for RANKL-mediated bone erosion requires further studies, as outlined 
in Chapter V.  
In conclusion, this dissertation demonstrates the essential role of inflammation in 
the regulation of osteoblast-mediated bone formation at the various microenvironments in 
bone.  At the pannus-bone interface, inflammation suppresses osteoblast activity, while at 
periosteal bone surfaces inflammation induces bone formation.  Inflammation at these 
sites creates an imbalance of factors critical for osteoblast differentiation and function, 
leading to alterations in bone formation.  sFRP1, sFRP2, and BMP3, antagonists of the 
Wnt and BMP signaling pathways, respectively, are shown in this dissertation to be 
altered by inflammation in synovial fibroblasts and osteoblasts.  Agonists of the Wnt and 
BMP signaling pathways, such as BMP2 and Wnt10b, have also been shown to be 
expressed by synovial fibroblasts and macrophages.  As such, resolution of inflammation 
promotes osteoblast-mediated erosion repair, concurrent with upregulation of bone 
anabolic signaling factors. This data strongly suggests that controlling inflammation may 
be a key therapeutic target for inflammatory diseases with altered bone formation. 
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APPENDIX I 
 
Factors Contributing to Periosteal Osteophyte Formation in Inflammatory Arthritis 
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Introduction 
 Periosteal bone formation is a prominent feature of several inflammatory 
arthropathies including psoriatic arthritic and ankylosing spondylitis (AS) as well as 
osteoarthritis (OA), a degenerative arthritis.  These bony outgrowths, or osteophytes, lead 
to pain, loss of mobility, and ultimately ankylosis of affected joints.  While the initial 
triggers of osteophyte formation are undoubtedly different in these diseases, several 
interesting observations in these diseases have provided insight into the potential 
mechanisms of periosteal bone formation.  Ultimately, these finding may have relevance 
to future therapeutic interventions. 
Inflammation and osteophyte formation at the entheses, the sites of ligament and 
tendon attachment to bone, are hallmarks of AS (355, 356) and psoriatic arthritis (357, 
358).  In AS, T and B cell aggregates as well as macrophages have been observed at the 
entheses (359-362).   CD3+ T cells and CD14+ macrophage lineage cells localized 
adjacent to areas of bone formation (361), suggesting that these cells contribute to 
pathologic bone formation.  In addition, inhibition of TNF and cyclooxygenase-2 (Cox-
2), which are abundantly expressed in AS and OA synovial tissue (361, 363), effectively 
controls inflammation (364, 365). However, bone formation continues unabated in 
patients treated with TNF blockers (350, 366, 367).  Similar results are seen with TNF 
blockade in a murine AS model (351) and in periosteal bone formation in murine 
inflammatory arthritis (352).  In contrast, Cox-2 inhibition reduces radiographic 
progression in AS patients in one study (354).  Thus, TNF and Cox-2 appear to play 
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different roles in pathologic bone formation, but the contribution of Cox-2 to bone 
formation has not been definitely established.  
RANKL is also upregulated in the synovial tissue of AS and OA joints (368, 369). 
However, osteoprotegerin and bisphosphonate treatment did not inhibit the development 
of periosteal osteophytes in inflammatory arthritis or joint ankylosis in murine AS (352, 
353) respectively, suggesting that neither osteoclasts nor erosive activity is required for 
periosteal bone formation.  However, in both of these models, depletion of osteoclasts is 
incomplete, thus the role of the osteoclast in osteophyte formation is unclear. 
The process of periosteal osteophyte formation occurs through a typical 
endochondral ossification sequence, a process whereby a cartilage intermediate is used as 
a template for the construction of mineralized bone (370).  Specifically, cells on the 
periosteal surface proliferate and by an unknown mechanism, differentiate into 
chondrocytes.  These chondrocytes secrete collagen type X and other matrix molecules, 
such as aggrecan, forming a cartilage template.  Subsequently, the chondrocytes undergo 
hypertrophy and secrete numerous soluble factors that regulate the growth, 
vascularization, and mineralization of the new cartilage matrix.  Following the apoptosis 
of the hypertrophic chondrocytes, osteoprogenitors migrate into the empty lacunae, 
differentiate into osteoblasts, and produce a mineralized bone matrix.  Lastly, osteoclasts 
resorb and remodel the newly formed bone.  It has been suggested that formation of 
periosteal bone in inflammatory arthritis also occurs through endochondral ossification 
(352).   
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The process of endochondral osteophyte formation in AS and OA has been linked 
to activation of BMP signaling, a pathway essential for osteoblast differentiation and 
activity.  BMP signaling is mediated by a family of BMP ligands that induce 
heterodimerization of the serine/threonine kinase type I and type II BMP receptors 
leading to the phosphorylation of the R-SMADs 1, 5, and 8.  Activated R-SMADs form a 
complex with SMAD4 to mediate osteoblast target gene transcription.  In AS patients, 
serum levels of BMP2, 4, and 7, classical BMP ligands, were elevated, correlating with 
clinical and radiographic measures of disease (371, 372). BMP2, 5, 6, and 7 expression 
was observed in various mesenchymal-derived cells within developing osteophytes from 
OA patients (246, 373).  Furthermore, expression of BMP2 and 4 is upregulated in the 
synovium following papain-induced OA (374).   Inhibition of BMP signaling reduced 
osteophyte formation in experimentally-induced OA and spontaneous AS models (374, 
375).  In addition, repeated injections of BMP2 into healthy murine knees stimulated 
osteophyte formation (376, 377), which was dependent on synovial macrophage-
mediated BMP2 and 4 expression (378, 379).   
  While inflammation-induced bone erosions are a distinguishing feature of the 
murine serum transfer arthrits (STA) model, there are also distinct microenviroments in 
the arthritic joint which exhibit periosteal bone formation (96).  Erosions occur in STA at 
the sites where pannus tissue attaches to the cortical bone surface and at endocortical 
bone surfaces where inflammatory tissue has penetrated into the bone marrow cavities.  
In contrast, inflammation also reproducibly induces bone formation on the periosteal 
surface of the distal tibia and the dorsum of the navicular bone, where inflammation is 
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juxtaposed to the bone surface.  Therefore, the STA model serves as an excellent model 
to evaluate the contributions of potential cellular and soluble mediators to inflammation-
induced bone formation.   
Together, these data have implicated certain cellular mediators and factors as 
contributors to osteophyte formation, but the mechanisms of periosteal bone formation in 
diseases of inflammation-induced bone formation are still largely unknown.  Using the 
STA model, evaluation of periosteal bone formation sites in this study definitively 
demonstrated that Cox-2, TNF, RANKL, and lymphocytes are not required for 
endochondral bone formation at the periosteal surface.  However, BMP2 mRNA 
expression at tendon insertion sites into the periosteal bone implicates BMP2 as a factor 
in inflammation-induced bone formation. 
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Materials and Methods 
Serum Transfer Model of Inflammatory Arthritis  
All animal procedures were performed in accordance with protocols approved by 
the Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School.  As previously described, K/BxN mice were generated by crossing KRN 
T cell transgenic mice (Drs. Benoist and Mathis, Harvard Medical School) with NOD 
mice (Jackson Laboratories) (279, 280).  Serum from individual arthritic K/BxN mice 
was isolated and pooled for STA studies as described (69, 96).   
Twelve week old male C57BL/6J mice and B6.129S7-Rag1tm1Mom/J (RAG-/-) mice 
were obtained from The Jackson Laboratory.  TNF-/- (290, 380), RANKL-/-(69, 381), and 
appropriate litter mate control mice were generated as previously described.  STA was 
induced in by intraperitoneal injection of 150µl of arthritogenic K/BxN serum on days 0, 
2, 7, and 14.  Non-arthritic mice received 150µl of sterile PBS.   
 
Histopathologic Analyses  
Hind limbs were fixed in 4% paraformaldehyde for 24 hours, decalcified in 15% 
EDTA/0.5% PFA, and paraffin embedded.  For evaluation of inflammation and bone 
erosion, sections were stained with hematoxylin and eosin or tartrate resistant acid 
phosphatase (TRAP), respectively, as previously described (326) and detailed in Chapter 
II.   
Immunohistochemical analysis of Runx2, Sox9, Col X, and Cox-2 protein 
expression was adapted from previously described methods (77, 96).  Briefly, paraffin 
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sections were dewaxed and rehydrated.   Runx2 and Sox9 antigen retrieval was 
performed in 10mM EDTA, pH7.5 and Col X antigen retrieved with 10mg/ml 
hyaluronidase (Sigma).  No antigen retrieval was required for Cox-2 antigen staining.  
Endogenous peroxidase activity was inhibited with 3% hydrogen peroxide and non-
specific binding was blocked using 10% fetal bovine serum/10% species specific serum.  
Slides were stained with rabbit polyclonal anti-mouse Cbfa1 (Runx2) (Santa Cruz, 
catalog number sc-10758, 1:25 dilution), rabbit anti-human Sox-9 (Santa Cruz, catalog 
number sc-20095, 1:50 dilution), rabbit polyclonal anti-mouse collagen X (Calbiochem, 
catalog number 234196, 1:75 dilution), and rabbit ant-mouse Cox-2 (Caymen, catalog 
number 160126, 1:100 dilution).  Bound antibody was detected with biotin-conjugated 
swine anti-rabbit F(ab) secondary antibody (DAKO) followed by HRP-conjugated 
streptavidin (DAKO).  Positive antibody staining was visualized using DAB liquid 
chromogen (DAKO) and nuclei were counterstained with hematoxylin.   
For detection of BMP2 mRNA, digoxigenin labeled anti-sense and sense 
riboprobes were generated as previously described (96) using plasmid constructs 
provided by Dr. Vicki Rosen (Harvard Dental School).  In situ hybridization was 
performed according to previously described methods (96) and described in Chapter I. 
 Images were acquired with a Nikon Eclipe E600 microscope with a Nikon Plan 
Fluor objective and a Nikon DS-Ri1 camera with Nikon NIS-Elements BR 3.10 software. 
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Results and Discussion 
Periosteal Bone Formation Occurs via Endochondral Ossification. 
Similar to osteophyte formation in OA, it has been suggested that formation of 
periosteal bone in inflammatory arthritis occurs through endochondral ossification (352).  
To demonstrate endochondral ossification at the periosteal bone surface in inflammatory 
arthritis, the expression of markers for the various stages of the endochondral process 
were evaluated at sites of inflammation-induced bone formation in STA.  
At the leading edge of osteophyte growth in STA, Sox9, an essential transcription 
factor for the commitment of mesenchymal progenitors to the chondrocyte lineage, is 
expressed by cells with hypertrophic chondrocyte morphology (Figure A1.1A).  
Hypertrophic chondrocytes, which are responsible for the deposition of the cartilage 
intermediate, also express collagen type X (Col X), a primary component of the matrix.  
As such, in the inflammation-induced osteophyte, hypertrophic chondrocytes are positive 
for Col X as is the surrounding cartilage matrix (Figure A1.1B). In the last stages of 
endochondral bone formation in the inflammation-induced osteophyte, the cartilage 
template is resorbed and Runx2 expressing osteoblasts are recruited to the bone surface 
(Figure A1.1C).  As the osteophytes develop, Sox9, Col X-expressing hypertrophic 
chondrocytes are present on the superficial surface of the osteophyte, while Runx2 
positive osteoblasts are present deeper in the osteophyte, near the periosteal surface of the 
tibia, where mineralized bone formation and remodeling of the osteophyte occurs. 
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Cox-2, TNF, RANKL, and Lymphocytes are not Required for Periosteal Bone Formation. 
The observation that Cox-2 inhibition reduces radiographic progression in AS 
(354) suggests that Cox-2 contributes to joint ankylosis. While Cox-2 drives the 
expression of prostaglandin E2 (PGE2), a principle mediator of inflammation, PGE2 also 
acts via its cognate receptors, EP2 and 4, to stimulate osteoblast differentiation and bone 
formation (382).  In addition, Cox-2 and PGE2 upregulation the context of inflammatory 
arthritis may also mediate inflammation-induced bone formation.  To address this 
hypothesis, we evaluated the expression of Cox-2 at sites of periosteal bone formation; 
however, the lack of available reagents for the EP receptors precluded the identification 
of PGE2 responsive cells at these sites.   
Interestingly, three days after the induction of STA, Cox-2 was expressed by 
periosteal cells and by day 5, Cox-2 was also observed in cells within the adjacent 
inflammatory tissue (Fig A1.1d).  These Cox-2 expressing cells were not found across the 
entire periosteal surface, but coalesced exclusively at sites where periosteal bone 
formation reproducibly occurs.  While Cox-2 expressing cells were observed prior to the 
induction of bone formation, with the onset of endochondral ossification, Cox-2 was no 
longer detected at the periosteum.  Subsequently, by day 15, osteoclasts remodeling the 
newly formed periosteal bone were the only cells expressing Cox-2.   
Absence of Cox-2 during the period of periosteal bone formation in STA (383) 
however, did not alter the development of osteophytes (data not shown, tissue kindly 
provided by Dr. Peter Nigrovic, Brigham and Women's Hospital).  As such, the data from 
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this murine model suggests that the positive effect of Cox-2 inhibition on preventing 
bone formation in AS patients may not due to direct effects on bone formation.   
Similar to the Cox-2 observations, blockade of TNF and RANKL has previously 
been shown to have no effect on inflammation-induced periosteal bone formation (352).  
However, in these studies, neutralization of TNF and RANKL was initiated after the 
onset of periosteal bone formation; thus, a role for these factors in the initial phases of 
bone formation cannot be excluded.  TNF therapy in this study also significantly reduced 
inflammation, thus complicating the analysis of the effects of inflammation on bone 
formation.   
To more fully address the contribution of TNF and RANKL to periosteal bone 
formation, mice deficient in TNF and RANKL were administered arthritogenic K/BxN 
serum to induce STA, a model which does not require TNF for the development of 
inflammation (290), but does require RANKL for osteoclast-mediated bone erosion (69).  
In the absence of TNF or RANKL, endochondral ossification proceeded normally leading 
to periosteal bone formation that was similar to wildtype controls (Figure A1.2A and B).  
These observations definitively demonstrate the TNF and RANKL are not required 
during the initial phases of inflammation-induced endochondral ossification or 
mineralized bone formation.  Furthermore, unlike previous studies which suggest that an 
initial osteoclast-mediated resorption event is required for the initiation of periosteal bone 
formation (352), the absence of osteoclasts from the onset of arthritis in this study 
definitely demonstrates that osteoclast activity is not required.    
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Published reports also suggest that B cell aggregates found within bone marrow 
infiltrates contribute to bone formation at the endosteal surface of eroded bone.  
Specifically, these B cells have been shown to express BMP6 and 7 (95, 99), but no 
direct role for B cells in bone formation was proven.  T cell involvement in bone 
formation at the endosteal or periosteal surface has not been investigated.  In this study, 
we demonstrated that T and B lymphocytes are not required for periosteal bone formation 
in inflammatory arthritis by inducing STA in RAG-1 deficient mice, which lack T and B 
lymphocytes (Figure A1.2C).  Similar to the TNF and RANKL knockout out mice, 
periosteal bone formation occurred normally with no obvious differences in osteophyte 
development.   
 
BMP2 mRNA is Expressed at Sites of Tendon Attachment in Periosteal Bone Formation. 
 Having demonstrated that Cox-2, TNF, RANKL, and lymphocytes are not 
mediators of periosteal bone formation, we were interested in elucidating the key factors 
that are involved in regulating inflammation-induced bone formation.  Since exogenous 
BMP2 has been shown to promote osteophyte formation in murine OA (376, 377), the 
expression of BMP2 mRNA in the initiation and progression of inflammation-induced 
periosteal bone formation was evaluated. Five days after the induction of STA, BMP2 
expressing cells were present on the periosteal surface of the tibia near the site of tendon 
insertion.  These cells were localized within the fibrocartilage as well as in the 
inflammatory infiltrate (Figure A1.3).  As inflammation progressed, the number of cells 
expressing BMP2 and the intensity of BMP2 staining increased.  By day 18, when 
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significant periosteal bone had formed, BMP2 mRNA was primarily expressed in 
differentiating chondrocytes on the leading edge of bone formation.  Scattered cells 
expressing BMP2 mRNA were also detected in the inflammatory tissue surrounding the 
forming bone.  In contrast, BMP2 mRNA was not detected on the periosteum of non-
arthritic mice at any time point.   
These results establish that BMP2 mRNA is induced at sites of periosteal bone 
formation in inflammatory arthritis, but the role of BMP2 in regulating bone formation at 
these sites is still unknown.  However, in addition to the observations in OA, other 
studies have conclusively demonstrated that BMP2 is a critical mediator of bone 
formation in pathologic settings.  Mice deficient in BMP2 specifically in the limb 
developed spontaneous fractures that did not repair with time (209), while BMP2 deletion 
at the onset of fracture eliminated fracture repair (384).  Inhibition of fracture healing in 
both models correlated with little to no activation and proliferation of periosteal cells at 
the callus site with most mesenchymal progenitors remaining undifferentiated (209, 384).  
During inflammatory arthritis, inflammation at the periosteal surface may mimic the 
inflammatory phase of fracture healing.  As such, the upregulation of BMP2 required for 
callus formation and fracture healing may also be an initial trigger for chondrogenic and 
osteogenic differentiation at periosteal sites in inflammatory arthritis.  The mechanisms 
responsible for inflammation-induced BMP2 expression during fracture healing and 
periosteal bone formation are not known.  
In addition to the BMP pathway, the Wnt signaling pathway has also been 
implicated in the regulation of pathologic bone formation.  The Wnt pathway is another 
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critical regulator of osteoblast differentiation and activity, which is antagonized by 
sclerostin and the Dickkopf (DKK) protein family.  In AS patients, serum DKK1 levels 
were lower than those of RA patients (264, 265) and decreased SOST expression 
correlated with syndesmophyte growth (385).  Furthermore, in the hTNFtg murine model 
of inflammatory arthritis, DKK1 blockade promoted bone formation and β-catenin 
expression in the sacroiliac joints (386).  Together these studies suggest that Wnt 
signaling may be another mechanism responsible for pathologic bone formation; 
however, the expression of Wnt antagonists was not evaluated in these studies. 
 In conclusion, this study demonstrates that osteophyte formation at the periosteal 
surface during inflammatory arthritis is a complex process, but Cox-2, TNF, RANKL, 
and lymphocytes are not involved in the initiation or progression of the endochondral 
process.  Interestingly, BMP2 mRNA is expressed at the site of osteophyte formation.  
This observation in combination with previously published data demonstrating the 
contribution of BMP2 to fracture repair and osteophyte formation in OA, strongly 
implicates BMP2 in periosteal bone formation in inflammatory disease.  Future studies 
with conditional BMP2 knockout mice are planned to establish the contribution of BMP2 
to periosteal bone formation.  
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APPENDIX II 
 
Expression of Bone Anabolic and Catabolic Factors by M1 and M2 Macrophages  
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Introduction 
 Accumulating evidence in clinical studies and animal models of inflammatory 
arthritis highlights the importance of macrophages to the development and progression of 
inflammation in RA (19, 387-389).  There is growing interest in understanding the 
heterogeneity of macrophage populations present at various stages of disease and their 
relative contributions to the disease process.  Two subsets of macrophages, M1 and M2, 
in particular, have garnered considerable attention for their microbicidal/tumoricidal and 
tissue repair capacity, respectively.   
 Classically activated or M1 macrophages traditionally require a two-step 
activation process of IFN-γ stimulation followed by lipopolysaccharide (LPS)-mediated 
toll-like receptor (TLR) agonism (390).  Once activated, M1 macrophages secrete 
superoxide anions and nitrogen oxide via the expression of inducible nitrogen oxide 
synthase (iNOS).  M1 secretion of pro-inflammatory cytokines, such as IL-1β, TNF, IL-
6, IL-12, and IL-23, is indispensable for augmenting Th1-mediated host defense against a 
variety of intracellular pathogens.  In contrast, polarization of macrophages with IL-4 or 
IL-13 generates alternatively activated or M2 macrophages (391).  Unlike M1 
macrophages, M2 macrophages do not release pro-inflammatory mediators or participate 
in killing of intracellular pathogens.  M2 macrophages express chitinases and arginase 1, 
which are involved in extracellular matrix synthesis and reorganization.  As a result, M2 
macrophages have been associated with Th2 immune responses, allergy, parasite 
encapsulation, wound healing, and tissue remodeling.   
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While M1 and M2 macrophages have been extensively explored in cancer and 
infectious diseases, little is known about these cells in inflammatory arthropathies.  M2 
gene signatures have been identified in peripheral blood cells of new-onset juvenile 
idiopathic arthritis patients and in synovial fluid cytokine profiles of psoriatic arthritis 
and spondylarthropathy patients (392, 393).  In contrast, M1 cytokine signatures in 
synovial fluid were correlated with inflammation in RA (393).  The differential 
expression of M1 and M2 macrophages in these inflammatory diseases suggests that 
macrophage subsets are involved in disease; however, their function in the disease 
process is not known.   
In addition to their traditional roles in inflammation, homeostasis, and wound 
healing, macrophages have also been linked to bone formation.  Osteal macrophages, or 
OsteoMacs, form a canopy over osteoblasts lining the endosteal and periosteal bone 
surfaces and are required for osteoblast-mediated mineralization of bone matrix in vitro 
(345).  BMP2 derived from murine and human macrophages stimulates bone formation in 
vitro; however, LPS treatment abolishes their osteogenic potential (343).  LPS-stimulated 
M1 macrophages express oncostatin M, an IL-6 cytokine family member, which 
promotes osteoblast differentiation in vitro (394).  Furthermore, deletion of macrophages 
decreased intramembranous bone formation during fracture healing, while M-CSF 
therapy promoted fracture repair, demonstrating the significance of macrophages to bone 
formation (344).    
Interestingly, in the model of resolving inflammation characterized in Chapter II, 
it was demonstrated that synovial hyperplasia persisted during the resolution phase as 
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well as the repair and remodeling phase.  From this observation, we speculated that 
macrophages, particularly M2 macrophages, may be one of the cellular infiltrates 
remaining in the synovium during the resolution phase to mediate tissue repair and 
remodeling.  In addition, we further hypothesized that the temporal expression of M2 
macrophages may contribute to osteoblast-mediated bone formation by modulating the 
expression Wnt and BMP signaling mediators.  To explore this hypothesis, M1 and M2 
macrophages were polarized in vitro and the expression of bone anabolic and catabolic 
factors was quantified in preliminary experiments.  
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Materials and Methods 
Generation of Bone Marrow Derived Macrophages 
 Bone marrow stromal cells were flushed from the tibia and femur of C57Bl/6J 
mice (Jackson Labs) and red blood cells were lysed with RBC lysis buffer 
(eBiosciences).  2x106 cells were plated in 15cm petri dishes in DMEM supplemented 
with L-glutamine, penicillin/streptomycin, 1µg/ml polymyxin B, 10% fetal calf serum 
(Hyclone), and 20% conditioned medium from M-CSF-expressing L929 fibroblasts 
(kindly provided by Dr. Ann Marshak-Rothstein).  Medium was replaced on days 3 and 
6.  Between days 7 and 9, cells were removed by gentle scraping, seeded at 5x105 
cells/well in 12-well plates, allowed to incubate overnight, and used for polarization 
experiments.  
 
Macrophage Polarization 
 M1 and M2 macrophages were generated as previously described (395).  Briefly, 
to generate M1 macrophages, cells were pre-incubated for 2 hours in DMEM 
supplemented with L-glutamine, penicillin/streptomycin, 1µg/ml polymyxin B, and 10% 
fetal calf serum.  Cells were primed with 150 U/ml IFN-γ (R&D Systems) for 12 hours 
and subsequently stimulated with 10ng/ml LPS (Sigma, L2630) for 4 or 6 hours.  To 
generate M2 macrophages, cells were pre-incubated for 2 hours in DMEM supplemented 
with L-glutamine, penicillin/streptomycin, and 10% fetal calf serum.  Cells were 
stimulated with 20U/ml of IL-4 for 4 or 6 hours. 
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Macrophage Gene Expression 
RNA was isolated from cultured macrophages using Trizol.  cDNA was 
synthesized from 500ng of RNA using iScript (BioRad).  qRT-PCR was performed on 
cDNA samples using the iScript Sybr Green RT-PCR mix (BioRad).  Guanine 
nucleotide-binding protein subunit beta-2-like 1 (GNBP2L1) primers were obtained from 
MWG-Operon (forward 5’-GAGTGTGGCCTTCTCCTCTG-3’, reverse 5’-
GCTTGCAGTTAGCCAGGTTC-3’), Arg1 and iNOS primers were obtained from IDT 
(designed and supplied by Dr. Ann Marshak-Rothstein), and BMP2 primers were 
obtained from Qiagen (catalog number QT01054277).  Gene expression was normalized 
to the expression of GNBP2L1, a reference gene, and data was expressed as the fold 
increase in gene expression in polarized macrophages compared to unstimulated 
macrophages at the 0 hour time point using the 2ΔΔCt method (314).  
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Results and Discussion 
M2, but not M1, Macrophages Express BMP2.   
To determine the differential contribution of macrophages subsets to bone 
formation, M1 and M2 polarized macrophages were generated in vitro.  IFN-γ and LPS 
polarization of macrophages led to an approximately 1000-fold induction of iNOS 
mRNA, a classical M1 macrophage marker, but not arginase 1 mRNA, a M2 macrophage 
marker (Figure A2.1A and A2.1B).  In contrast, IL-4 polarized macrophages had an 
approximately 20-fold increase in arginase 1 mRNA, but did not express iNOS mRNA.  
These studies demonstrate that polarization of macrophages with IFN-γ and LPS 
generates M1 macrophages, while IL-4 induces an M2 macrophage phenotype, as 
expected. 
 Expression of various agonists and antagonists of the Wnt and BMP signaling 
pathways was evaluated in M1 and M2 macrophages.  BMP2 mRNA was upregulated 
approximately 2-fold in M2 macrophages, compared to controls after 4 and 6 hours of 
stimulation (Figure A2.1C).  IFN-γ and LPS suppressed BMP2 mRNA expression in M1 
macrophages, similar to previously published data (343). However, select BMP and Wnt 
agonists, including Wnt3a, Wnt10b, BMP4, BMP6, and BMP7, were not differently 
expressed in M1 and M2 macrophages (data not shown).    
 Only a limited panel of Wnt and BMP agonists and antagonists was evaluated in 
this study, therefore the extent to which macrophages might contribute to bone loss or 
formation in inflammatory arthritis cannot be definitely demonstrated.  In addition, 
immunohistochemistry efforts to localize M1 and M2 macrophages to the synovium and 
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bone during the resolution phase have proven unsuccessful.  However, the expression of 
BMP2 mRNA expression by M2 macrophages implies that macrophages may stimulate 
local bone formation.  Indeed, if M2 macrophages are present during the resolution of 
inflammation, M2-mediated BMP2 expression may be one mechanism by which bone 
formation is induced during this phase.  Published findings in macrophage-depleted 
models of fracture healing support that notion that macrophages contribute to bone 
formation (344, 345).   
These preliminary data suggest that macrophage-mediated bone formation may be 
an important direction for future experimental work.  To expand the findings of this 
preliminary study, a microarray could be used to identify additional bone anabolic and 
catabolic factors differentially expressed in M1 and M2 macrophages.  As previously 
described (343), cell culture supernatants from the macrophage subsets could be cultured 
with osteoblasts in vitro in order to demonstrate a direct effect on osteoblast 
differentiation and/or function.  The specific contribution of individual factors could be 
determined in these studies by antibody neutralization, siRNA knockdown, and gene 
overexpression.  Translation of these in vitro findings to the arthritis models would 
initially require identification of the macrophage subsets in the joint by FACS, 
immunohistochemistry, and/or in situ hybridization.  Isolation of M1 and M2 
macrophages directly from synovial tissue would further allow for characterization of the 
phenotype of these cells.  Lastly, to establish a role for macrophages in bone loss and 
erosion repair, inflammatory arthritis could be induced in mice genetically, 
pharmacologically, or conditionally depleted of macrophages and the bone phenotype 
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quantitated.  Together, these studies could be used to demonstrate the mechanisms by 
which macrophage subsets may regulate bone formation during peak and resolving 
inflammation in inflammatory arthritis.  
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